Cytochrome P450 enzymes and oxidative stress in  tobacco/nicotine mediated HIV pathogenesis by Ande, Anusha
 
 
CYTOCHROME P450 ENZYMES AND OXIDATIVE STRESS IN TOBACCO/NICOTINE 
MEDIATED HIV PATHOGENESIS  
 
A DISSERTATION IN 
Pharmacology  
and 
Pharmaceutical Sciences 
 
 
Presented to the Faculty of the University 
of Missouri-Kansas City in partial fulfillment of  
the requirements for the degree 
 
 
DOCTOR OF PHILOSOPHY 
 
 
by 
ANUSHA ANDE 
B.S., Andhra University, 2010 
 
Kansas City, Missouri 
2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
© 2016 
 
ANUSHA ANDE 
 
ALL RIGHTS RESERVED 
 
 
iii 
 
CYTOCHROME P450 ENZYMES AND OXIDATIVE STRESS IN TOBACCO/NICOTINE 
MEDIATED HIV PATHOGENESIS  
Anusha Ande, Candidate for the Doctor of Philosophy Degree 
University of Missouri-Kansas City, 2016 
  
ABSTRACT 
In the US, the prevalence of cigarette smoking in the HIV-infected population is 50-70% 
compared to 15-20% in the general population, which further increases the risk of smoking-related 
health problems in this group. For example, HIV-infected smokers show decreased immune 
responses, poorer responses to antiretroviral therapy (ART), and greater risk of virological 
rebound, compared to HIV-infected non-smokers. Several in vivo and in vitro studies have shown 
that smoking/nicotine is associated with decreased immune responses, increased inflammation, 
increased oxidative stress, and increased numbers of opportunistic infections. Furthermore, in vitro 
studies have shown that smoking/nicotine enhances HIV replication in alveolar macrophages, 
microglia, and T cells. However, the mechanism by which smoking or nicotine increases HIV 
replication is largely unknown. As an exception, a report suggests that iron and oxidative stress 
are possible mechanisms of enhanced production of HIV by alveolar macrophages in cigarette 
smokers. 
The role of CYP enzymes has not been studied in context with smoking/nicotine and HIV 
pathogenesis. However, there are several elegant studies that show the involvement of CYP2A6, 
CYP2A13, CYP1A1, and CYP1B1 in smoking/nicotine-mediated toxicity leading to various types 
of cancers and hepatic toxicity. The majority of tobacco constituents, including nicotine, are 
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metabolized and/or activated by CYP enzymes to generate reactive oxygen species (ROS) and/or 
reactive metabolites, NNK. Based on the fact that CYP pathways play a critical role in smoking-
mediated cell/organ toxicity, there is a critical need to explore the involvement of CYP pathways 
in smoking/nicotine-mediated HIV pathogenesis. The present study was based on the central 
hypothesis that tobacco/nicotine, or its metabolites, enhance HIV replication in 
monocytes/macrophages through CYP pathway. 
The key findings of our studies presented in this thesis indicate that (a) CYP2A6-mediated 
metabolism of nicotine increased the generation of ROS in HIV cell model, SVGA astrocytes, (b) 
Cigarette smoke condensate caused significant induction of CYP1A1, CYP2A6, ROS production, 
and cytotoxicity in U937 monocytes as well as enhanced HIV replication in HIV-infected primary 
macrophages, (c) Mild-to-moderate smoking increased viral load in HIV-infected individuals. 
Furthermore, our study suggested that smoking and HIV independently increase oxidative stress 
in the plasma as well as in monocytes. (d) There was a decrease in the level of nicotine and 
subsequent increase in the level of nicotine metabolites, suggesting an increase in nicotine 
metabolism in HIV-infected smokers compared with uninfected smokers. 
In conclusion, our in vitro and ex vivo results are consistent with the hypothesis that CYP 
and CYP-mediated oxidative stress by tobacco/nicotine are associated with increased viral load by 
smoking/smoking constituents. This study has clinical implications in terms of targeting CYP and 
oxidative stress pathways to find potentially novel therapeutic interventions, as well as drug dose 
adjustment to treat HIV-infected smokers effectively.   
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CHAPTER 1 
TOBACCO SMOKING MEDIATED OXIDATIVE STRESS IN ORGAN TOXICITIES: 
ROLE OF CYTOCHROME P450 SYSTEMS 
1.1 Prevalence, diseases, and lifestyles 
 According to WHO, tobacco continues to kill nearly 6 million people annually, 
including more than 600,000 non-smokers who are exposed to tobacco smoke[1]. Further, 
WHO predicts that the smoking related deaths will reach approximately 8 million annually by 
2030[2]. Cigarette smoking is associated with three major diseases; lung cancer, chronic 
obstructive pulmonary disease (COPD), and cardiovascular diseases, which are responsible 
for the highest rate of mortality in the US [3]. Another study has recently suggested that 
cigarette smoking is the cause of 30% of all deaths by cancers, 10% of deaths by 
cardiovascular diseases, 9% of deaths by respiratory diseases, and 7% of deaths by digestive 
diseases[4].  Numerous literatures suggest that smoking-mediated adverse effects of human 
health, including premature death, occur not only because of nicotine, but through other 
cigarette smoke constituents[5]. Tobacco smoke contains 61 known carcinogens, which 
increase the risk of cancers including lung, oro-pharyngeal, pancreatic, and renal cancers[6]. 
Chemicals found in tobacco smoke, including carcinogens, can cross the placenta[7] and cause 
chromosomal damage to the fetus[8]. Further, animal studies have shown that the developing 
brain is much more likely to develop tumors as a result of exposure to neurocarcinogens in 
utero than later in life[9]. Therefore, it is necessary to assess the biological pathways 
responsible for tobacco-mediated toxic effects on disease in order to identify potential targets 
for future drug development and improve the health outcomes of tobacco users. 
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 1.2. General mechanisms of tobacco-mediated toxicities 
 In addition to carcinogens, cigarette smoke (CS) contains over 4000 different chemical 
substances.  Some of the mainstream cigarette smoke constituents are ammonium hydroxide, 
benz[A]anthracene (B[a]A), benzo[A]pyrene (B[a]P), carbon monoxide (CO), diammonium 
phosphate, 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK), and N-
nitrosonornicotine (NNN), “tar”, acetaldehyde, acrolein, acrylonitrile, benzene, 
formaldehyde, and hydrogen cyanide[10, 11]. Tobacco constituents have shown to be both 
proliferative [12-15] and apoptotic or cytostatic[16]. It has been shown that tobacco induces 
cell death via nitric oxide and through the formation of ROS [12]. It has also been reported 
that many tobacco constituents and nicotine-derived nitrosamine ketones (NNK) induce 
mutations through DNA damage. In a study, Elias et al. have shown that tobacco crude extract 
(TCE) induces apoptosis (dose-dependent) in oral squamous carcinoma cell line (OSCC-3) 
via caspase activation, which was accompanied by DNA fragmentation. This suggests that 
despite tobacco’s role in tumor formation, it may have some component that is useful in 
fighting cancer [17]. However, additional work is needed to further explore its beneficial use 
in cancer treatment.  
 When oral mucosa cells are exposed to lead and benzo[A]pyrene, another cigarette 
constituents, caspase-3 activity and 8-epi prostaglandin F2 alpha (8e PGF2a) are increased, 
while 3-nitrotyrosine levels are increased with chronic exposure to lead [18]. 8e PGF2a is of 
non-enzymatic origin, which is produced by random oxidation of tissue phospholipids. In 
other words, these cigarette constituents may increase oxidative and nitrosative stress. 
 Nicotine is the major addictive and abundant (95%) substance present in tobacco 
smoke.  Nicotine is metabolized by liver CYP2A6 through 5’ oxidation to its major metabolite 
cotinine (75%) and many other metabolites (25%) [19]. CYP2A6 is known to further 
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metabolize these compounds into procarcinogenic compounds, including nicotine-derived 
nitrosamine ketone (NNK). CYP2B6 enzyme is also known to be involved in the formation 
of cotinine from nicotine in those who lack CYP2A6 enzyme [20].  NNK, the major tobacco 
specific carcinogen is metabolically activated by 2A6, 1A2, 3A4, and 2B6 CYP isoforms. 
These enzymes are involved in α-hydroxylation of NNK forming unstable diazohydroxides 
and aldehydes [20]. These diazohydroxides then form carcinogenic methyl or pyridyloxobutyl 
adducts by reacting with DNA. CYP2A13, a lung specific enzyme, is also known to 
metabolize nicotine and cotinine as well as activate NNK [21, 22]. NNK is also known to 
cause increase in the levels of reactive oxygen and nitrogen species in mouse microglia cell 
line leading to neuronal damage [23]. Several reports from literature have shown that NNK is 
responsible for generating oxidative stress in neurons and white blood cells [24, 25].  
 Smoking frequency may be determined by the polymorphisms in CYP2A6.  In some 
individuals with low expression of CYP2A6, the half-life of nicotine is increased making these 
individuals crave for nicotine less often, lowering cigarette consumption per day [26]. In 
contrast, smokers with relatively high expression of CYP2A6 have increased nicotine 
metabolism and metabolism of other constituents, which leads to increased smoking 
frequency in these individuals. These individuals would also produce increased ROS, 
carcinogens, and reactive metabolites, which will make them more susceptible to cancers and 
organ toxicities.  
 1.3. Respiratory tract disorders 
 Lung cancer is the leading cause of cancer deaths and about 90% of the lung cancer 
cases are attributed to cigarette smoking [27]. In addition to nicotine metabolism, CYP 
enzymes are also responsible for the oxidation of aromatic moieties and olefins of tobacco 
constituents in the lungs tissues. Further, CYP enzymes are known to activate NNK, a tobacco 
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specific carcinogen, by α hydroxylation leading to the formation of ROS and carcinogenic 
DNA adducts in the lungs tissues. Further, ROS-mediated lipid peroxidation products may 
enhance the inflammation through activation of stress kinases (JNK, MAPK, p38) and redox 
sensitive transcription factors such as AP-1  [28]. The overexpression of the Wnt5a gene, 
followed by PKC activation, has been implicated in cigarette smoke-mediated lung 
carcinogenesis [29]. One study has shown the chemopreventive effects of isothiocyanates 
(ITC) by dual mechanisms involving the inhibition of CYP enzymes and induction of Phase 
II enzymes [27].  The inhibition of CYP enzymes leads to reduced activation of 
procarcinogens e.g. NNK, and increased expression of Phase II enzymes eliminates the toxic 
metabolites generated by CYP enzymes. 
 Glutathione peroxidase-1 (gpx-1) is a detoxifying enzyme that may protect lungs from 
ROS-induced protein denaturation, lipid peroxidation, and DNA damage.  Gpx-1 converts 
two molecules of glutathione (GSH) and one molecule of H2O2 into oxidized glutathione 
(GSSG) and two molecules of water.  One study has shown that gpx-1 knockout mice exposed 
to cigarette smoke has enhanced bronchoalveolar lavage fluid (BALF) neutrophils, 
macrophages, proteolytic burden, and whole lung IL-17A compared to WT mice. Ebselen, a 
gpx-1 mimetic, inhibits the established BALF inflammation when administered 
therapeutically. Thus, it is suggested that gpx-1 protects against cigarette smoke-induced lung 
inflammation, and gpx-1 mimetics may have therapeutic use in inflammatory lung diseases in 
smokers [30]. 
 Manganese SOD2 eliminates anion superoxide free radicals, and is a major 
determinant of antioxidants in matrix mitochondria. One study isolated leukocyte cells of 20 
lung cancer patients, and compared the SOD2 activity to 50 healthy smokers and 50 non-
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smokers.  They found that SOD2 activity is lower in lung cancer patients, and plasma carbonyl 
levels are elevated.  Free radical production in lung cancer patients thus appeared high. 
Smokers also tended to exhibit lower SOD2 and higher carbonyl radicals compared to non-
smokers, thus suggesting a strong role of oxidative stress in lung cancers [31]. 
 1.4. Cardiovascular diseases 
 Women who smoke are 2.4-fold more likely to have sudden cardiac death than non-
smoking women; this risk subsides linearly, with 20 years smoking cessation completely 
abolishing the risk [32]. Cigarette smoke particulate matter-treated human vascular epithelial 
cells has been shown to increase osteopontin (OP), a matrix protein found in bone, which is 
implicated in vascular disease. This effect is diminished following treatment with ascorbate, 
an antioxidant [33]. Increased oxidative stress may activate NFκB and AP-1, transcription 
factors that regulate pro-inflammatory cytokines. Inflammation of vascular endothelial cells 
may lead to serious cardiovascular events, especially in the presence of an atherosclerotic 
plaque. 
            A recent study conducted in mice highlights the negative effects of short-term CS 
exposure (STCSE) on several organ systems. They have shown that STCSE enhances the 
generation of ROS and causes increased lipid peroxidation in heart, liver, and kidneys [34].  
On the other hand, it has been shown that the increase in SOD activity counteracts the 
damaging effects of ROS. This is a protective mechanism in acute exposure of CS but in case 
of chronic smoking the antioxidant defense system is largely impaired leading to ROS induced 
damage. 
 1.5. Reproductive system 
 Cigarette smoke has been found to significantly affect the reproductive system of 
treated mice via oxidative stress [35]. This was confirmed by upregulation of peroxiredoxin, 
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decreased glutathione levels, and increased 8-OHdG in the epithelial cells of the epididymis. 
Structural proteins involved in normal epididymal cell motility, such as Odf2 and Actg1, were 
down-regulated post-treatment [36]. Cigarette smoke has also been associated with reduced 
fertility and possibly the health of newborns. One study has confirmed the role of cigarette 
smoke-induced ROS generation in genotoxicity by exposing mouse embryos to cigarette 
smoke condensate that showed increased oxidative stress and telomere shortening and loss. 
The administration of an antioxidant, N-acetyl-L-cysteine, greatly reduced this toxicity, 
implicating the role of oxidative stress in cigarette-smoke induced genotoxicity [37]. 
             Furthermore, a study has shown the role of the metabolism of benzo[A]pyrene (BAP) 
into (+)-7,8-Diol-9,10-epoxide, which may subsequently form deoxyguanosine BAP adducts, 
on ovotoxicity. They found significantly increased levels of mitochondrial ROS, lipid 
peroxidation, and severely reduced sperm-egg binding in both low and high dose treatments. 
This suggests that BAP is partially responsible for the effects of cigarette smoke on follicular 
development and subfertility [38]. 
 Inhaled cigarette smoke is known to contain trace amounts of cadmium [39], which 
can traverse the placental barrier and exert toxic effects on the fetus.  Gestational cadmium 
exposure has been found to delay puberty.  In the ovary cadmium-treated rats show an increase 
in peroxide and lactoperoxidase (LPO) activities, while a decrease in SOD activity [40].  Since 
LPO is known to oxidize estrogenic hormones, it is implicated in the initiation of breast 
cancer[41].  Lipid peroxidation and other oxidative stress markers were reduced in cadmium-
treated rats upon treatment with diallyl tetrasulfide, a CYP inhibitor [42].  Overall, these 
studies suggest that constituents of cigarette smoke disrupt normal reproductive system via 
CYP pathway-mediated oxidative stress. 
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 1.6. Neurodegenerative diseases 
 Several studies have reported the regulation of CYP enzymes by nicotine in the brain. 
CYP2B6 is expressed in a region specific manner in the brain and is also found in astrocytes 
and neurons [43]. CYP2B6 is known to metabolize several centrally acting drugs and 
endogenous hormones. Smoking and alcoholism are known to induce CYP2B6 protein in 
different regions of brain which interfere with the metabolism of centrally acting drugs leading 
to neurotoxicity [43].  Since smoking is known to increase CYP2B6 levels, studies were done 
to examine the effect of nicotine on the induction of CYP2B6. Nicotine binds to nicotinic 
acetylcholine receptors (nAChRs) and exerts its pharmacological effects, however, it was 
shown that the induction of CYP2B6 by nicotine is not mediated through nAChRs [44]. Other 
studies also reported the induction of CYP2B6 in astrocytes and neurons of African green 
monkeys upon chronic nicotine treatment without affecting their hepatic levels [45].  Together 
these studies suggest that smoking-mediated induction of CYP enzymes may have altered 
therapeutic response leading to neurotoxicity. 
 Several studies have shown that nicotine and NNK cause oxidative stress in many 
other cells such as neurons, microglia, and white blood cells [23-25]. These cell types are very 
important for HIV pathogenesis and neuroAIDS which will be discussed in detail in chapter 
2.   
1.7. Clinical implications 
 Selective inhibition of CYP2A6 and CYP2A13 is considered as a potential therapeutic 
approach to treat nicotine dependence and tobacco-mediated cancers and organ toxicities.  In 
addition, isothiocyanate dietary supplements can be used to prevent tobacco-mediated lung 
carcinogenesis. The use of benzyl isothiocyanate (BITC) and phenethyl isothiocyanate 
(PEITC), which are present in high levels in cruciferous vegetables, such as watercress, 
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gardencress, cabbage, cauliflower, and broccoli, have been extensively studied to prevent 
CYP-mediated lung cancer[46]. Our findings involving the role of CYP2A6 in nicotine-
mediated oxidative stress suggest the potential use of CYP2A6 inhibitors in treating smoking 
related diseases. Furthermore, since our recent findings have shown that CYP2A6 is induced 
by oxidative stress-mediated PKC/MEK/Nrf-2 pathway in monocytes and astrocytes, this 
pathway may also be targeted for the development of potentially novel pharmaceuticals for 
smoking-mediated neurodegenerative diseases. Furthermore, CYP2A6, oxidative stress, and 
PKC/JNK/Nrf-2 pathways can also be utilized for developing novel pharmaceuticals for HIV-
infected smokers.  
 
Tobacco constituents are metabolized/activated by CYP isozymes, leading to the formation 
of ROS and reactive metabolites that cause cancers and organ toxicity.  CYP, cytochrome 
P450; ROS, reactive oxygen species; NNK, nicotine-derived nitrosamine ketone or 4-(N-
nitrosomethylamino)-1-(3-pyridyl)-1-butanone; NNN, N'-nitrosonornicotine; NNAL, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol. 
  
Figure 1. Tobacco associated organ toxicity 
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CHAPTER 2 
TOBACCO SMOKING EFFECT ON HIV PATHOGENESIS: ROLE OF 
CYTOCHROME P450 ISOZYMES 
2.1. Introduction 
HIV infection is a global pandemic that affects 34 million people worldwide, among 
which, sub-Saharan Africa accounts for 67% of this population [47]. Recent reports reveal 
that the HIV infection is highly prevalent among pregnant women in Africa [48], and this 
increases pediatric infections due to mother-to-child transmission [49]. However, the majority 
of African populations don’t have access to effective treatment to circumvent the increase in 
transmission. The co-infection by hepatitis C virus (HCV) in HIV- infected individuals is 
highly prevalent in the US (25% co-infected individuals)[50]. Similarly, HIV infection is also 
known to be associated with an increased risk of acquiring Mycobacteria tuberculosis (TB) 
infection in sub-Saharan Africa[51]. The advent of highly active antiretroviral therapy 
(HAART) has not only decreased the mortality rates substantially among individuals living 
with AIDS [52], but has also significantly decreased the incidence of HIV-associated 
dementia (HAD) [53]. However, the incidence of HIV-associated neurocognitive disorders 
(HAND), especially the milder form, has actually increased, perhaps due to central nervous 
system (CNS) toxicities mediated by HAART [54, 55]. Consumption of drugs of abuse, such 
as alcohol, tobacco, cocaine, methamphetamine, and marijuana, has also been shown to 
exacerbate HIV pathogenesis by accelerating the incidence and progression of HAND/HAD 
[56].  
Tobacco-related deaths are the highest among  addictive substances, and tobacco-
associated deaths are estimated to increase from 3.0 million in 1990 to 8.4 million in 2020 
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[57]. Further, according to the World Health Organization (WHO) predictions, smoking 
related deaths though are not as severe as predicted by National Institute of Drug Abuse 
(NIDA), but will account for about 8 million annually by 2030 [2]. Furthermore, tobacco use 
is projected to account for 9% of global disability-adjusted life years by 2020, which would 
make it the world’s single largest health problem [58]. In the US, the prevalence of cigarette 
smoking in the HIV-infected population is 50-70% [59] compared to 15-20% in the general 
population [60], which further increases the risk of smoking-related health problems in this 
group. For example, HIV-infected smokers show decreased immune responses, poorer 
responses to antiretroviral therapy (ART), and greater risk of virological rebound, compared 
to HIV-infected non-smokers [61]. Several in vivo and in vitro studies have shown that 
smoking/nicotine is associated with decreased immune responses [62-64], increased 
inflammation [62, 65, 66], increased oxidative stress [67, 68], and increased numbers of 
opportunistic infections [66]. Several in vitro studies have shown that smoking/nicotine 
enhances HIV replication in alveolar macrophages [69], microglia [70], and T cells [71]. 
However, the mechanism by which smoking or nicotine increases HIV replication is largely 
unknown. As an exception, a report suggests that iron and oxidative stress are possible 
mechanisms of enhanced production of HIV by alveolar macrophages in cigarette smokers 
[72].  
Tobacco constituents are known to be metabolized by different isozymes of 
cytochrome P450 (CYP), and this leads to the generation of reactive metabolites and reactive 
oxygen species (ROS) in various organ systems such as, liver, lung, esophagus, and brain [22, 
23, 73]. In view of the fact that ROS is known to play an important role in HIV pathogenesis, 
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the authors propose a novel pathway involving the role of CYP enzymes in oxidative stress-
mediated HIV pathogenesis in tobacco users. 
In this chapter, we discuss the possible role of CYP pathways in tobacco/nicotine-
mediated effects in HIV/AIDS with respect to: 1) the effect of smoking on HIV pathogenesis, 
2) the general mechanism of smoking-mediated oxidative stress and toxicity, 3) the potential 
role of the CYP pathway in tobacco/nicotine-mediated oxidative stress in HIV model systems, 
4) conclusions, and 5) an expert opinion on this subject. 
2.2. Role of smoking on HIV pathogenesis  
A recent study conducted on the assessment of the mortality rates among AIDS 
patients has revealed that the risk of death is twice as high among smokers in the HIV-infected 
population than the non-HIV-infected population[74]. In part, this could be because smoking 
is known to increase the prevalence of other viral infections such as human papilloma virus 
(HPV) leading to the risk of cervical cancer in HIV seropositive women [75]. Similarly, the 
incidence of emphysema is also reported to occur earlier and at an increased level among HIV-
infected smokers than in non-HIV-infected smokers [76]. There is an evidence from the 
literature suggesting that smoking is associated with decline in CD4 cell counts in the HIV-
infected population, despite of the higher baseline CD4 cell counts observed among smokers 
than non-smokers [77]. However, the role of smoking in the progression to AIDS is unknown. 
Recent reports from the literature have also demonstrated the toxic effects of the tobacco 
constituents, nicotine and nicotine-derived nitrosamine ketones (NNK) in neurons, microglia, 
and white blood cells, which are exposed to the virus or viral proteins [23, 24]. For example, 
the treatment with NNK to mouse microglial cells and in vivo injection of mouse with NNK 
showed an increase in ROS, as well as an increase in the levels of proinflammatory cytokines 
[23]. In addition, a multisite longitudinal study for up to 7.9 years using 924 women has shown 
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that tobacco smoking negates the effect of HAART medication in relation to CD4 recovery 
[61]. However, the mechanism of tobacco-mediated toxicity and decreased efficacy of 
HAART is largely unknown. 
Limited studies have addressed the effects of smoking on cognitive function and 
neurological disorders in the HIV-infected individuals with controversial findings [78]. Of 
relevance, it has been reported that chronic nicotine exposure can lead to the disruption of the 
blood brain barrier (BBB) integrity, which may enhance the exposure to HIV-infected 
monocytes, tobacco constituents, and antiretroviral drugs [79]. The exposure of these agents 
to CNS might exacerbate neuroAIDS and neurodegenerative diseases [79]. Another report 
from an observational cross-sectional study conducted in 56 women (36 HIV-infected and 20 
non-HIV-infected) suggests that there is no correlation between smoking and cognitive 
dysfunction [78] in the HIV-infected population. Collectively, the available evidence suggests 
that there is an increase in smoking-mediated HIV pathogenesis among individuals with 
HIV/AIDS and patients may benefit from the development of novel therapeutic agents and/or 
drug dose adjustments that can be used to treat HIV-infected smokers effectively.  
2.3. Mechanism of tobacco smoking-mediated toxicity: Role of cytochrome P450 
The role of CYP enzymes has not been studied in context with smoking/nicotine and 
HIV pathogenesis. However, there are several elegant studies that show the involvement of 
CYP2A6, CYP2A13, CYP1A1, and CYP1B1 in smoking/nicotine-mediated toxicity leading 
to various types of cancers and hepatic toxicity [19, 80]. The majority of tobacco constituents, 
including nicotine, are metabolized and/or activated by CYP enzymes to generate reactive 
oxygen species (ROS) and/or reactive metabolites, NNK [81]. ROS and reactive metabolites 
are known to cause DNA damage, lipid peroxidation, and protein oxidation that leads to cell 
toxicity [82]. Nicotine, the major constituent of tobacco, is predominantly metabolized by 
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liver CYP2A6 and lung-specific CYP2A13 to cotinine (75%) and other metabolites (15%) 
[22, 80, 83, 84]. In addition, CYP2A6 and CYP2A13 are involved in the metabolic activation 
of tobacco-specific nitrosamines into reactive compounds that lead to liver and lungs toxicities 
[21].  Other tobacco constituents, such as polyarylhydrocarbons (PAH) are mainly activated 
by CYP1A1, and CYP1B1[85, 86] that leads to the formation of recative metabolites, which 
has been shown to be associated with oral toxicity [86]. Furthermore, a study comprising 600 
patients has demonstrated that CYP1A1 is a risk factor in oral cancer among smokers [85]. 
Based on the fact that CYP pathways play a critical role in smoking-mediated cell/organ 
toxicity, there is a critical need to explore the involvement of CYP pathways in 
smoking/nicotine-mediated HIV pathogenesis.  
2.4. Potential role of cytochrome P450 in tobacco/nicotine-mediated oxidative stress 
and toxicity in HIV systems  
In the following sections we discuss whether CYP enzymes, especially those that are 
related to tobacco/nicotine, are expressed in monocytes/macrophages, lymphocytes, 
astrocytes, and neurons (Figure 2). We then discuss the role of CYPs in tobacco/nicotine-
mediated oxidative stress in these cells, and their possible link to HIV pathogenesis and 
neuroAIDS. Finally, we identify the future course of investigation in this area of research.       
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Cells or organs that are involved in tobacco/nicotine metabolism or activation in context to 
HIV infection. The metabolism and/or activation of tobacco/nicotine may be involved in the 
toxicity of lymphocytes, monocytes/macrophages, microglia, astrocytes, and neurons causing 
HIV pathogenesis and neuroAIDS. 
 
 
 
 
 
Figure 2: Smoking mediated Organ toxicity 
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2.5. Monocytes/Macrophages 
Monocytes/Macrophages are considered to be one of the major cellular targets of HIV 
and are thought to function as important viral reservoir [87]. Compared to activated CD4+ T 
lymphocytes, macrophages are more resistant to the cytopathic effect of HIV and survive HIV 
infection for extended periods of time [88, 89]. Furthermore, infiltration of macrophages into 
the brain results in spreading of the virus to resident glia, including perivascular macrophages, 
microglia, and astrocytes [90-92]. Migration of HIV-infected monocytes through the BBB is 
thought to be one of the major mechanisms responsible for the neuropathogenic effects of 
HIV, such as HAD and HIV encephalitis (HIVE)[93, 94]. Investigations to study the effect of 
tobacco/nicotine in monocytes/macrophages in vivo are therefore clinically relevant.  
The major nicotine-metabolizing CYP2A6 mRNA and protein are expressed in U937 
monocytic cell line [95]. A comparison between the levels of CYP2A6 mRNA in U937 cells 
and previously reported hepatocytic cells demonstrated that the level of CYP2A6 mRNA is 
similar in both the cells [96-98]. More importantly, the relative levels of the mRNA of 
CYP2A6 are much higher than the other CYP enzymes, including the mRNA of CYP1A1 and 
CYP1A2 [95, 96]. A relatively high abundance of CYP2A6 in U937 cells is intriguing and 
suggests further investigation on its role in HIV-infected smokers. Other investigations in 
macrophages derived from the U937 monocyte cell line have shown that nicotine is 
metabolized to cotinine and NNK by CYP2A6, a finding that was later confirmed using a 
CYP2A6 selective inhibitor, tryptamine [99]. In addition, it has been demonstrated that the 
metabolism of nicotine by CYP2A6 results in the generation of ROS [99]. Since oxidative 
stress has been linked to increased HIV replication in human primary macrophages in vitro 
[100], we hypothesize that CYP2A6-mediated nicotine metabolism and resultant oxidative 
stress may be a mechanism for the increase in viral replication among HIV-infected smokers. 
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This hypothesis is also supported by the fact that alcohol-mediated oxidative stress through 
CYP2E1 pathway increases the replication of another deadly virus, hepatitis C virus 
(HCV)[101, 102]. In one of these studies, it has been shown that CYP2E1-mediated alcohol 
metabolism, which produces ROS, increases the replication of HCV in hepatic cells and 
decreases the antiviral action of interferon [101]. The study involving the role of CYP2A6 
and other tobacco/nicotine-metabolizing CYPs in oxidative stress and HIV pathogenesis in 
monocytes/macrophages of HIV-infected smokers and non-smokers is needed. 
In addition to CYP2A6, CYP2E1 and CYP3A4 are abundantly expressed in U937 
monocytic cell lines [96]. Furthermore, CYP2E1 and CYP3A4 (mRNA and protein) are both 
induced by alcohol by approximately 2-fold in U937 cells [96]. CYP3A4 is mainly involved 
in the metabolism of ART drugs, non-nucleoside reverse trascriptase inhibitors (NNRTI) and 
protease inhibitors (PI) [103]. Thus an altered level of CYP3A4 in the HIV model systems by 
agents, such as alcohol and other medications, is expected to affect the response to ART drugs, 
especially NNRTI and PI.   
2.6. Lymphocytes 
Smoking has been shown to be associated with a reduction in CD4+ T cells [77] and 
an increase in mortality in HIV-infected individuals [74, 104], but the mechanism for 
smoking-mediated effects on lymphocytes is unknown. From these studies it appears that 
tobacco constituents, especially nicotine, decrease immune response possibly by altering 
cytokines and chemokines in these cells. In addition, other studies have shown that nicotine 
toxicity in lymphocytes is mediated through superoxide anion formation [105]. It has been 
further shown that the ROS generated in lymphocytes, by smoking, results in the oxidation of 
lipids, protein, and DNA. It also decreases the levels of AOE (GST and SOD) [105]. This 
finding is further supported by the fact that DNA fragmentation in lymphocytes is mediated 
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by oxidative stress resulting from nicotine [106]. Earlier study using quantitative RT-PCR 
showed that CYP1A1 mRNA is present at very low levels in human blood lymphocytes [107]. 
Furthermore, this study demonstrated that CYP1A1 mRNA is induced 20-fold by 2, 3, 7, 8-
tetrachlorodibenzo-p-dioxin in lymphocytes. Since the residual levels of tobacco/nicotine-
metabolizing CYP enzymes (CYP1A1, CYP1A2, and CYP2A6) are extremely low in 
lymphocytes, a study involving recombinant expression of these enzymes was performed to 
examine the role of these enzymes in lipid peroxidation through CYP pathways[108]. The 
results showed that these CYP enzymes increased lipid peroxidations by 2.1-fold, suggesting 
their role in oxidative stress. Further, a recent report showed that CYP2A6 is significantly 
induced in peripheral blood lymphocytes of lung cancer patients, suggesting that the 
expression of CYP2A6 could potentially be used to predict environment-induced disease and 
toxicity in humans[109]. However, there is nothing known about the expression of CYP2A6 
or other tobacco/nicotine-metabolizing CYPs in the lymphocytes of HIV-infected smokers or 
non-smokers. Studies are underway to investigate the role of CYP pathway in smoking-
mediated HIV pathogenesis in peripheral blood lymphocytes.        
2.7. Astrocytes 
Despite of the fact that HAART therapy increases the life span of HIV-infected 
individuals, the neurological complications, such as HAND, continue to be a source of 
significant morbidity. This is increasingly important, because since HIV-infected individuals 
live longer, this trend is expected to continue [110]. Astrocytes, the most abundant glial cells 
in the brain, which are important to protect the integrity as well as nourishment of neurons, 
play a major role in the pathology of HAND [111]. Astrocytes are also known to be infected 
by HIV, though to a lesser extent compared to microglia [112]. In addition, viral proteins and 
cytokines released by HIV-infected microglia are known to damage astrocytes [111], which 
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may ultimately lead to HAND. It has been shown that HIV protein gp120 induces 
proinflammatory cytokines/chemokines such as IL-6, IL-8 and CCL5 in SVGA astrocytic cell 
lines and primary astrocytes [113, 114]. The expression of these cytokines/chemokines is 
regulated through the nuclear factor-kappa B-dependent (NF-κB) pathway [113, 114]. In these 
studies, the involvement of NF-B in the regulation of the inflamatory cytokines/chemokines 
was shown using specific chemical inhibitors, as well as siRNA of NF-B pathway.  
Nicotine has been shown to increase BBB permeability by modulating tight junction 
proteins [115]. Since BBB integrity is critical to prevent the development of HAND, smoking 
could enhance the development and progression of these disorders through the effect of 
nicotine on the BBB. It has been reported that a decreased uptake of methyllycaconitine, (a 
selective antagonist for the nicotinic acetylcholine receptor alpha7 subtype), in chronic 
nicotine exposed rodent models, is due to diminished blood–brain passive diffusion of 
compounds with very low extraction rates [116]. Hence it is vital to understand the interactions 
of smoking and HAART with the BBB, which may affect the pharmacokinetic profile of these 
drugs leading to decreased efficacy and increased toxicity. 
2.8. Neurons 
There is very limited information on the effects of smoking on HAND. A recent report 
has shown that genetically expressed HIV viral proteins in rats attenuate nicotine-induced 
behavioral sensitization, which is associated with altered cAMP response element binding 
protein and extracellular regulated kinase signaling pathway in mesocorticolimbic system 
[117]. In vitro and in vivo studies reveal that NNK is known to cause neuroinflammation in 
brain [23]. NNK activates microglia and astrocytes to induce proinflammatory 
cytokines/chemokines with subsequent neuronal damage [23]. In addition, NNK treatment 
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increases phosphorylation of inflammatory signaling molecules such as NF-κB, ERKs, JNK, 
and p38 MAPK in the brains of BALB/c mice [23]. Since HIV gp120, a major viral protein, 
induces proinflammatory cytokines in astrocytes [113, 114], NNK-mediated 
neuroinflammation could further aggravate HAND. 
Another nicotine metabolizing enzyme, CYP2B6, is expressed in both astrocytes and 
neurons [43]. An earlier report has shown that rat CYP2B1 (homologous to human 2B6) is 
induced by nicotine in the brain, however, in this case, induction is not mediated through 
nicotinic acetyl choline receptors (nAChRs) [44]. Similarly, the level of CYP2B6 is increased 
in the brains of smokers compared to non-smokers, specifically in cerebellar purkinje cells 
and hippocampal pyramidal neurons [43]. Similarly, a study  in African green monkeys shows  
the induction of CYP2B6 in the brain, but not in hepatic cells following chronic nicotine 
treatment [45]. An increased level of CYP2B6 in smokers could lead to an altered metabolism 
of CYP2B6 substrates. For example, CYP2B6 metabolizes nicotine and also activates NNK, 
which may lead to increased oxidative stress and damage [118]. In addition, CYP2B6 
metabolizes an important HAART drug, efavirenz, which may cause tobacco-HAART 
interaction. Further studies are needed to examine the role of CYP enzymes in 
tobacco/nicotine-mediated neuropathogenesis and tobacco-HAART interactions in neurons.  
2.9. Conclusions 
Although smoking is highly prevalent in HIV-infected individuals and it is known to 
increase mortality [74, 104], studies related to the effects of smoking on HIV pathogenesis are 
very limited. Therefore, there is an urgent need to investigate the complexities of these 
pathways that are responsible for decreased immune responses, increased HIV replication, 
and increased AIDS related conditions in HIV-infected smokers. Recent findings suggest that 
cytochrome P450 plays an important role in smoking-mediated effects on HIV model systems, 
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such as monocytes/macrophages, lymphocytes, astrocytes, and neurons. In addition, it is 
known that smoking decreases the efficacy of HAART, especially NNRTI and PI, which may 
also involve the CYP pathway. CYPs are the major drug metabolizing enzymes for HAART, 
nicotine, and drugs used to treat opportunistic infections such as tuberculosis. A differential 
expression of CYP enzymes may alter the pharmacokinetic profiles of these drugs, including 
efficacy and toxicity. Therefore, it is imperative not only to examine the role of smoking on 
the CYP pathways, but also the impact of smoking on drug-drug interactions. Future studies 
in the following areas are necessary: 1) investigation of CYP pathway in HIV-infected 
smokers, especially the CYP enzymes by which tobacco-mediated oxidative stress enhances 
HIV replication in macrophages, astrocytes, and neurons, 2) a similar study with women and 
diverse ethnic groups who have CYP2A6 and CYP2B6 polymorphisms, which would provide 
an opportunity for personalized medicine in the future, 3) an investigation in HIV-infected 
patients co-infected with TB/hepatitis who receive HAART and/or anti-tubercular drugs that 
are metabolized through the CYP pathway, 4) studies to determine the role of smoking on the 
immune system in HIV infection, 5) clinical trials to identify potent CYP inhibitors as 
therapeutic agents that block nicotine-mediated HIV replication, 6) investigation of the role 
of the CYP pathway in the combined effect of alcohol and nicotine on oxidative stress-
mediated HIV replication because alcohol consumption is common among smokers and 
appears to follow a similar CYP pathway (CYP2E1)[95].  
2.10. Central hypothesis 
Smoking is common among HIV-infected individuals and smoking/nicotine has been 
shown to enhance HIV replication in alveolar macrophages [69], microglial cells [70], and T 
cells [71]. Monocytes are considered to be one of the major cellular targets for HIV and also 
found to be the crucial viral reservoirs [87]. Infiltration of HIV infected monocytes into the 
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brain through blood brain barrier is found to be one of the major mechanism responsible for 
the development of HIV associated dementia (HAD) and HIV encephalitis (HIVE). These 
infiltrated macrophages carry the virus into the brain and spread the virus to perivascular 
macrophages, microglia and astrocytes [90-92]. Astocytes are the most abundant glial cells in 
the brain providing support and protection to neurons. Studies have shown that HIV affects 
astrocytes leading to induction of neuroinflammatory responses [119]. Similarly HIV proteins 
such as gp120, Tat, Nef transfection in SVGA astrocytes have induced proinflammatory 
cytokine release [113, 120, 121] with implications in neuroAIDS. As neurons don’t get 
infected, the disruption of their supportive astrocytes might be responsible for overall neuron 
damage. The major nicotine metabolizing enzyme CYP2A6 is found to be predominantly 
expressed in monocyte-derived-macrophages (MDM’s) as well as astrocytes. Therefore, it is 
critical to study the role of CYP2A6 in the metabolism of nicotine and resultant oxidative 
stress in HIV replication in monocytes/macrophages, as well as in astrocytes. Furthermore, 
oxidative stress is known to enhance nicotine-mediated HIV replication in alveolar 
macrophages and monocyte-derived macrophages [72, 100]. However, little is known about 
the mechanism/pathways by which nicotine or other constituents of smoking exert its effect 
on these cells. Our approach explores the in vitro effect of nicotine/tobacco on 
monocytes/macrophages, and astrocytes as well as an ex vivo study involving 
monocytes/macrophages of peripheral blood mononuclear cells (PBMC) obtained from HIV-
infected smokers.  
We propose that tobacco/nicotine, or its metabolites, enhance HIV replication in 
monocytes/macrophages through CYP pathway (Figure 3). This is supported by the fact that 
CYP2A6 induces oxidative stress in monocytes/macrophages upon nicotine metabolism [99]. 
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These findings suggest a fruitful new area of study to explore the role of CYP2A6 in nicotine 
metabolism and oxidative stress in HIV replication in HIV-infected smokers. Furthermore, it 
provides an opportunity to explore the use of selective inhibitors to prevent nicotine/tobacco-
mediated oxidative stress and reduce HIV replication. In addition to CYP2A6, several CYP 
enzymes, such as CYP1A1 and CYP2A13, are expected to metabolize or activate other 
tobacco constituents (PAH, NNK, benzopyrene) into procarcinogens and produce oxidative 
stress in monocytes/macrophages, lymphocytes, astrocytes, and neurons (Figure 2). 
Therefore, examination of the role of these CYP enzymes would further aid in development 
of novel pharmaceuticals using selective inhibitors of these CYP enzymes. It is possible that 
specific anti-oxidants, such as vitamin C, vitamin E, melatonin, and taurine, which are very 
effective in alleviating oxidative stress-mediated damage in alcoholic liver disease [122],  
could also reduce nicotine/tobacco-mediated HIV pathogenesis. 
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The proposed mechanistic pathway involving the role of CYP enzymes in nicotine metabolism 
and/or activation of tobacco constituents, especially nicotine, which may lead to HIV 
pathogenesis. 
  
Figure 3: Role of CYP enzymes in nicotine metabolism  
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Tobacco/nicotine causes CYP-mediated oxidative stress [99] as well as inflammation 
through the release of inflammatory cytokines in monocytes/macrophages and astrocytes 
[123].These findings suggest that there is a cross talk between CYP and cytokines in HIV-
infected patients, which may occur through a common pathway in these cells. This hypothesis 
is strengthened by the fact that nicotine activates CYP1A1 in macrophages, which releases 
cytokines that further activate T-lymphocytes leading to chronic inflammation [123]. 
Furthermore, IL-6, an important proinflammatory cytokine, has been shown to be involved in 
the regulation of CYP3A4 [124]. Thus, the cross talk between CYP and cytokines is very 
important to study within the context of HIV pathogenesis.  
In conclusions, smoke extract/nicotine is known to enhance HIV replication in both T cells 
and macrophages, and therefore it would be expected to exacerbate HIV pathogenesis leading 
to accelerated disease progression. This chapter puts forward a novel hypothesis where CYP 
enzymes would be involved in increased oxidative stress that will in turn accelerate HIV 
replication. Since CYP enzymes are not abundantly present in T-cells, we believe that further 
studies using monocytes from in vitro, in vivo/ex vivo human samples from HIV-infected non-
smokers and smokers will substantiate the role of CYP pathway in HIV pathogenesis and 
neuroAIDS. These studies, if successful, will provide a novel and additional target for drug 
development for effective treatment of HIV infected smokers.    “The central hypothesis of 
this project is that, in monocytes and astrocytes, CYP and oxidative stress pathways play 
important role in tobacco-mediated cell toxicity and/or HIV replication. The hypothesis will 
be tested using the following four specific aims.    
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2.11. Specific aims 
In order to study our central hypothesis, we designed the following specific aims: 
Specific Aim 1: To determine the role of CYP2A6 in nicotine metabolism in HIV cell models, 
SVGA astrocytes (chapter 4).  
Specific Aim 2: To study CSC-mediated oxidative stress and cell death in U937 monocytes 
and HIV replication in primary macrophages (chapter 5) 
Specific Aim 3: To determine the levels of CYP enzymes, antioxidant enzymes (AOE), 
oxidative stress, cytokines, and HIV replication in blood plasma/monocytes isolated from a 
cohort of patients (Healthy, smokers, HIV and HIV smokers) (chapter 6) 
Specific Aim 4: To study the nicotine metabolism in plasma samples of smokers and HIV 
Smokers (chapter 7) 
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CHAPTER 3 
GENERAL MATERIALS AND METHODS 
3.1. Chemicals 
RPMI 1640, DMEM, gentamicin and FBS were all purchased from Mediatech Inc. 
(Manassas, VA). Qiagen RNeasy kit for RNA extraction and all prep DNA/RNA/Protein kit 
were brought from Qiagen (Valencia, CA). The dynabeads flowcomp human CD14 kit was 
purchased from Invitrogen (Grand Island, New York). Ficoll hypaque plus was obtained from 
GE Healthcare (Piscataway, NJ). Bicinchoninic Acid (BCA) assay kit was obtained from 
Thermo Scientific (Rockford, IL). Protease inhibitor cocktail, tryptamine, ritonavir, nicotine, 
ascorbic acid (vitamin C), were bought from Sigma-Aldrich (St. Louis, MO). Gene expression 
kits and primer probes (CYP1A1, Hs01054794_m1; Catalase, Hs00156308_m1; SOD1, 
Hs00533490_m1; CYP2A6, Hs0071162_m1; CYP2E1, Hs00559367_m1; CYP3A4, 
Hs00430021_m1; AHR, Hs00169233_m1; CYP1A2, Hs01070369_m1; CYP2A13, 
Hs00426372_m1; CYP2B6, Hs03044636_m1; CYP2C9, Hs00426397_m1; CYP2C19, 
Hs00426387_m1; CYP2D6, Hs_00164385_m1; CYP3A5, Hs0024417_m1; Nrf2, 
Hs00232352_m1; GAPDH 4333764F) were obtained from Applied Biosystems (Foster City, 
CA). Radioimmunoprecipitation assay (RIPA) buffer was obtained from Boston BioProducts, 
(Ashland, MA).  All primary and secondary antibodies were from Santa Cruz Biotechnology 
Inc. (Santa Cruz, CA). Luminata™ Crescendo western HRP substrate was obtained from 
EMD Millipore Corporation (Billerica, MA). Cigarette smoke condensate (CSC) was 
obtained from Murty Pharmaceuticals (Lexington, KY). HIV type 1 p24 antigen ELISA kit 
was bought from ZeptoMetrix Corporation (Buffalo, NY). Multiplex cytokine assay kit was 
purchased from Bio-Rad (Hercules, CA). Oxiselect oxidative DNA damage ELISA kit was 
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purchased from Cell Biolabs (San Diego, CA). EpiQuik™ 8-OHdG DNA Damage 
Quantification Direct Kit (Fluorometric) was obtained from Epigentek (Farmingdale, NY).  
Human-mCSF was obtained from Peprotech (Rockyhill, NJ). Dichlorofluoroscein diacetate 
(DCFDA) was purchased from Life Technologies (Grand Island, NY). Cotinine and NNK 
were bought from Toronto Research Chemicals (North York, On, Canada). Annexin V PE 
apoptosis detection kit was purchased from BD Bioscience (San Jose, CA). MTT salt was 
purchased from Sigma-Aldrich (St. Louis, MO). MTT reagent was prepared by dissolving 
MTT in cell culture medium to a final concentration of 0.1 mg/ml which was used to treat 
cells. AhR inhibitor CH223191 was purchased from Tocris (Minneapolis, MN). Nicotine, 
cotinine, trans-3-hydroxycotinine, nornicotine, norcotinine, nicotine-d4, and cotinine-d3 were 
purchased from Cerilliant Analytical Reference Standards (Round Rock, TX). HPLC-grade 
methanol, acetonitrile, ammonia solution, and formic acid were procured from Fisher 
Scientific (New Brunswick, NJ). An Exterra HPLC reverse phase MS C18 column was 
obtained from Waters Corporation (Milford, MA) and strong cation SPE cartridges from 
Agility DVB; Orochem Technologies (Lombard, IL). 
3.2. Cell culture and treatments 
All experiments were conducted in U937 human monocytic and SVG human 
astrocytic cell lines. U937 cell line was obtained from ATCC (Manassas, VA), and maintained 
in Roswell Park Memorial Institute (RPMI) 1640 media containing 10% fetal bovine serum 
(FBS) and 1% gentamicin. Cells were cultured at an initial concentration of 2 × 105 cells per 
ml and media was refreshed every two days. The human SVGA astrocytic cell line was 
generously provided by Dr. Avindra Nath. SVGA astrocytes were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum and 50 
μg/ml gentamycin. SVGA cells were cultured in 10 ml media in a 75 mm2 flask with an initial 
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amount of 0.8 × 106 cells and passaged every other day. Both U937 and SVGA cells were 
incubated at 37°C in the incubator containing 5% CO2, and passaged 2 to 3 times before using 
them for experiments. For treatment purposes, U937 cells were plated at a cell density of 0.8 
× 106 per mL and SVGA cells were seeded at 0.25 × 106 per mL in a 12-well plate the night 
before the treatment. Astrocytes were treated with 1 μM nicotine in triplicate in a 6-well plate 
containing 2 ml of medium. Each experiment was repeated 2-3 times. The nicotine 
concentration was optimized by using various concentrations of nicotine ranging from 0.25 – 
10 μM. The final concentration of nicotine that was used was 1 μM for subsequent 
experiments. This concentration was selected based on our preliminary observations that ≤0.5 
μM nicotine did not show significant induction of CYP1A1 and CYP2A6, whereas 
concentrations ≥2.5 μM were unable to further enhance CYP1A1 and CYP2A6 expression 
levels. In addition, nicotine treatments at ≤0.5 μM showed a very low amount of cotinine and 
NNK formation in SVGA astrocytes. For inhibition experiments, the cells were preincubated 
with 20 μM of tryptamine, a specific inhibitor of CYP2A6, for 30 min prior to nicotine 
treatment. U937 cells were treated with 50 μg/ml CSC (40mg/ml stock solution in DMSO) in 
triplicate in a 12-well plate containing 1 ml of medium. DMSO Vehicle control was employed 
to compare with effects of CSC treatment. For inhibition experiments, the cells were 
preincubated with 50 μM of AHR antagonist, 100 μM of Vit-C for one hour prior to CSC 
treatment. 
3.3. RNA extraction and quantitative reverse transcriptase-polymerase chain reaction  
 RNA was extracted from nicotine treated astrocytes using Qiagen RNeasy Kit as per 
manufacturer’s protocols. RNA (120 ng) from each sample was used for quantitative reverse 
transcription polymerase reaction (qRT-PCR) using a two-step TaqMan_Gene Expression Kit 
in an iCycler iQ system (Bio-Rad Laboratories, Hercules, CA). Relative fold expression of 
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the genes was calculated using the 2-ΔΔCt method with glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as the internal control. 
3.4. Western blot analysis 
 Total cell lysates were prepared in RIPA Buffer containing protease inhibitor and 
protein concentration was measured using a Pierce BCA protein assay kit. Protein (20 μg) was 
loaded on an acrylamide gel and electrophoresed, followed by transfer to a PVDF membrane. 
After blocking the membrane in 5% non-fat dry milk, it was incubated with primary antibody 
(1:1000 dilution) followed by secondary antibody (1:2000 dilution). The blot was visualized 
by LuminataTM crescendo western HRP substrate using the Alpha Innotech FluorChem HD2 
gel documentation system (Alpha Innotech, San Leandro, CA), and the densitometric data 
was analyzed using AlphaEase FC StandAlone software (version 6.0.0.14; Alpha Innotech). 
β-Actin was used as an internal loading control to normalize the expression of proteins. 
3.5. Measurement of Reactive Oxygen Species (ROS) 
 The production of ROS was measured by flow cytometry using dichlorofluoroscein 
diacetate (DCFDA). Briefly, the cells were treated with nicotine or CSC for different times in 
a 12-well plate. After treatment the cells were washed with PBS and incubated with 10 μM 
DCFDA in PBS for 30 min at 37°C. Then the cells were harvested and dissolved in 1 ml PBS 
to measure the DCF emission at 525 ± 20 nm by flow cytometer (BD Biosciences, San Jose, 
CA), and Mean Fluorescence Intensity (MFI) was measured and analyzed. 
 3.6. MTT cell viability assay 
 Cell viability test was performed in 12-well plates in triplicate, using MTT assay [3-
(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] in U937 monocytes. Cells 
from each well were centrifuged at 2000 rpm for 5 min to remove treatment medium. After 
washing once with PBS, cells of each well were incubated for 4 h in 5 ml flow tubes with 500 
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μl 0.2 mg/ml MTT solution in fresh media. After incubation the tubes were spun down and 
the formazan crystals formed were dissolved in 300 μl of DMSO. Then absorbance was 
measured at 570/630 nm on Biorad Benchmark Plus microplate spectrophotometer (Biorad, 
Hercules, CA) using the Microplate Manager 5.2.1 software.  
3.7. Annexin V apoptosis assay 
Annexin V apoptosis assay was performed in U937 monocytes to measure the effect 
of CSC on apoptosis. Briefly, media was removed and cells of each well were suspended in 
binding solution at a final concentration of 1 × 106 cells per ml, 100 μl of which was 
transferred into a 5 ml tube. Then, 5 μl PE and 5 μl 7-AAD were added to the 100 μl cell 
solution, followed by 15 min incubation at room temperature in darkness. For setting up 
compensation, the following controls were used: unstained, PE stained, 7-AAD stained tubes. 
After incubation, 400 μl binding solution was added to each tube and fluorescence was 
detected using a flow cytometer (BD Biosciences, San Jose, CA). Mean fluorescence intensity 
(MFI) was measured and analyzed. 
3.8. Preparation of standard stocks and spike solutions 
For measurement of nicotine, cotinine and NNK in astrocytes, calibration curve and 
quality control dilutions were prepared and processed as follows: calibration curve standards 
(0.33-663.14 ng/mL for nicotine and 0.11-663.14 ng/mL for both cotinine and NNK) and 
quality control standards (0.33-435.26 ng/mL for nicotine and 0.11-435.26 ng/mL for cotinine 
and NNK). Spike standards dilutions 0.33-663.14ng/mL for nicotine and 0.11-663.14 ng/mL 
for both cotinine and NNK were made in astrocyte cell matrix samples from untreated cells. 
The internal standard, ritonavir (15 μg/mL) was prepared in 20% methanol. All the spike 
standards were stored in a freezer at -800C until further analysis. 
31 
 
For measurement of nicotine and its metabolites in plasma samples of HIV-negative 
smokers and HIV-positive smokers, nicotine, cotinine, trans-3-hydroxycotinine, nornicotine, 
norcotinine, and the internal standards (ISs) (deuterated nicotine-d4 and cotinine-d3) were 
dissolved at a concentration of 1 mg/ml in 80% methanol (v/v). To prepare the standard curve, 
20 ml of a working solution at different concentrations (12.60 to 5.04, 2.02, 0.76, 0.25, 0.076, 
0.027, and 0.013 mg/ml) was spiked into 500 ml plasma from a nonsmoker (blank) to obtain 
calibration 
standards of decreasing concentrations (504.0, 201.6, 80.6, 30.6, 10.1, 3.03, 1.06, and 0.53 
ng/ml). Similarly, the quality control (QC) samples were independently prepared at four 
concentrations (504.0, 80.6, 3.03, and 1.06 ng/ml) in plasma from nonsmokers. 
3.9. Determination of CD4 count and viral load 
Whole blood was drawn in EDTA tubes from each subject who qualified for the study 
followed by confirmation of HIV status and a CD4 count by flow cytometry (Becton 
Dickenson, San Jose, CA). The viral load of HIV-infected individuals was determined in 
plasma using quantitative reverse transcriptase polymerase chain reaction (RTPCR) (Roche 
Amplicor System, Biocentric) at Pasteur Institute, Yaounde, Cameroon. The remaining 
sample of plasma from each patient was frozen immediately and shipped on dry ice to the 
University of Missouri-Kansas City for analysis of cytokines and determination of markers of 
oxidative stress and CYP enzymes. 
3.10. Preparation of peripheral blood mononuclear cells and monocytes 
For the peripheral blood mononuclear cells (PBMC) isolation, gradient centrifugation 
technique was employed using ficoll hypaque plus. From the PBMCs, monocytes were 
isolated using dynabeads flowcomp human CD14 kit (Invitrogen, Grand Island, New York). 
The monocytes were immediately lysed using RLT buffer provided in the All prep 
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DNA/RNA/Protein kit (Qiagen, Valencia, CA). The lysed samples were frozen and shipped 
to the University of Missouri-Kansas City for further studies. 
3.11. CSC treatment and HIV replication in primary macrophages 
Primary monocytes were differentiated into macrophages and infected with HIV, prior 
to treatment with CSC, using previously reported protocol [125, 126]. Briefly, PBMCs were 
plated in T-75 flask and non-adherent cells were removed after 1 h at 37 °C. Cells were 
cultured for 6-8 days in media containing human mCSF to facilitate macrophage 
differentiation. Mature macrophages were collected and activated by treating with polybrene 
(2 μg/ml) for 30 min before HIV infection. Macrophages were infected with TCID50 of HIV 
for 2 h and cultured in 6-well plates (1 million/well) for 6 days. Cell supernatant was collected 
on days 0, 3, and 6 to analyze p24 levels. Starting day 7, HIV-infected macrophages were 
treated, once daily, with 25 ug/ml CSC or equivalent amount of DMSO. During the treatment 
period, one-half milliliters of fresh media was added daily to each well to avoid cytotoxicity. 
Supernatant collected on day 11 (24 h after last treatment) was analyzed for viral load using 
the HIV type 1 p24 antigen ELISA. 
3.12. Multiplex cytokine assay 
The protein levels of various pro-inflammatory cytokines/chemokines; RANTES, IL-
6, IL-8, monocyte chemotactic protein-1 (MCP-1), IL1-β, and TNF-α were measured using 
multiplex cytokine assay kit (Bio-Rad, CA, USA) as per the manufacturer’s protocol. Briefly, 
plasma samples were centrifuged at 3000 g for 10 min and the supernatants were diluted with 
three volumes of sample diluent. Next, 50 µl of each sample and standards were mixed with 
magnetic beads and incubated on a shaker at room temperature for 30 min. The beads were 
washed and 25 µl of detection antibody was added to each well followed by incubation for 30 
min at room temperature. Furthermore, the samples were washed and incubated with 50 μl 
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streptavidin-PE conjugate for 10 min. Finally, 125 μl of the assay buffer was added and the 
samples were analyzed using Biorad Bioplex HTS (Bio-Rad, CA, USA). The concentrations 
of the cytokines were determined with Bio-plex manager 5 using 5-PL statistics using standard 
curve.   
3.13. Quantitation of 8-hydroxy-2′-deoxyguanosine content 
The concentration of 8-Hydroxy-2′-deoxyguanosine (8-OHdG) was determined in the 
plasma samples using oxiselect oxidative DNA damage ELISA kit according to 
manufacturer’s instructions. Briefly, after diluting the plasma 50:50, the samples along with 
the 8-OHdG standards provided in the kit were added to an 8-OHdG/BSA conjugate on a 
preabsorbed EIA plate. After incubation for an hour, an anti-8-OHdG primary antibody was 
added, followed by an HRP conjugated secondary antibody. After incubation with substrate 
solution for an hour, the reaction was terminated using the assay “stop solution” and the 
absorbance was measured at 450 nm using a plate spectrophotometer. The 8-OHdG content 
of the DNA in monocytes was estimated using EpiQuik™ 8-OHdG DNA Damage 
Quantification Direct Kit (Fluorometric) following manufacturer’s instructions. It is a highly 
sensitive fluorometric technique to detect 8-OHdG by using as low as 300 ng of unmodified 
DNA. Initially, DNA is bound to the wells that have a high DNA binding affinity. Then the 
8-OHdG present in the samples is detected by using capture and detection antibodies. The 
enhancer solution is used to enhance the signal followed by quantification by reading the plate 
in a fluorescence microplate reader equipped with an excitation filter of 530 nm and emission 
filter of 590 nm. The amount of 8-OHdG in each sample is calculated by using a standard 
curve generated from a series of standards. 
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3.14. DNA/RNA/protein isolation  
Isolation of DNA, RNA, and protein was done from the lysed samples using the All 
prep DNA/RNA/Protein QIAGEN Kit by following the manufacturer’s instructions. Briefly, 
the lysed sample was homogenized and transferred to the DNA column and the flow through 
was transferred to RNA column for obtaining RNA. The flow through from RNA column was 
used to precipitate protein using APP buffer. The RNA and DNA were quantified using UV 
spectrophotometer by measuring their absorbance at 260nm. The protein was quantified using 
BCA protein assay kit (Thermo scientific, Rockford, IL). However, the quantity of protein 
from the some samples, especially HIV positive smokers and HIV positive nonsmokers, were 
very low and insufficient for complete analysis.    
3.15. Statistical analysis 
Statistical analysis for in vitro studies was performed to determine mean ± SD and a 
student t-test was applied to determine p values. A p value of ≤ 0.05 was considered 
significant. For ex vivo study, demographic variables (age, sex ratio) were summarized using 
descriptive statistics. All outcome variables were summarized as the mean plus or minus the 
standard error. Comparisons among the four groups were conducted using one way ANOVA 
with no corrections for multiple comparisons. All tests were two-sided and results that were 
statistically borderline significant at p≤0.1 (#) and significant at p ≤0.05 (*) and ≤0.01 (**). 
A two-way ANOVA was done to determine whether they interact synergistically or additively 
in HIV positive smokers. All analyses were performed using IBM SPSS version 21. 
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CHAPTER 4 
AN LC-MS/MS METHOD FOR CONCURRENT DETERMINATION OF NICOTINE 
METABOLITES AND THE ROLE OF CYP2A6 IN NICOTINE METABOLITE 
MEDIATED OXIDATIVE STRESS IN SVGA ASTROCYTES 
4.1. Introduction 
Recent studies by Jin et al have shown that CYP2A6 is the most abundantly expressed 
CYP (36% of the total CYPs) in the U937 macrophage cell line [96]. Since macrophages are 
critical HIV reservoirs and migration of these cells into the brain may result in neuroAIDS 
[90], Jin studied the role of CYP2A6 in nicotine metabolism and nicotine-mediated oxidative 
stress in U937 macrophages [128]. Results from those studies clearly demonstrate a role for 
CYP2A6 in nicotine metabolism and associated oxidative stress in these cells. Nicotine can 
cross the blood-brain barrier and exert its toxic effects on various brain cells, including 
astrocytes. Therefore, in the present study we examined the role of CYP2A6 in nicotine 
metabolism in astrocytes and its involvement in oxidative stress. However, in order to study 
nicotine metabolism in astrocytes, it was necessary to develop an extremely sensitive 
analytical technique to measure nicotine metabolites. In recent years, tandem triple 
quadrupole linear ion Qtrap mass spectrometry (LC-MS/MS) method has been increasingly 
used for the measurement of nicotine and its metabolites in urine samples and other cell lysates 
[128-132]. Since the level of CYP2A6 enzyme is much lower in astrocytes than most other 
cells, we developed a relatively more sensitive LC-MS/MS method to determine nicotine 
metabolites.  
Nicotine, the major bioactive constituent of tobacco, is metabolized into cotinine and 
other less abundant metabolites, primarily by liver CYP2A6 and to some extent by CYP2B6 
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and CYP2D6 [19]. Some of the nicotine and cotinine metabolites are further metabolized by 
CYP2A6 into procarcinogenic compounds, including nicotine-derived nitrosamine ketones 
(NNK). For example, nicotine is directly metabolized by 2’hydroxylation to aminoketone, 
which is converted into the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
[127]. In addition, nasal and lung CYP2A13 are involved in the biotransformation of NNK 
into a carcinogen [19, 21, 128]. CYP2A6-mediated nicotine metabolism and the subsequent 
activation of reactive metabolites into procarcinogens and formation of reactive oxygen 
species (ROS) have been shown to be involved in liver damage and lung/pancreatic cancers 
[19, 128-130]. Nicotine and NNK have also been demonstrated to generate oxidative stress in 
microglia [23], neurons [25], and white blood cells [24]. However, the mechanism by which 
nicotine induces oxidative stress in these cells has not been determined. We hypothesize that 
CYP2A6 plays a critical role in nicotine metabolism-mediated oxidative stress in SVGA 
astrocytes. Therefore, our specific aim is to determine the role of CYP2A6 in nicotine 
metabolism-mediated oxidative stress in SVGA astrocytes.  
4.2. Development of an analytic method for the measurement of nicotine, cotinine, and 
NNK in SVGA astrocytes 
4.2.1. Extraction procedures and sample preparation 
The liquid-liquid extraction technique was optimized for method development and 
subsequently used for SVGA astrocyte sample analysis. Astrocyte samples were thawed and 
200 µL was aliquoted followed by addition of 25 µL of 15.0 µg/mL freshly prepared internal 
standard stock. Then, 30 µL of 30 % v/v ammonia solution was added to the samples and 
vortexed for 1 minute. The samples were extracted by adding 1000 µL of ethyl acetate then 
vortexed for 2 minutes followed by centrifugation at 12,000 rpm at 40C for 45 min. 
Subsequently, 850 µL of the organic layer was withdrawn and evaporated to dryness using a 
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Speed-Vac at 40C for 60 minutes. The dried samples were redissolved in 200 µL of mobile 
phase and vortexed for 1 minute. To prepare samples for LC-MS/MS analysis 200 µL 
calibrator, control, and nicotine-treated astrocytes, 25 µL working internal standard, and 30 
µL of 30% ammonium hydroxide were mixed and evaporated to dryness at 40°C and the 
samples were reconstituted in 0.2 mL of mobile phase for chromatography. The final 
concentration of working internal standard was 1.5 µg/mL. 
4.2.2. HPLC and mass spectrometry  
HPLC and mass spectrometry were performed with modifications of our  previously 
described method [131]. Briefly, complete column separation was performed  on a Hybrid 
particle organosiloxane Xterra reverse phase carbon 18 HPLC column (50 mm x 4.6 mm (i.d.); 
5µm bead size; 50-Å pore size; Waters Corporation) using a mobile phase consisting of 250 
ml HPLC water, 750 mL acetonitrile and 1 mL formic acid (88%). Sample injection volume 
used was 15 μL and the total analytical run time was 4 min at a flow rate 0.3 mL/min. The 
HPLC system consisted of a high-pressure liquid pump and autosampler (LC-20AD and SIL-
20AST, Shimadzu USA) and a tandem mass spectrometer (API 3200; AB Sciex, Sciex, Faster 
City, CA). The HPLC column was connected directly to the heated nebulizer source of the 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) system and the experiment 
was performed under conditions as described earlier [131].  
The mass spectrometry parameters for LC-MS/MS were optimized as follows: curtain 
and CAD gases (20 psi), gas 1 (45 psi), gas 2 (50 psi), ion spray voltage (4800 V), ionization 
source temperature (400C), and dwell time (200 milliseconds). The de-clustering potentials 
for nicotine, cotinine, and NNK were fixed to 80, 40, and 40 V, respectively, while collision 
energies for nicotine, cotinine, and NNK were adjusted to 26, 28, and 15 V, respectively. The 
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optimization of MS/MS mass spectra for nicotine, cotinine, NNK, and ritonavir was 
performed by MRM positive mode using ion mass transitions of m/z 163.2/130.1 for nicotine, 
m/z 177.4/98.3 for cotinine, m/z 208.4/122.1 for NNK, and 721.6/296.4 for ritonavir (Table 
1).  
Table 1: LCMS/MS method calibration in SVGA astrocytes 
Compounds MRM 
Transitions 
(m/z) 
Retention 
time 
(min) 
Correlation  
coefficient 
equation 
(y=mx+c) 
Coefficient 
of 
determination  
Calibration 
curve 
range 
(ng/ml) 
LOQ 
(ng/ml) 
Nicotine 163.2→130.1 1.79 y = 175.98x 
+140.36 
R² = 0.9998 0.33 - 
663.14 
0.33 
Cotinine 177.4→98.3 1.89 y = 511.19x - 
16.834 
R² = 0.9997 0.11 - 
663.14 
0.11 
NNK 208.4→122.1 2.1 y = 215.68x 
+21.742 
R² = 0.9935 0.11 - 
663.14 
0.11 
 
4.2.3. Quantification 
The concentration of each analyte was determined by calculating the ratio of each 
analyte peak response relative to its respective internal standard peak response. Results from 
calibration analyses were used to create a calibration curve using simple linear regression 
analysis. The slopes and intercepts from the resulting calibration equations were used to 
calculate control and specimen results (Table 1). The calibration curves were linear within the 
concentration range of 0.11-663.1 ng/ml for cotinine (r2 = 0.9998) and NNK (r2 = 0.9935) 
and 0.3-663.1 ng/ml for nicotine (r2 = 0.9963). 
The LC-MS/MS MRM chromatograms of nicotine, cotinine, NNK, and ritonavir in 
SVGA astrocytes showed no interference in the blank at the retention time of nicotine, 
cotinine, NNK, and ritonavir (Fig. 4). Similarly, there was a small base line peak at the lower 
level of quantification of all the analytes, suggesting a high signal to noise ratio (S/N). In 
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addition, the results suggested that this LC-MS/MS method is extremely sensitive, rapid, and 
robust for quantifying these analytes at very low concentration levels (0.3 ng/mL for nicotine 
and 0.11 ng/mL for both cotinine and NNK). Finally, the peak response was directly 
proportional and uniform to concentrations ranging from the lower limit to the upper limit of 
quantification for all the analytes, demonstrating that the results are highly reproducible 
(Figure 4). 
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Figure 4: Chromatograms of extracted cotinine samples 
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Figure 5: Chromatograms of extracted nicotine samples 
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Figure 6: Chromatograms of extracted NNK samples 
LC-MS/MS MRM chromatograms of cotinine, nicotine, and NNK along with the internal 
standard ritonavir in SVGA astrocytes. The level of the blank, the lower limit of 
quantification, and upper limit of quantification for nicotine (top three panels), cotinine 
(middle three panels), and NNK (bottom three panels) are shown in the left panels. Ritonavir 
is shown in the right column except for the blank for each compound. The intensity (cps) is 
presented in the Y-axis and time (min) is presented in the X-axis.  The standard linear curve 
of nicotine, cotinine, and NNK are shown from top to bottom in the right side of the 
chromatograms. 
43 
 
4.2.4. Recovery, precision, and accuracy 
Recovery of samples was analyzed by preparing six replicates of each of two standard 
concentrations in human astrocytes. Recovery was performed and reported as the percentage 
difference between extracted and non-extracted samples as previously described [131, 132]. 
Precision and accuracy were evaluated by analyzing calibration curve and quality control 
(QC) samples. Accuracy was determined by analyzing six replicates of each QC sample. 
Accuracy was reported as the percentage difference between the mean and the nominal 
concentrations divided by the nominal concentration. Precision was reported using the 
coefficient of variation (CV) (standard deviation/mean concentration) multiplied by 100. The 
limit of quantitation was optimized for each analyte, 0.33 ng/mL for nicotine and 0.11 ng/ml 
for both cotinine and NNK. The recoveries, accuracy, precision, and coefficient of variation 
(CV) of nicotine, cotinine, and NNK in astrocytes are presented in Table 2. The recoveries for 
nicotine, cotinine, and NNK were 97.5%, 85.9%, and 78.4%, respectively. The accuracies for 
nicotine, cotinine, and NNK were in the range of 82-114%, 89-118%, and 86-117%, 
respectively. The coefficients of variation for nicotine, cotinine, and NNK were within 14.6%, 
11.9%, and 17.0%, respectively. The limits of quantitation accuracy were 115.2% for nicotine, 
96.5 for cotinine and 83.3 for NNK and precision were within 14.9% for nicotine, 4.5% for 
cotinine and 9.3% for NNK (Table 2).  
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Table 2: Validation and Stability Experiment in SVGA astrocytes  
 
 
 
 
  
  Nicotine Cotinine 
Nitrosamine ketone 
(NNK) 
 
Nominal 
Conc 
(ng/ml) 
Calculated 
Conc (ng/ml) 
% CV 
(±) 
Calculated 
Conc (ng/ml) 
% CV  
(±) 
Calculated 
Conc (ng/ml) 
% CV 
(±) 
CC-1  0.11   0.105 ± 0.005 4.5 0.091 ± 0.016 17.3 
CC-2  0.33 0.28±0.041 14.9 0.32 ± 0.0091 2.8 0.29 ± 0.043 11.9 
CC-3  1.09 1.12 ± 0.03 2.1 1.18 ± 0.09 7.6 1.25 ± 0.16 14 
CC-4  10.86 12.0 ±1.135 9.4 12.02 ± 1.10 9.6 11.02 ± 0.05 0.5 
CC-5  36.21 31.98 ±3.89 12.5 35.65 ± 0.89 2.5 32.65 ± 3.51 10.7 
CC-6  103.45 119.21 ±17.1 14.1 111.21 ± 7.30 6.5 121.21 ± 19.3 16 
CC-7  258.62 278.34 ±18.63 6.6 240.34 ± 19.3 8 235.43 ± 22.92 9.9 
CC-8  431.04 420.59 ±14.1 3.4 430.57 ± 5.0 1.1 475.59 ± 50.10 10.2 
CC-9  663.14 689.92 ±21.1 3 642.36 ± 5.97 8.7 672.39 ± 95.59 14.3 
QCV-1  0.11   0.091 ±0.016 17.3 0.091±0.0082 9 
QCV-2  0.33 0.28 ±0.041 9.6 11.7 ± 1.9 9 12.2 ± 2.6 1.2 
QCV-3  10.97 11.03 ± 0.06 0.6 10.4 ± 0.1 8.2 10.49 ±0.63 9.9 
QCV-4  36.56 37.59 ± 4.1 13.8 340.9 ± 6.6 9.8 35.9 ± 21.7 9.3 
QCV-5  104.46 120.9 ± 13.1 10.5 118.3 ± 17.5 14.7 119.3 ± 23.5 19.6 
QCV-6 435.26 470.8 ± 19.7 4.1 479.7 ± 34.1 7.2 467.7 ± 35.1 7.4 
STQC-1  0.11   0.091 ±0.016 17.3 0.095 ± 0.0082 8.6 
STQC-2  0.33 0.28±0.041 9.6 0.27 ± 0.04 18.5 0.36 ± 0.016 4.4 
STQC--3  10.97 12.2 ± 2.6 1.2 10.4 ± 0.1 0.96 10.49 ± 0.63 9.9 
STQC--4  36.56 31.98±3.89 12.4 34.9 ± 4.6 13.4 35.9 ± 1.7 5.9 
STQC--5  104.46 124.9 ± 23.1 18.5 100.4 ± 0.1 1.2 96.3 ± 13.5 14.03 
STQC--6 435.26 465.8 ± 17.9 3.8 479.7 ± 34.1 7.5 473.7 ± 31.1 6.5 
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4.2.5. Stability analysis 
In order to evaluate the stability of nicotine, cotinine, and NNK in astrocytes, we 
prepared six individual specimens of SVGA astrocytes containing nicotine, cotinine, and 
NNK of each of six concentration levels and we assessed analyte stability at different 
temperatures (ambient, 4°C, and -80°C), after  34 days. The mean results from six replicates 
for each replicate, temperature, and concentrations were compared with the standard 
calibration values and expressed as percentages of accuracy and coefficient of variation (CV). 
The results are shown in Table 2. 
4.2.6. Statistical analysis  
Statistical analysis was performed to determine mean ± SD and a student t-test was 
applied to determine p values. A p value of ≤ 0.05 was considered significant. 
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4.3. Results  
4.3.1. Induction of CYP1A1 and CYP2A6 by nicotine in SVGA astrocytes 
First, the basal levels of mRNA of CYP enzymes were determined in the SVGA 
astrocyte cell line. Interestingly, the relative mRNA expression levels of CYP2A6 and 
CYP1A1 were 56% and 43% of the total CYPs’ mRNA expression in SVGA. The remaining 
1% accounted for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, 
and CYP3A5. Furthermore, exposure of astrocytes to nicotine resulted in significant up 
regulation of CYP1A1 mRNA at 1h (150%) and CYP2A6 mRNA between 1 and 6 h (~200%) 
(Figure 7). Although there was no change in CYP1A1 mRNA level at later time points, 
CYP2A6 mRNA was down regulated at 12 h nicotine treatment. To ensure that the mRNA 
induction was consistent with the protein induction, we measured levels of CYP1A1 and 
CYP2A6 proteins (Fig. 8). Nicotine induced levels of CYP1A1 that were  170%  relative to 
that of control CYP1A1 at 3 h, as well as levels of CYP2A6 that were 140% and 230%  relative 
to that of control  at 1 h and 3 h, respectively. Similar to CYP2A6 mRNA, nicotine down 
regulated CYP2A6 protein at 12 h. Our findings that CYP2A6 is the most abundant CYP in 
astrocytes and that even higher levels of expression are induced by nicotine, suggest its 
important role in nicotine metabolism and nicotine metabolite-associated oxidative stress in 
astrocytes.  
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The SVGA astrocytes were treated with 1 µM nicotine for 0.5, 1, 3, 6, and 12 h. The 
percentage mRNA levels were calculated using qRT-PCR, with 100% expression normalized 
for the control at every time point. Expression of both the CYP genes was normalized to 
glyceraldehyde 3-phosphate dehydrogenase. In the above figures, the X-axis represents 
treatment time (hours) and Y-axis represents % mRNA expression. * Represents p ≤ 0.05 
compared to respective controls. 
Figure 7: Effect of nicotine on mRNA expression of CYP1A1 and 
CYP2A6 in SVGA astrocytes 
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The SVGA astrocytes were treated with 1 µM nicotine for 0.5, 1, 3, 6, and 12h and the protein 
was isolated. The percentage protein expression was calculated by quantifying the 
immunoblots, with 100% expression normalized to the untreated cells (control) at every time 
points. Expression of CYP1A1 and CYP2A6 was normalized against β-actin. In the above 
figures, X-axis represents treatment time (hours) and Y-axis represents % protein expression. 
* Represents p ≤ 0.05 compared to respective controls. 
Figure 8: Effect of nicotine on levels of protein expression of CYP1A1 
and CYP2A6 
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4.3.2. Metabolism of nicotine by CYP2A6 in SVGA astrocytes 
The metabolism of nicotine in SVGA astrocytes was analyzed using the LC-MS/MS 
method as described in Materials and Methods and depicted in Figure 9. Figure 10 shows 
representative MRM chromatogram profiles of nicotine, cotinine, and NNK. Figure 11 shows 
the kinetic profile of cotinine and NNK formation. A very low amount of cotinine (5-7 ng/ml) 
and NNK (1-3 ng/ml) was detected in astrocytes. To ensure that CYP2A6 is involved in 
nicotine-metabolism, cotinine and NNK levels were measured in the presence of tryptamine, 
a CYP2A6 specific inhibitor [133]. Tryptamine decreased cotinine formation by 
approximately 80% at both 1 h and 2 h, whereas NNK formation was reduced by 60% at 1h 
and was almost completely abolished at 2 h (Fig. 12). 
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   Figure 9: Schematic of nicotine metabolism by CYP2A6 
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Figure 10: Representative MRM chromatogram profiles of nicotine, 
cotinine, and NNK 
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Metabolism of nicotine in SVGA astrocytes. The cells were incubated with 1 µM nicotine for 
0.5, 1, 2, and 4h and cotinine and NNK levels were measured using the LC-MS/MS method. 
A. Diagram depicting the metabolism of nicotine and the metabolic products cotinine and 
NNK. B. Representative MS2 profiles of nicotine, cotinine, and NNK with parent molecular 
ion transition and its fragmentation pattern in MS2 of nicotine, cotinine, and NNK. C. Kinetic 
profiles of cotinine and NNK formation. In the figures, X-axis represents the treatment time 
(hours) and Y-axis represents concentration of cotinine and NNK. The graphs were plotted as 
mean ± SD using three replicates for each time point. 
  
Figure 11: Kinetic profile of cotinine and NNK formation 
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Effect of tryptamine (20 µM), a CYP2A6 selective inhibitor, on the formation of cotinine and 
NNK in 1 µM nicotine treated SVGA astrocytes. In the figures, percent of cotinine and NNK 
formation are presented in Y-axis. The time points of nicotine treatment are presented on the  
X-axis. The graphs were plotted as mean ± SD using three replicates for each time point. * 
Represents p ≤ 0.05 compared to respective controls.   
Figure 12: Effect of Tryptamine on Cotinine and NNK formation 
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4.3.3. Formation of ROS by CYP2A6-mediated nicotine metabolism in SVGA 
astrocytes  
We measured the generation of ROS in nicotine-treated SVGA astrocytes using flow 
cytometry. Figure 13 shows the mean fluorescence intensity (MFI) of ROS formation in 
nicotine-treated astrocytes from 15 - 120 min. The results showed a slight decrease in MFI at 
15 min, a peak at 30 min, and then a decrease at 90 and 120 min. To ensure that ROS is formed 
as a result of nicotine metabolism by CYP2A6, we pre-incubated astrocytes with CYP2A6-
specific inhibitor tryptamine. The results showed that tryptamine significantly quenched the 
formation of ROS, suggesting the role of CYP2A6-mediated nicotine metabolism in ROS 
formation. Since our results showed a decrease in the levels of ROS at later time points (Fig. 
13), we determined the expression level of the antioxidant enzymes superoxide dismutase 
(SOD) and catalase at 1, 3, 6, and 12 h (Fig. 14). The results showed that nicotine significantly 
induced SOD, especially at 3 h (~200%). In contrast, nicotine significantly reduced the 
expression of catalase at 1 and 12 h.  
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The ROS production was measured using a flow cytometer from untreated and 1 µM nicotine 
treated cells from 15, 30, 60, 90, and 120 min. A. Bar graphs representing mean fluorescence 
intensity (MFI) from control and nicotine-treated cells. MFI is presented in Y-axis and the 
time points of nicotine treatment are presented in X-axis. The graphs were plotted as mean ± 
SD from three replicates. B. Effect of 20 µM tryptamine, a CYP2A6 selective inhibitor on the 
formation of oxidant contents in untreated and 1 µM nicotine treated cells for 30 min. * 
Represents p value ≤ 0.05 and # represents p value ≤ 0.1. 
Figure 13: Role of CYP2A6 in nicotine mediated oxidative stress in 
SVGA astrocytes 
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The SVGA astrocytes were treated with 1 µM nicotine for 1, 3, 6, and 12h. The percentage 
mRNA levels of both the enzymes were calculated using qRT-PCR, with 100% expression 
normalized to the control. Expression of both the genes was normalized against 
glyceraldehyde 3-phosphate dehydrogenase. X-axis represents the treatment time and Y-axis 
represents % mRNA expression. * Represents p value ≤ 0.05 and # represents p value ≤ 0.1. 
Figure 14: Effect of 1 µM nicotine on the mRNA expression of 
SOD and catalase in SVGA astrocytes 
57 
 
4.4. Discussion 
4.4.1. Abundance of CYP1A1 and CYP2A6 in SVGA astrocytes 
The current study demonstrates very high levels of CYP1A1 (43%) and CYP2A6 
(56%) in SVGA astrocytes, which account for only 3% and 0.1% of the total CYPs, 
respectively, in the liver [134]. Similarly, our previous studies revealed that CYP2A6 is the 
second most abundant (30%)  CYP enzyme in the U937 macrophage cell line. [96]. It should 
be noted that, in many respects, macrophages are similar to microglia in the CNS. Although 
CYP2A6 is the most abundant CYP in SVGA astrocytes, its expression level in SVGA 
astrocytes is approximately 10-fold lower than in U937 macrophages. However, the level of 
CYP1A1 mRNA in astrocytes was comparable to that of U937 macrophages. This is the first 
report that demonstrates the presence of CYP2A6 and CYP1A1 in SVGA astrocytes. CYP2A6 
is the major enzyme involved in the metabolism of nicotine, whereas CYP1A1 is responsible 
for the metabolism/activation of other tobacco constituents, such as polycyclic aromatic 
hydrocarbons (PAH) [135].  
4.4.2. Induction of CYP2A6 by nicotine in SVGA astrocytes 
This is the first report that demonstrates the induction of CYP1A1 and CY2A6 by 
acute nicotine treatment. To our knowledge, there is no report in the literature that 
demonstrates the induction of CYP2A6 and CYP1A1 by nicotine in hepatocytes or lungs. 
Similarly, our recent study did not show an induction of CYP1A1 and CYP2A6 by nicotine 
in U937 macrophages [131]. It is possible that CYP1A1 and CYP2A6 are inducible in 
astrocytes but not in hepatocytes or macrophages because their levels in astrocytes are much 
lower than that of hepatocytes [134] and macrophages [96]. Thus, CYP2A6 and CYP1A1 in 
macrophages and liver may already be at maximal expression levels. Alternatively, the 
inducibility of CYP1A1 and CYP2A6 is a tissue-specific phenomenon. This is quite possible 
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as other CYP’s have been demonstrated to be inducible in a tissue-specific manner. An earlier 
study showed an induction of rat CYP2B1 in certain regions of the brain upon chronic nicotine 
treatment [136]. Similarly, a recent study showed that while nicotine does not induce hepatic 
CYP2B1, it induces CYP2B1 in the frontal cortex, brain stem, and olfactory tubercle [44]. 
Furthermore, chronic nicotine treatment in African green monkeys increased CYP2B6 
(homologous to rat CYP2B1) in astrocytes and neurons (frontal cortex, caudate, thalamus) 
whereas hepatic levels of CYP2B6 were unchanged [45]. These reports are consistent with 
another finding that smokers have higher levels of CYP2B6 in the brain [43], which may 
increase the metabolism of certain drugs such as bupropion and propofol, and lead to a 
decreased response to these drugs.  
We speculate that nicotine induces CYP1A1 and CYP2A6 in astrocytes through 
nicotine metabolism-mediated oxidative stress. Our speculation is based on a recent report 
which demonstrated that increased CYP2A6 expression is associated with increased CYP2E1-
mediated alcohol metabolism and oxidative stress in the liver [137]. Additional observations 
suggest that oxidative stress mediates CYP2A6 induction by alcohol in U937 cell line [95]. 
Although the mechanism by which nicotine induces CYP2B1 or CYP2B6 is not clear, it has 
been shown that nicotine induces CYP2B1/CYP2B6 through transcriptional regulation, and 
in this way  enhances its own metabolism [44]. In contrast to CYP2B6 induction, another 
study suggests that a non-transcriptional mechanism, perhaps a post-translational 
modification, is responsible for the induction of CYP2D6 and CYP2E1 by chronic nicotine 
treatment [138]. 
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4.4.3. Development of LC-MS/MS method for concurrent measurements of nicotine, 
cotinine, and NNK in SVGA astrocyte 
We have demonstrated a simple, rapid, highly sensitive and reproducible LC-MS/MS 
analytical technique for concurrent determination of nicotine, cotinine, and NNK in SVGA 
astrocytes. Nicotine, cotinine, and NNK achieved requisite recovery by a simple liquid-liquid 
extraction procedure. This extraction method is efficient, simple, fast, sensitive, and cost-
effective and has been developed for the first time for astrocytes. We and other investigators 
have previously described   LC-MS/MS methods in other cell types that because of low 
sensitivity were inadequate to determine the intracellular concentrations of nicotine, cotinine, 
and NNK in SVGA astrocytes [131, 139-142]. Our previously reported LC-MS/MS method 
for nicotine, cotinine, and NNK in U937 macrophages [131] was not sufficiently sensitive to 
estimate these analytes in SVGA astrocytes, because astrocytes express a much lower level of 
CYP2A6 than macrophages. Nicotine metabolism in astrocytes is much lower than the 
macrophages, thereby the conversions of nicotine to cotinine and NNK levels are very low in 
SVGA astrocytes. The current method has been successfully applied for determination of 
intracellular levels of nicotine, cotinine and NNK in astrocytes. This is a very important step 
towards the determination of very low levels of cotinine and NNK in brain samples, especially 
in smokers (ex-vivo study), because these compounds may be associated with increased 
oxidative stress and astrogliosis leading to neuronal damage.   
4.4.4. Nicotine metabolism by CYP2A6 in SVGA astrocytes 
The nicotine metabolic profile obtained from SVGA astrocytes is different from those 
obtained with U937 macrophages, in which cotinine and NNK formation was relatively high 
and achieved a peak at 2-4h [131]. In addition, nicotine was metabolized rapidly (within 30 
min) in macrophages [131], whereas the nicotine concentration was decreased by only 25% 
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in 4h in astrocytes (data not shown). These results are consistent with the fact that astrocytes 
express much lower level of CYP2A6 than do macrophages. 
Several CYP enzymes such as CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, 
CYP2E1, CYP2F1 and CYP4B1 [143] are known to metabolize nicotine to cotinine. 
However, CYP2A6 plays a major role in metabolizing nicotine to cotinine (~80%) and NNK, 
as well as to some extent in activating NNK into procarcinogens [144, 145]. CYP2A13 is 
another isoform of the CYP2A family which is known to activate NNK into procarcinogens, 
and is expressed at very high levels in nasal mucosa, lungs, and trachea [146].  However 
CYP2A13 was not detected in astrocytes and other nicotine-metabolizing CYPs were present 
at very low levels (data not shown). CYP2A5, a homologue of human CYP2A6, is the major 
enzyme involved in nicotine metabolism in mouse [147]. Similarly, CYP2B1 and CYP2B6 
are present at high levels in brain and they are further induced by nicotine [44, 45], which also 
correlates with a higher CYP2B6 level in the brains of smokers [43]. However, there has been 
no characterization of the role of CYP enzymes in nicotine metabolism in the brain (astrocytes 
or neurons). Using SVGA astrocytes as a model cell line, our study provides the first evidence 
of nicotine metabolism by CYP2A6 in the brain.  
4.4.5. Nicotine metabolism-mediated oxidative stress in SVGA astrocytes 
The increase in nicotine metabolism-mediated ROS formation in SVGA astrocytes is 
relatively lower than in U937 macrophages [131], which is consistent with the  relatively low 
level of CYP2A6 in astrocytes compared to macrophages. Our results suggest that acute 
nicotine metabolism-mediated oxidative stress is ameliorated by the increase of the 
antioxidant enzyme SOD. However, the chronic exposure of nicotine in smokers, especially 
in astrocytes, would produce high levels of ROS, which can activate astrocytes. Astrocytes 
are the major non-neuronal cell type which are situated in close association with neurons, and 
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provide the neurons with structural, metabolic and trophic support [148]. Activation of 
astrocytes as a result of increased oxidative stress has  been shown to  disrupt the support to 
neurons [149]. Our study would help better understand the role of astrocytes in 
neurodegenerative diseases. Increased oxidative stress is known to occur in various chronic 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease, and amyotrophic lateral sclerosis and is associated with neuronal cell death [150]. 
    The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway has been shown to 
be activated in astrocytes, which protects the neurons from oxidative insult [150, 151]. Nrf2 
is a transcription factor which is translocated into nucleus when cells are subjected to oxidative 
stress. In the nucleus, Nrf2 binds to an antioxidant response element and leads to 
transcriptional activation of antioxidant genes (e.g. SOD and phase II detoxifying enzymes). 
Recently, HIV gp120 has been shown to induce Nrf2 in astrocytes, which is associated with 
stimulation of antioxidant genes such as hemoxygenase (HO-1) and NADPH dehydrogenase 
quinone 1 (Nqo1) [152]. A recent report also demonstrates transcriptional regulation of 
CYP2A6 by the Nrf2 pathway in human hepatocytes [153]. Our unpublished observations 
suggest a similar role for Nrf2 in the induction of CYP2A6 by alcohol-mediated oxidative 
stress in monocytes. Our study opens the way to test the hypothesis that CYPA6-mediated 
nicotine metabolism facilitates the oxidative stress induced by HIV in astrocytes. Our 
hypothesis is consistent with the findings that chronic exposure of nicotine/smoke increases 
the expression of other CYP enzymes, including CYP2A6 in the brain [43, 45]. Nicotine-
induced brain CYP enzymes have relevance to several neurodegenerative diseases, including 
Parkinson's disease [154]. 
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4.5. Clinical relevance 
     In the U.S. cigarette smoking is about three times more prevalent in HIV-infected 
people than in the uninfected population [59]. Nicotine, the major constituent of tobacco, is 
known to enhance HIV replication in alveolar macrophages [69] and microglia [70]. Although 
the mechanism is not known, studies have suggested that oxidative stress plays a role in 
increased viral replication in smokers [72, 155]. A study has also correlated smoking with 
increased infection, decreased immune response, poor response to antiretroviral drugs, and 
enhanced risk of virological rebound [61, 156]. Our recent study with macrophages [96], and 
the current study with astrocytes, suggest an important role for CYP2A6 in nicotine/smoking-
mediated oxidative stress and HIV replication in monocytes and astrocytes. Since HIV protein 
gp120 is known to stimulate oxidative stress pathways [152], we speculate that 
nicotine/smoking in the presence of HIV infection may further enhance oxidative stress in a 
synergistic manner leading to increased HIV replication. Inhibition of the CYP2A6-mediated 
oxidative stress pathway has the potential to decrease viral replication and increase the 
response to ART that would reduce the progression of AIDS in smokers.  
4.6. Conclusion 
In conclusion, this is the first report on the expression levels of CYP1A1 and CYP2A6 
in SVGA astrocytes, and their further induction by nicotine. We also developed a highly 
sensitive LC-MS/MS method for simultaneous determination of nicotine, cotinine, and NNK 
in SVGA astrocytes, which allowed us to determine the role of CYP2A6 in nicotine 
metabolism in astrocytes. Furthermore, the role of CYP2A6 in nicotine metabolism-mediated 
oxidative stress was analyzed in these cells. These findings have clinical relevance because 
smoking among HIV-infected individuals is highly prevalent and these individuals show 
increased HIV replication. Since our previous study in monocytes (Jin et al) specifically used 
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nicotine, one of the major constituents of tobacco smoke, our further goal is to study the net 
effect of cigarette smoke in U937 monocytes by treating these cells with CSC. 
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CHAPTER 5  
CIGARETTE SMOKE CONDENSATE (CSC) MEDIATED OXIDATIVE STRESS AND 
CYTOTOXICITY IN U937 MONOCYTES 
 
5.1. Introduction 
Cigarette smoke contains 4000 different chemical constituents; of which 60 are 
identified as known carcinogens [157]. CSC contains several other constituents along with 
nicotine including dioxins, halogenated and nonhalogenated polycyclic aromatic 
hydrocarbons (PAHs), among which benzo[a] pyrene and semiquinones are few examples 
[158, 159]. CSC constituents are known to induce oxidative stress leading to alterations in 
gene expression in various cell and tissue type [160, 161]. For instance, CSC treatment in oral 
cancer cells resulted in upregulation of genes including CYPs and keto reductases that are 
responsible for metabolism of PAHs [162]. Most of these gene expressions are known to be 
modulated through activation of AHR by its agonists present in CSC [163]. Similarly, reactive 
oxygen species (ROS) produced by CSC can also activate nuclear factor-erythroid2-related 
factor 2 (Nrf2), the master regulator of oxidative stress which in turn transcriptionally 
regulates genes driven by antioxidant response elements (AREs).  
In our earlier studies we explored the role of nicotine (major addictive constituent of 
tobacco) alone in ROS formation and CYP2A6 regulation in U937 monocytes and SVGA 
astrocytes. Since CSC contains most of the cigarette smoke constituents, it represents a better 
smoking model for in vitro use. Our hypothesis for this chapter is that CSC induces CYPs, 
oxidative stress, cytotoxicity and HIV replication in monocytes/macrophages. Our specific 
aim is to study the CSC-mediated CYP induction, oxidative stress, and cell death in U937 
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monocytes, and HIV replication in HIV-infected primary macrophages. In the current chapter, 
we discussed the effects of CSC on AHR-mediated CYP1A1 induction, ROS formation and 
cytotoxicity in U937 cells. We also determined the effects of CSC treatment on viral 
replication in HIV-infected primary macrophages. 
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5.2. Results 
5.2.1. Induction of CYP1A1 and CYP2A6 by CSC in U937 monocytes 
CSC treatment at 50 µg/ml in U937 monocytes resulted in significant up regulation of 
CYP1A1 mRNA from 1H to 96H. CSC treatment significantly induced CYP2A6 mRNA at 
48H and 72H that was quenched at 96H (Fig. 15). To ensure that the mRNA induction was 
consistent with the protein induction, we measured levels of CYP1A1 and CYP2A6 proteins 
(Fig. 16 & 17). Although much lower than the respective mRNA expression, CSC also 
induced CYP1A1 protein levels from 3H to 12H, as well as CYP2A6 at later time points of 
12H and 24H. Our findings that CYP1A1 and CYP2A6 expression are induced by CSC, 
suggest their important role in PAH and nicotine metabolism, respectively, and metabolite-
associated oxidative stress in monocytes.  
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The U937 monocytes were treated with 50 µg/ml CSC for 1, 3, 6, 9, 12, 24, 48, 72, and 96 H. 
The percentage mRNA levels were calculated using qRT-PCR, with 100% expression 
normalized for the control at every time point. Expression of both the CYP genes was 
normalized to glyceraldehyde 3-phosphate dehydrogenase. In the above figures, the X-axis 
represents treatment time (hours) and Y-axis represents % mRNA expression. * Represents p 
≤ 0.05 compared to respective controls. 
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Figure 15: Effect of CSC on mRNA expression of CYP1A1 and CYP2A6 
in U937 monocytes 
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Figure 16: Effect of CSC on protein expression levels of CYP1A1  
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The U937 monocytes were treated with 50 µg/ml CSC for 1, 3, 6, 9, 12, 24, 48, 72, and 96 H 
and the protein was isolated. The percentage protein expression was calculated by quantifying 
the immunoblots, with 100% expression normalized to the untreated cells (control) at every 
time points. Expression of CYP1A1 and CYP2A6 was normalized against GAPDH. In the 
above figures, X-axis represents treatment time (hours) and Y-axis represents % protein 
expression.  
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Figure 17: Effect of CSC on protein expression levels of CYP2A6 
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5.2.2. CSC mediated changes in CYP1A1 gene expression are AHR dependent 
CSC is comprised of PAHs which are known to activate AHR pathway. To determine 
whether CSC-mediated CYP1A1 mRNA induction involved AHR signaling, we used a 
specific AHR antagonist, CH223191, to block its effects. We selected CH223191 because of 
it competitive binding to AHR receptor thus preventing its translocation to the nucleus without 
demonstrating any agonistic action. We treated monocytes with 50 µM CH223191 followed 
by 50 µg/mL CSC for 3 H and examined CYP1A1 mRNA expression level by q-RTPCR. As 
shown in Fig. 18, pretreatment with the AHR antagonist significantly attenuated the CSC-
mediated CYP1A1 mRNA induction. 
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Figure 18: Effect of AHR antagonist on CYP1A1 gene expression 
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5.2.3. Time kinetics of CSC induced ROS formation  
We measured the generation of ROS in 50 µg/mL CSC treated U937 monocytes using 
flow cytometry. Figure 19 shows the mean fluorescence intensity (MFI) of ROS formation in 
nicotine-treated monocytes from 1 - 48 hours. CSC treatment showed a time dependent 
increase in ROS until 6H, where the peak ROS formation was observed and then declined to 
basal level at 48H. Furthermore, our studies showed significant reduction in CSC induced 
ROS formation upon 1H pretreatment with 100 µM Vitamin-C (Vit-C), a potent antioxidant 
compound (Fig. 20). The results suggest that a general antioxidant is not capable of completely 
quenching the ROS induce by CSC.  
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The ROS production was measured using a flow cytometer from untreated and 50 µg/ml CSC 
treated cells from 1H to 48H. Bar graphs representing mean fluorescence intensity (MFI) from 
control and CSC-treated cells. MFI is presented in Y-axis and the time points of CSC 
treatment are presented in X-axis. The graphs were plotted as mean ± SD from three replicates. 
  
Figure 19: Effect of CSC on oxidative stress in U937 monocytes 
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The ROS production was measured using a flow cytometer from untreated and 50 µg/ml CSC 
treated cells for 3H upon 1H pretreatment with 100 µM Vitamin-C. Bar graphs representing 
mean fluorescence intensity (MFI) from control and CSC-treated cells. MFI is presented in 
Y-axis and the time points of CSC treatment are presented in X-axis. The graphs were plotted 
as mean ± SD from three replicates. 
  
Figure 20: Effect of Vitamin-C pretreatment on CSC induced ROS formation in 
U937 monocytes. 
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5.2.4. CSC induced cell death in U937 monocytes 
To determine if CSC treatment is leading to cell death in U937 monocytes, the cells 
were treated with 50 µg/mL CSC for 48 H and MTT assay was performed. Annexin staining 
was also performed to determine the apoptotic cells. As shown in Fig. 21, CSC treatment 
caused significant increase in apoptosis in these cells. To find out if CSC-mediated apoptosis 
involves caspase-3 activation, caspase-3 activity was measured upon CSC treatment for 24H. 
The results showed that CSC significantly increased caspase-3 activity by 2 fold (Fig. 22 A). 
Cleaved caspase-3 protein levels are also increased as determined by western blot (Fig.22 B). 
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Cell death was measured using MTT assay from vehicle control and 50 µg/ml CSC treated 
cells for 48H. Apoptosis was measured using a flow cytometer from vehicle control and 50 
µg/ml CSC treated cells for 48H upon staining with Annexin-PE reagents. Bar graphs 
representing % apoptotic cells in Q2 from control and CSC-treated cells. The graphs were 
plotted as mean ± SD from three replicates. 
Figure 21: Effect of CSC on apoptosis in U937 monocytes 
77 
 
 
 
 
Caspase-3 activity is measured in cell lysates obtained from vehicle control and 50 µg/ml CSC 
treated cells for 24H using a colorimetric assay kit. (A) Bar graphs representing fold caspase-
3 activity in DMSO and CSC-treated cells. The graphs were plotted as mean ± SD from three 
replicates. (B) Western blot stained for cleaved caspase-3 antibody and GAPDH in DMSO 
and 50 µg/ml CSC treated cells for 24H. 
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5.2.5. Effect of CSC on HIV replication in primary macrophages 
To determine the effect of CSC treatment on HIV replication in monocytes, we treated 
HIV-infected primary macrophages with CSC for four days (once-daily). The results showed 
that the amount of p24 antigen in cell free supernatant was found to be significantly higher in 
CSC treated HIV-infected macrophages compared to DMSO treated HIV-infected 
macrophages (Figure 23).  
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The viral load in macrophages was determined by measuring p24 antigen levels using ELISA. 
The data for the above assay represents mean of multiple analysis of p24 titer obtained from 
HIV-infected macrophages from three different donors. The p values (** represent p≤0.01) 
are calculated using one way-ANOVA and presented in the graph. 
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Figure 23: Determination of p24 antigen levels in DMSO and CSC 
treated HIV-infected macrophages 
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5.3. Discussion 
In our previous studies, nicotine treatment alone didn’t cause significant induction of 
CYP1A1 and CYP2A6 levels in U937 monocytes. However in the current study, CSC caused 
AHR-mediated CYP1A1 induction as well as CYP2A6 induction, which is significantly 
higher than the effect of nicotine. CSC treatment also caused significantly higher production 
of ROS compared to our earlier study with nicotine. It is possible that since CSC comprises 
of PAHs, the amount of ROS produced was very high compared to that of nicotine alone. CSC 
also caused significant apoptosis as measured by caspase-3 activity as well as cleaved caspase-
3 formation. This may occur both directly, by genotoxicity of CSC constituents, and indirectly 
through generation of reactive oxygen species. Future studies will be conducted to determine 
the role of ROS in CSC-mediated cell death by using general as well as specific antioxidants 
that quench the formation of ROS. Further studies also need to be performed to decipher the 
involvement of CYP1A1 in the generation of ROS as well as oxidative stress-mediated cell 
death. We conducted few studies using nonspecific CYP1A1 inhibitors which didn’t yield 
conclusive findings portraying the need to design novel inhibitors targeted against CYP1A1 
specifically. In addition, in HIV-infected mature macrophages, HIV replication was found to 
be significantly higher in CSC treated macrophages compared to control cells supporting the 
effects of smoking on HIV pathogenesis. Although this study did not decipher the molecular 
mechanism of CSC-mediated induction of ROS and HIV-replication, it led the foundation that 
CSC increases HIV replication and apoptosis, which is consistent with increased induction of 
CYP enzymes and ROS.   
5.4. Conclusion 
In conclusion, as rationalized, in comparison to nicotine alone, the total extract of 
cigarette represented by CSC had a pronounced and significantly higher impact on expression 
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of CYPs and OS in monocytes. These dramatic changes induced by CSC translated into 
enhanced viral replication in primary macrophages. Since our in vitro findings thus far have 
shown CSC-mediated induction of CYPs, ROS formation, enhanced HIV replication, and the 
involvement of CYP2A6 in nicotine metabolism-mediated OS, further goal is to examine 
underlying mechanism, and to confirm the above findings in an ex vivo study using human 
smoker subjects.  
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CHAPTER 6 
EFFECT OF MILD-TO-MODERATE SMOKING ON VIRAL LOAD, CYTOKINES, 
OXIDATIVE STRESS, AND CYTOCHROME P450 ENZYMES IN HIV-INFECTED 
INDIVIDUALS 
6.1. Introduction 
The specific effects of mild-to-moderate smoking on the components of HIV 
pathogenesis such as inflammatory cytokines and oxidative stress, is poorly studied. 
Cytokines/chemokines play a crucial role in HIV pathogenesis by regulating HIV replication 
and immune responses [164, 165]. Several studies have shown that cytokine dysregulation 
contributes to HIV disease progression [166, 167]. For example, cytokines have shown to play 
an important role in development of viral latency and maintenance of latently infected CD4+ 
T cells during antiretroviral therapy (ART) [167]. Furthermore, the myriad of pro-
inflammatory cytokines including tumor necrosis factor (TNF-α), interleukin-2 (IL-2), and 
IL-18, present in the plasma and lymphoid tissues, induce HIV replication even after 
prolonged ART. Similarly, oxidative stress is known to play a significant role in HIV 
pathogenesis [100, 168, 169]. More specifically, oxidative stress has been linked to HIV 
replication in monocytes/macrophages [100, 170]. In addition, a report suggested the role of 
iron and oxidative stress in smoking-mediated HIV replication in alveolar macrophages [72]. 
Of importance, the pathway leading oxidative stress, especially in monocytes, in HIV-infected 
smokers is unknown.   
Our recent in vitro studies have also shown that acute nicotine exposure causes 
increased production of reactive oxygen species (ROS) through CYP2A6-mediated pathway 
in monocytic and astrocytic cell lines [95, 99, 171]. Since it is not feasible to conduct an ex 
83 
 
vivo study in astrocytes, we will be performing our ex vivo studies in peripheral monocytes 
isolated from human subjects. CYP3A4 metabolizes approximately 50% of commercially 
available drugs including ART in the liver [172] and results in the production of ROS [173, 
174]. However, the functional role of CYP3A4 is unknown in monocytes, which is an 
important site of viral infection and major viral reservoir. Our previous studies have 
demonstrated predominant expression of CYP2A6, CYP2E1, and CYP3A4 in monocytic cell 
lines [96]. The hypothesis in this aim is that smoking increases HIV replication, which is 
associated with increase in the expression of CYP enzymes and oxidative stress. Our specific 
aim is to determine the levels of CYP2A6, CYP2E1, CYP3A4, and antioxidant enzymes 
(AOE), oxidative stress, cytokines, and HIV replication in blood plasma/monocytes isolated 
from a cohort of patients belonging to uninfected non-smokers (Healthy), uninfected smokers 
(smokers), HIV-infected non-smokers (HIV) and HIV-infected smokers (HIV smokers). In 
the current study, we sought to determine whether smoking increases viral replication in 
clinical samples of HIV-infected smokers. Furthermore, we sought to determine whether there 
is a relationship between viral load, cytokines/chemokines, oxidative stress, and CYP 
pathways in HIV-infected smokers.  
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6.2. Experimental design 
6.2.1. Study population 
Thirty two human subjects were recruited and assigned to four different cohorts as 
follows: a) healthy HIV negative control subjects who reported that they were non-smokers 
(HIV negative non-smokers), b) HIV positive non-smokers, c) HIV negative mild-to-
moderate smokers, and d) HIV positive mild-to-moderate smokers. Participants were recruited 
in Cameroon, Africa, from within a long standing reference population of more than 2000 
known HIV positive subjects. The participants provided their written informed consent to 
participate in this study. The signed consent form from the participants was stored as hard 
copy as well as electronically on a password protected computer. The consent procedure was 
approved by Institutional Review Board (IRB) from the University of Missouri-Kansas City, 
Kansas City, MO and IRB/Institutional Ethic Committee (IEC) from the Provincial Regional 
Hospital, Ministry of Public Health, Bamenda, Cameroon. We performed power analysis 
using “Power and Precision” software by considering the magnitude of the known effects of 
smoking on HIV replication [70, 72] and oxidative stress [99, 171]. The results showed that 
6-8 samples from each group would provide a power of ≥0.80. Participants between the ages 
of 21-65 years were recruited, because individuals <13 years and >65 years of age generally 
have altered expression of metabolic (CYP) and to some extent antioxidant enzymes (AOEs) 
[25, 26]. For those individuals in the HIV negative non-smoker category, we recruited 
individuals who reported no history of “cough” and physical examination although some may 
have had malaria in the past (Plasmodium falciparum is indigenous in Cameroon). With 
respect to the HIV negative and positive smokers, mild-to-moderate smokers with a smoking 
history of ≤20 pack years (a pack year is defined as smoking at least one pack a day for one 
year), were enrolled in the study. The documentation of smoking was determined by a HIV 
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counselor and the phlebotomist following a personal interview. With respect to the HIV 
positive category, individuals with CD4+ counts <600 cells/µl were enrolled. Participants 
were recruited using the following strict exclusion criteria: 1) Pregnant or lactating women 
were excluded since they show increased metabolism of nicotine and cotinine [175] (smoking 
is rare among Cameroonian women); 2). Liver damage and lung disease since these alter the 
metabolism of tobacco constituents such as nicotine; 3) Individuals with other infectious 
diseases, such as documented malaria, tuberculosis, and hepatitis B since hepatitis and active 
TB are prevalent in HIV-infected population, and some of these diseases are known to interact 
with HIV [176]; 4) Individuals who were receiving ART. ART drugs or other medications are 
expected to interfere with tobacco constituents [99, 177]. Sufficient numbers of HIV-infected 
individuals who were not already receiving ART or other medication were available among 
village populations in Cameroon, because medications or access to CD4 counting is frequently 
not available in these areas (WHO, Cameroon 2004-2005 report 
http://www.who.int/hiv/HIVCP_CMR.pdf). In order to qualify for free therapy provided by 
the Cameroonian Government, an adult must obtain a CD4 count and that result must be under 
350cells/µl. The test to determine CD4 count is costly and not available in rural areas. Second, 
the local recommendation during the period of the study was to initiate therapy when the CD4 
count was <350 cell/µl. 5) Individuals who consume other recreational substances of abuse, 
e.g. methamphetamine, cocaine, or marijuana. These drugs are expected to interfere with HIV 
pathogenesis and/or oxidative stress [178, 179]. Applying these inclusion and exclusion 
criteria was challenging but subjects were recruited upon personal interview, analysis of their 
history, and following clinical screening for HIV, malaria, and hepatitis B. The clinical 
screening tests for malaria and hepatitis were conducted using standard procedures as 
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described [180] and patients with “cough” suggestive of TB received an AFB or were 
excluded. 
6.2.2. Statistical analysis 
Demographic variables (age, sex ratio) were summarized using descriptive statistics. 
All outcome variables were summarized as the mean plus or minus the standard error. 
Comparisons among the four groups were conducted using one way ANOVA with no 
corrections for multiple comparisons. All tests were two-sided and results that were 
statistically borderline significant at p≤0.1 (#) and significant at p ≤0.05 (*) and ≤0.01 (**). 
A two-way ANOVA was done to determine whether they interact synergistically or additively 
in HIV positive smokers. All analyses were performed using IBM SPSS version 21.  
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6.3. Results  
6.3.1. Characteristics of the study population 
A total of 32 subjects were selected upon screening approximately 2000 HIV positive 
individuals attending the HIV clinic at the Regional Hospital, Mezam Polyclinic HIV/AIDS 
Treatment Center, or at surrounding village health centers. The recruitment was very difficult 
and time consuming owing to strict exclusion criteria, paucity of smokers who also do not 
also drink alcohol and are not yet receiving ART or other medications. Furthermore, smoking 
was rare among women in this region, especially in HIV positive population in which it is 
discouraged. The subjects with such inclusion criteria are nearly impossible to recruit in the 
USA, because HIV-infected individuals receive ART promptly after diagnosis and most 
receive other medications and/or abuse illegal drugs. The recruitment of subjects who were 
not receiving ART was critical to determine the specific effects of mild-to-moderate smoking 
in HIV-infected individuals without an interference by drugs on the results of the study. The 
number of individuals in each group (HIV negative non-smoker, HIV negative smoker, HIV 
positive non-smoker, and HIV positive smoker) along with the age-range, median age, and 
male/female ratio of all the subjects are presented in Table 3. The median age of all the groups 
was 35-45. The male/female ratio varied in each group, with relatively low ratio in HIV 
positive group but high ratio in all smokers because of the low incidence of smoking among 
women with the strict exclusion criteria. Our analysis showed that the subject-to-subject 
variation in CD4 counts, viral load, cytokine production, and oxidative stress was not 
significant on the basis of age and gender differences (data not shown). This analysis was 
performed using HIV negative non-smokers and HIV negative smokers, in which, the number 
of subjects were sufficient to perform such analysis.  
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Table 3: Demography and clinical outcomes (CD4) of the subjects   
 
 
6.3.2. Effect of smoking and HIV on CD4 and viral load in plasma 
The mean CD4 count (cells/µL) and mean viral load (log copies/mL) of each cohort 
are presented in Table 3 and Figure 24. As expected, the CD4 count was lower in HIV positive 
non-smokers (374 ± 43) and HIV positive smokers (387 ± 130) than HIV negative non-
smokers (865 ± 45) or smokers (1037 ± 100). There was a significant increase in the CD4 
count in HIV negative smokers compared with non-smokers (1037 ± 100 vs. 865 ± 45). Our 
results showed that the viral load is significantly increased in HIV positive smokers (4.5 ± 
0.7) compared to the HIV positive non-smokers (3.1 ± 0.5) (Figure 24). These results suggest 
that smoking is associated with increased viral replication.  
Subjects  HIV negative 
non-smokers 
HIV 
positive 
non-smoker 
HIV negative 
smokers 
HIV 
positive 
smokers 
Number, age 
(years), 
male/female 
ratio 
# 11 6 11 4 
Age range 20-64 23-42 31-60 38-57 
Median age 45 34.5 45.5 42 
Male/female 1.2 0.5 1.75 3 
CD4 count 
(cells/µL) 
Range  631-1086 256-551 500-1488 13-584 
Mean ± SE   865 ± 45 374 ± 43 1037 ± 100 387 ± 130 
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The viral loads in the plasma of human subjects were determined by analyzing HIV RNA 
using q-RTPCR. The p values (# and ** represent p≤0.1 and p≤0.01, respectively) are 
calculated using one way-ANOVA and presented in the graph. 
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Figure 24: Determination of Viral load in plasma of HIV-infected and 
HIV-infected smoker subjects 
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6.3.3. Effect of smoking and HIV on cytokine/chemokine production in plasma 
 
We determined the levels of various pro-inflammatory cytokines, IL-1β, IL-6, IL-8, 
RANTES, TNF-α and MCP-1 in all plasma samples. The levels of IL-1β were not detectable 
in any plasma sample within the detection limit of the assay (2 pg/mL). The concentrations of 
cytokines in each group showed significant subject-to-subject variations, and therefore, we 
presented these results in box plot as shown in Figure 25. The concentrations of most of the 
cytokines were in the range of 10-80 pg/mL, while the concentration of RANTES ranged from 
500-12,000 pg/mL. The concentrations of MCP-1 and IL-8 were significantly lower in HIV 
positive non-smokers and HIV negative smokers and marginally lower in HIV positive 
smokers than HIV negative non-smokers (Figure 25). The concentration of RANTES was 
marginally higher in HIV positive non-smokers and smokers than HIV negative non-smokers 
and smokers. However, there were no significant differences in the levels of IL-6 and TNF-α 
between the test and control groups (Figure 25).   
  
91 
 
 
Box and whisker plots of cytokine/chemokine levels in plasma of HIV negative non-smokers 
(HEALTHY), HIV positive non-smokers (HIV), HIV negative smokers (SMOKER), and HIV 
positive smokers (HIV SMOKER) groups. The box represents the 25th-75th quartile, the 
whiskers represent the range of values, the median is presented as a line inside the box, and 
the out of range values are presented as circles or stars above and below the whiskers. The p 
Figure 25: Box plots of Cytokine levels in plasma samples 
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values (* and ** represent p≤0.05 and p≤0.01, respectively) are calculated using one way-
ANOVA and presented above the bars in the graph. The concentrations of RANTES, IL-6, 
IL-8, MCP-1 and TNF-α were shown in the figure.   
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6.3.4. Effect of smoking and HIV on oxidative stress in plasma and monocytes 
To evaluate oxidative stress in clinical samples, we determined the oxidative DNA 
damage by measuring 8-OHdG content. The results showed that the oxidative damage is 
significantly increased in plasma from HIV negative smokers (2-fold), and HIV positive non-
smokers (2.5-fold) groups compared with HIV negative non-smokers (Figure 26A). 
Furthermore, there was an additive increase in the levels of oxidative damage in HIV positive 
smokers (4-fold) compared to HIV positive non-smokers and HIV negative smokers (two-
way ANOVA for testing the interaction gave p=0.39 suggesting the absence of synergy). 
Similarly, we determined the oxidative DNA damage in the monocytes of all the cohorts. Our 
results demonstrated an increase in 8-OHdG levels in HIV negative smokers (~30%) and HIV 
positive non-smokers (~40%) compared to HIV negative non-smokers (Figure 26B). An 
additive increase was also observed in 8-OHdG levels in the DNA of HIV positive smokers 
(~75%) compared to HIV positive non-smokers and HIV negative smokers. Overall, the 
results suggest an increase in oxidative stress as a result of HIV infection and smoking. 
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Measurement of oxidative stress in plasma (A) and monocyte (B) samples of HIV negative 
non-smokers (HEALTHY), HIV positive non-smokers (HIV), HIV negative smokers 
(SMOKER), and HIV positive smokers (HIV SMOKER) groups. The 8-OHdG contents are 
plotted as a bar graph for each category, and the p values ≤0.05 and ≤0.01 are represented as 
* and **, respectively. * represents the significance with respect to HEALTHY, # represents 
the significance with respect to HIV and @ represents the significance with respect to 
SMOKER in HIV SMOKER group.  
  
Figure 26: 8-OHdG levels in plasma and monocyte samples 
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6.3.5. Effect of smoking and HIV on the expression of antioxidants in monocytes 
The expression of antioxidant enzymes (AOEs) are generally induced to combat 
increased oxidative stress triggered by an agent. Therefore we measured the levels of 
antioxidant genes; SOD1, SOD2, catalase, and Nrf2 in our four cohorts. Our results 
demonstrated that the levels of mRNA of the most antioxidant genes are not altered in HIV 
positive and/or smoker groups compared to HIV negative non-smokers (Figure 27). However, 
we found a 2-fold increase in the level of Nrf2 in HIV negative smokers compared to the HIV 
negative non-smoker. In general, lack of induction of the most AOEs suggests their inability 
to counterbalance oxidative stress generated by smoking and HIV infection.  
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Determination of antioxidant gene expression in HIV negative non-smokers (HEALTHY), 
HIV positive non-smokers (HIV), HIV negative smokers (SMOKER), and HIV positive 
smokers (HIV SMOKER) groups. The mRNA expressions of SOD1, SOD2, catalase, and 
Nrf2 were measured by qRTPCR. A one way-ANOVA was employed to calculate the p value 
(* represent p≤0.05) with respect to HEALTHY in all the groups. 
  
Figure 27: Antioxidant gene expression levels in monocytes from human cohorts 
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6.3.6. Effect of smoking and HIV on the levels of CYP enzymes in monocytes 
CYP enzymes play important role in generating oxidative stress by generating 
superoxide and peroxide as a result of P450-mediated reaction cycle. Therefore, we measured 
the levels of important CYP enzymes (CYP2A6, CYP2E1, and CYP3A4), which are known 
to produce oxidative stress by metabolizing endogenous compounds or xenobiotics such as 
tobacco constituents and marketed drugs. As expected, the results showed that the levels of 
CYP2A6 mRNA is increased (p=0.07; borderline significance) in HIV negative smokers (1.5-
fold) compared to HIV negative non-smokers (Figure 28). However, the level of CYP2A6 
mRNA was only marginally increased in HIV positive non-smokers and HIV positive smokers 
compared to HIV negative non-smokers. Interestingly, the level of CYP3A4 was increased in 
HIV positive non-smokers and HIV positive smokers by approximately 5-fold compared to 
HIV negative non-smokers (Fig 28). However, its level was not significantly increased in the 
HIV negative smokers. As expected, there was no significant increase in the level of CYP2E1 
in HIV positive and/or smoker cohorts, suggesting that CYP2E1, which is induced by alcohol, 
does not play role in inducing oxidative stress in these cohorts.  
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Determination of CYP levels in HIV negative non-smokers (HEALTHY), HIV positive non-
smokers (HIV), HIV negative smokers (SMOKER), and HIV positive smokers (HIV 
SMOKER) groups. The expression levels of CYP2A6, CYP3A4, and CYP2E1 mRNA were 
determined by qRTPCR in all the groups. A one way-ANOVA was employed to calculate the 
p value (** represent p≤0.01; # represents p≤0.1, borderline significance) with respect to 
HEALTHY in all the groups. 
Figure 28: CYP gene expression levels in monocytes from human cohorts 
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6.4. Discussion 
Nicotine/tobacco smoking has shown to increase HIV replication in in vitro studies 
[69, 70]. In vitro studies have also shown an association between oxidative stress and HIV 
replication [72, 100, 168]. However, there is no clear evidence from the clinical samples of 
HIV-infected smokers, especially in ART-naïve patients. Similarly, to date, there is no clinical 
evidence of the involvement of CYP and oxidative stress pathways in HIV and/or smoking in 
HIV-infected individuals. We have recently shown the involvement of CYP enzymes in 
nicotine metabolism and oxidative stress in in vitro in HIV monocyte and astrocyte model 
systems (Chapter 4). Furthermore, we have shown an association between induction of 
CYP/ROS and HIV replication by CSC in monocytes (Chapter 5). In the current study, we 
used clinical samples from HIV-infected smokers to establish possible involvement of CYP 
and oxidative stress pathways in smoking-mediated HIV pathogenesis. This is the first clinical 
evidence of an increase in viral load in HIV-infected smokers, as well as, possible involvement 
of CYP and oxidative stress pathways in HIV positive smokers and non-smokers.  
Several studies have shown that mild-to-moderate smoking leads to increased CD4 
cell count and CD4/CD8 ratio [181]. In contrast, another study reported that heavy smoking 
caused a decline in CD4 cell count [182]. Our findings are generally consistent with the former 
literature in which smoking showed an increase in the CD4 counts. Our study also suggest an 
increase in HIV replication by tobacco smoking, which is consistent with previous in vitro 
findings [69, 71]. However, this is the first report on clinical samples obtained from HIV-
infected smokers. An earlier study in HIV-seropositive women has shown an association of 
cigarette smoking with viral immune and cognitive function [78]. However, the underlying 
mechanism of the effects of smoking on viral immune, cognitive function, and HIV 
pathogenesis is largely unknown.  
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HIV infection is known to increase the expression of pro-inflammatory cytokines 
including IL-1, IL-6, RANTES, MCP-1 and TNF-α [183, 184]. In contrast, our results did not 
show an increase in the levels of these cytokines in HIV positive cohorts, rather there were 
significant decrease in the levels of IL-8 and MCP-1. There is a report demonstrating that the 
levels of TNF-α, IL-1β and IL-8 are significantly higher in asymptomatic HIV-infected 
African women than women living with AIDS, suggesting the role of cytokines in early phase 
of HIV infection [185]. Thus, it is likely that unaltered/decrease in cytokines levels in our 
study is because the HIV-infected patients had in many cases already progressed to full-blown 
AIDS. Likewise, cigarette smoking is associated with an increased production of pro-
inflammatory cytokines, especially IL-1β and IL-1RA in bronchoalveolar lavage [186], and 
IL-6, IL-1β and TNF-α in the serum [187, 188]. In contrast, in our study, smoking was not 
associated with an increase in the levels of pro-inflammatory cytokines, except RANTES, 
rather it showed a decrease in the levels of IL-8 and MCP-1.  
Tobacco smoking has been shown to affect cytokine network balance and thereby alter 
the host immune responses in the pathogenesis of both periodontal disease and cardiovascular 
disease. For instance, both nicotine and CSC treatment to human endothelial cells had 
significantly reduced MCP-1 levels in those cells compared to control [189]. Similarly, a study 
conducted in smokers with computed tomography (CT) detected emphysema and without 
airway obstruction had demonstrated decreased plasma levels of cytokines including EGF, 
IL-8, IL-15, and IL-1RA than the smokers without CT detected emphysema [190]. In contrast, 
patients with COPD usually exhibit higher IL-8 levels. Therefore these studies suggest that 
the plasma cytokine profiles of smokers widely vary in individuals with either emphysema or 
COPD. This also suggests that smoking could differentially affect the cytokine levels based 
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on their respiratory disease conditions which may be responsible for the decreased levels of 
cytokines observed in our smokers and HIV positive smokers. Moreover, it is well known that 
HIV infection alters the levels of cytokine production in vitro as well as in vivo [191]. 
Nonetheless, there is no report till date about correlation between smoking associated 
increased viral load and cytokine levels. Therefore an extensive longitudinal study that 
monitors the clinical status of smokers can provide us with a better understanding of the 
relation between smoking prompted viral load and their cytokine profiles. In general, we 
acknowledge that our data show contrasting findings, which needs to be investigated further. 
However, it can be noted that the population demography in our study is different from other 
studies in terms of strict exclusion criteria of the subjects (non-HIV medication as well as use 
of other substances of abuse).    
An increase in the oxidative stress in both plasma and monocytes in smokers and HIV-
infected individuals is consistent with the previous reports, especially with monocytes [72, 
100, 168, 192]. However, this is the first evidence of increased oxidative DNA damage in the 
plasma and monocytes using clinical samples from HIV-infected smokers. It is noteworthy 
that while a previous report has shown higher serum 8-OHdG levels in males versus females 
[193], no gender difference in 8-OHdG level was observed in our study, at least in HIV 
negative non-smokers and HIV positive smokers. Further, relatively higher levels of oxidative 
DNA damage in plasma compared with monocyte samples in all the groups suggests that there 
may be increased oxidative stress in other tissues draining into plasma. While the DNA 
damage in plasma may be as a result of ROS generated by liver and other blood cells including 
monocytes, DNA damage in monocytes is expected to entirely come from increased ROS in 
monocytes.     
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An optimal level of ROS is required for cellular functions. However, when the level 
of ROS is elevated, defense mechanism may counterbalance the increased ROS to protect the 
cells. As one of the major defense mechanism, the Nrf2 signaling pathway is activated, which 
results in the transcription of a myriad of AOEs such as SOD1 and catalase to protect the cells 
from oxidative insult [194]. However, if the ROS reaches a threshold level, the AOEs pathway 
is compromised leading to cellular death. On the other hand, a defect in the defense system 
may cause either a decrease or no change in the levels of these AOEs leading to increased 
level of ROS. Since there is no significant increase in the levels of AOEs determined in 
smokers, we suggest that the levels of ROS has reached the threshold level, or the defense 
system through the Nrf2 pathway may be compromised in these individuals.  
The role of oxidative stress as a result of production of ROS, including nitric oxides 
has been implicated in HIV pathogenesis [100, 168, 169, 195, 196]. Similarly, previous 
literature [69-71, 99, 171, 177] and our current findings demonstrate that smoking and 
oxidative stress both are independently associated with increased HIV replication. Thus, we 
suggest that smoking-mediated oxidative stress may be responsible for increased HIV 
replication. Although several mechanisms have been implicated in the production of oxidative 
stress in the HIV systems, smoking-mediated production of ROS through CYP pathway may 
play an important role in HIV pathogenesis. Since CYP-mediated metabolism of tobacco 
constituents is known to produce reactive oxygen species in the liver [197], it is reasonable to 
conclude that CYP-mediated pathways contributes to the DNA damage in both plasma and 
monocytes. Our results relatively low levels of DNA damage in monocytes suggest that CYP-
mediated metabolic pathway also exists in monocytes. Our speculation is consistent with our 
earlier observation that although monocytes contain relatively low levels of CYP enzymes 
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compared to the liver, the relative level of CYP2A6 in monocytes is much higher that other 
CYP enzymes [198]. Therefore, we suggest that although CYP2A6 in smokers and HIV 
positive non-smokers are not induced, the basal level of CYP2A6 is sufficient to metabolize 
tobacco constituents and endogenous compounds and produce ROS. Furthermore, our 
observation is consistent with the recent finding that CYP2A6-mediated metabolism of 
nicotine produces ROS in monocytes and astrocytes [99], which may be responsible for 
increased DNA damage in monocytes. Another recent study from our laboratory, which 
demonstrated an increased metabolism of nicotine in HIV positive smokers compared to HIV 
negative smokers, is also consistent with this observation [199]. It is also possible that the 
increased metabolism is due to increased activity of enzyme rather than the actual protein 
level. An increase in enzyme activity through substrate-mediated enhance stability of enzyme 
is known in the P450 system [200].   
The CYP pathway is also known to produce oxidative stress through the metabolism 
of endogenous compounds and xenobiotics such as marketed drugs [201]. The major drug-
metabolizing enzyme CYP3A4, which is also known to metabolize many endogenous 
compounds and is present at relatively much higher level than other CYP enzymes in the liver, 
is expected to produce oxidative stress. A significant increase in the level of CYP3A4 in HIV-
infected non-smokers as well as in HIV-infected smokers suggests an important role of 
CYP3A4 in HIV pathogenesis. It is possible that induction of CYP3A4 by HIV pathogenesis 
increases the metabolism of many endogenous compounds as well as xenobiotics, which in 
turn leads to increased oxidative stress. Since oxidative stress is also linked with HIV 
replication, the induction of CYP3A4 would further increase HIV replication. In addition to 
its role in oxidative stress, CYP3A4 may play significant role in HIV patients who are 
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receiving ART, especially non-nucleoside reverse transcriptase inhibitor (NNRTIs), protease 
inhibitors (PIs), and more recently integrase inhibitors. CYP3A4 metabolizes majority of 
NNRTIs, integrase inhibitors, and all the PIs, which are an essential component of ART [174]. 
Thus, increased level of CYP3A4 in HIV positive smokers and HIV positive non-smokers 
would increase the metabolism of NNRTIs, PIs, and integrase inhibitors in these individuals. 
An increased metabolism of ART would subsequently decrease the bioavailability of these 
ARTs ultimately leading to decreased response to these drugs and increased toxicity. 
Therefore, further investigation to clarify the role of CYP3A4 in HIV-infected individuals 
over time is necessary.       
6.5. Conclusion    
In conclusion, the current study suggests that mild-to-moderate smoking increases 
viral load in HIV-infected individuals, thereby confirming our in vitro earlier findings in HIV-
infected macrophages. Furthermore, our study suggests that smoking and HIV independently 
increase oxidative stress in the plasma as well as in monocytes. An increase in oxidative stress 
could be as a result of both, CYP-mediated hepatic metabolism of smoking constituents and/or 
endogenous compounds and lack of induction of AOEs. Although we suggest a possible 
association of CYP and oxidative stress pathways in HIV replication, there is a lack of 
evidence supporting changes in metabolism of cigarette constituents in HIV-infected 
individuals. Hence, our next goal was to report the rate of metabolism of chief cigarette 
constituent, nicotine, in HIV-infected individuals.   
Patient consent 
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CHAPTER 7 
ENHANCED NICOTINE METABOLISM IN HIV-POSITIVE SMOKERS 
COMPARED TO HIV-NEGATIVE SMOKERS: SIMULTANEOUS 
DETERMINATION OF NICOTINE AND ITS FOUR METABOLITES IN THEIR 
PLASMA USING A SIMPLE AND SENSITIVE ESI-LC-MS/MS TECHNIQUE 
7.1. Introduction 
 Our findings from the ex vivo human samples demonstrated an increase in the 
oxidative stress in both plasma and monocytes in smokers and HIV-infected individuals. Since 
our recent in vitro findings in monocytes by Jin et al and astrocytes showed the role of nicotine 
metabolism by CYP2A6 in ROS production [99, 202], we sought to determine the plasma 
levels of nicotine and four of its metabolites that are formed by CYP2A6 in HIV-positive 
smokers subjects from the above ex vivo study. Our hypothesis is that HIV infection enhances 
nicotine metabolism in HIV-infected smokers. Therefore our specific aim for this chapter is 
to develop a sensitive and rapid method for simultaneous determination of plasma levels of 
nicotine and its major metabolites, and determine the levels of nicotine and its metabolites in 
plasma sample of the human subjects. 
Previously nicotine and its metabolites have primarily been studied in urine and to 
some extent in other biological matrices such as serum, plasma, hair, and nails using 
immunoassay, HPLC, GC-MS, and LC-MS with protein precipitation, liquid extraction 
methods, and SPE methods [141, 203, 204]. However, usefulness of these methods has been 
limited by factors like requirement of high sample volume, lengthy extraction process among 
other impediments. Generally, the plasma concentration of nicotine and its metabolites is 
much lower than that in urine [205]. It is therefore necessary to have a more sensitive 
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analytical technique using an LC-MS/MS instrument with a triple quadrupole linear ion trap, 
which is commonly employed for the determination of low levels of nicotine and its 
metabolites. A previous study has shown the application of the LC-MS/MS method for 
quantifying only cotinine at a sensitivity of 0.5 ng/mL [206, 207]. Subsequently, another LC-
MS/MS method using solid phase extraction (SPE) was developed that was able to quantitate 
two analytes, nicotine and cotinine with a sensitivity of 2 ng/mL [141]. Recently, several LC-
MS/MS analytical techniques have been reported to determine nicotine, cotinine, and trans-
3’-hydroxycotinine but also required a large volume of serum to achieve a sensitivity of 1 
ng/mL. Although these methods had a sensitivity of 1-2 ng/mL, the sample preparation and 
extraction methods were time-consuming and tedious, required high sample volume, and were 
limited to 2-3 analytes [140, 208]. Therefore, our objective in this study was to develop a 
sensitive, selective, and simple ESI-LC-MS/MS technique using a SPE cartridge for the 
simultaneous determination of nicotine and its four metabolites in plasma. In this 
communication, we report the concentrations of nicotine and its metabolites detected in 
plasma from HIV-positve and HIV-negative smokers using the above approach.   
7.2. Development of an analytic method for the measurement of nicotine and its 
metabolites in plasma  
7.2.1. Mass spectrometry optimization 
 The mass spectrometer (3200 QTRAP LC-MS/MS system, AB Sciex) was optimized 
for detection of nicotine and its metabolites along with IS by using 200 ng/mL. Mass 
spectrometry data of each compound was first acquired in full scan mode from the range 
between 50-300 Da to identify their precursor ions. The most suitable proton adduct in the 
positive mode [M+H]+ precursor  ions was determined for nicotine (163.3), cotinine (177.5), 
trans 3’-hydroxycotinine (193.2), nornicotine (149.5), norcotinine (163.4), nicotine-d4 
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(167.3), and cotinine-d3 (180.3) (Fig. 29 and Table 4). These precursor ions were optimized 
by setting the curtain gas, declustering potential, ion spray voltage, and source gas 1.  
7.2.2. Tandem (MS/MS) mass spectrometry conditions 
 The proton adduct m/z [M+H] + precursor ions of nicotine and its metabolites along 
with IS were selected in positive mode for collision cell quadrupole 2 (MS2). Precursor ions 
were fragmented by applying collisionally-activated dissociation gas and collision energy to 
obtain their most abundant and stable product ions. The product ions for nicotine (117.1), 
cotinine (80.3), trans 3’-hydroxycotinine (80.1), nornicotine (132.3), norcotinine (80.3), 
nicotine-d4 (121.4), and cotinine-d3 (101.2) were optimized by adjusting collision energy, 
curtain gas, entrance potentials, and source gas 2 (Fig. 29 and Table 4). The multiple reactions 
monitoring (MRM) transitions (m/z) [M+H]+, (Q1→Q3) selected for quantitative analyses 
were: 163.3→117.1 for nicotine, 177.5→80.3  for cotinine, 193.2→80.1 for trans 3’-
hydroxycotinine, 149.5→132.3 for nornicotine, 163.4→80.3 for norcotinine, 167.3→121.4 
for nicotine-d4, and 180.3→101.2 for cotinine-d3 (Fig. 29 and Table 4). A dwell time of 500 
ms and a source temperature of 4000C were employed for all the analyte determinations.  
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Table 4: MRM parameters for nicotine and its metabolites 
 
 
 
Analyte Precur
sor   
ion 
Q1 
(MS1) 
Product ions 
Q2 (MS2) 
DP 
(V) 
(MS1) 
EP 
(V) 
(MS1
) 
CEP 
(V) 
(MS1) 
MRM 
transitio
n [Q1→ 
Q3] 
CE 
(V) 
Nicotine 163.3 84.1, 106.0, 
117.1, 130.3, 
132.4 
36.0 5.5 10.0 163.3→ 
117.1 
33.0 
Nornicotine 149.5 80.1,117.1, 
130.1, 132.3 
36.0 5.0 11.0 149.5→ 
132.3 
17.1 
Nicotine-
d4(IS) 
167.3 84.3, 110.5, 
121.4, 134.2, 
136.4 
36.0 7.0 9.5 167.3→ 
121.4 
35.0 
Cotinine 177.5 80.3, 98.1, 146.2 46.0 7.0 12.0 177.5→ 
80.3 
23.0 
Norcotinine 163.4 80.3, 84.1, 135.2, 
146.3 
51.0 6.5 10.0 163.4→ 
80.3 
25.0 
Trans 3’-
hydroxy 
cotinine 
193.2 80.1, 134.3, 149.2 51.0 5.5 11.5 193.2→ 
80.1 
25.0 
Cotinine-
d3(IS) 
180.3 80.3, 101.2, 
118.1, 146.0 
46.0 7.5 12.0 180.3→ 
101.2 
29.0 
MS- mass spectrometry;  m/z- mass-to- charge ratio; DP- declustering potential; CE- 
collision energy; CEP- Cell exit potential; CAD- collisionally activated dissociation gas : 
3.0 psi; MRM- multiple monitoring reactions; Dwell time- 500 ms; Source gas (GS1)- 30.0 
psi;  Source gas (GS2)- 30.0 psi; Source temperature (TEM)- 4000C ;  Ion spray voltage 
(IS)- 5500 Volts; Interface heater- on and Analytical total run time-  4.0 min;  
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Figure 29: MS/MS spectra of nicotine and its metabolites with proton adducts in ESI 
positive mode 
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7.2.3. LC-MS/MS chromatographic separation 
 An LC-MS/MS chromatographic separation was achieved by a reverse phase Xterra 
MS C 18 column (50 x 4.6 mm, i.d, 5µm) using UFLC Shimadzu LC-20AD HPLC 
(California, USA). An isocratic mobile phase composed of 55% acetonitrile in water 
containing 0.05% of formic acid at a flow rate of 0.4 mL/min was used. The samples were 
reconstituted in a 500 µL of acetonitrile-water-formic acid (70:30:0.05) solution. A 15 µL 
aliquot of each sample was injected into LC-MS/MS for quantitative analysis for 5 min. The 
LC-MS/MS acquired MRM data was processed with Analyst software (version 1.4.2, AB 
Sciex).  
7.2.4. Sample preparation and extraction 
 A simple SPE technique was used for sample extraction. Five hundred microliters of 
plasma from a non-smoker was aliquoted and to this 20 µL of 3µg/mL IS (final concentration 
of ~0.1 µg/mL) was added. The mixture was vortex-mixed for 30 sec followed by addition of 
25 µL of an aqueous 0.6% formic acid solution, which was again vortex-mixed for 1 min prior 
to SPE. The strong cation SPE columns (SCX 30 mg, 1 mL cartridge) were preconditioned 
with 1 mL of methanol and equilibrated with 1mL of 0.6% formic acid in water. The plasma 
samples were loaded on the SPE cartridge and drained slowly by applying positive pressure 
at 15 psi with a 48 well plate Positive Vacuum Manifold. The SPE columns were washed with 
1 mL of 0.6% formic acid followed by 1 mL each of water and methanol. Next, the SPE 
columns were air dried under positive vacuum at 20 psi for 3 minutes, and analytes were eluted 
with 1 mL of a 7% ammonium hydroxide in methanol. After elution, the pH of the eluate was 
neutralized with 100 µL of 6% of formic acid in methanol and vortex-mixed prior to 
evaporation using a speed vacuum at 350C for 60 min. Samples were re-dissolved in 500 µL 
of reconstitution solution.    
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7.2.5. Specificity and selectivity  
The specificity and selectivity were tested by analyzing six blank plasma samples from 
HIV-negative non-smokers. These blank matrices were used for method standardization, 
which did not show measurable interference at analyte peak of interests for nicotine and its 
metabolites. Lower limit of quantitation (LLOQ, 0.53 ng/mL) of six samples were processed 
in order to assess the blank plasma interference at the analyte peak of interest (Fig. 30-35). 
The percentage of interference determined in the blank was calculated by comparing the mean 
peak area of LLOQ of the analyte with the peak response obtained from the blank samples. 
The peak areas of blanks co-eluting with the analytes were required to be less than 5 times of 
the mean peak area at the LLOQ.  
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Figure 30: LC-MS/MS-MRM chromatograms of nicotine, its metabolites, and IS for 
extracted lower limit of quantitation (LLOQ, 0.53 ng/mL) 
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Figure 31: LC-MS/MS-MRM chromatograms of nicotine, its metabolites, and IS for 
extracted upper limit of quantitation (ULOQ, 504 ng/mL) 
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Figure 32: LC-MS/MS-MRM chromatograms of nicotine, its metabolites, and IS for low 
quality control (LQC, 3.03 ng/mL) standard 
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 Figure 33: LC-MS/MS-MRM chromatograms of nicotine, its metabolites, and IS for 
extracted middle quality control (MQC, 80.6 ng/mL) 
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Figure 34: LC-MS/MS-MRM chromatograms of nicotine, its metabolites, and IS for 
extracted high quality control (HQC, 504 ng/mL) 
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 LC-MS/MS-MRM chromatograms of nicotine, its metabolites, and IS: 30. extracted lower 
limit of quantitation (LLOQ, 0.53 ng/mL) with IS, 31. Extracted upper limit of quantification 
(ULOQ, 504 ng/mL) with IS, 32. extracted low quality control (LQC, 3.03 ng/mL) standard, 
33. extracted middle quality control ( MQC, 80.6 ng/mL) and 34. extracted high quality 
control ( HQC, 504 ng/mL) from non-smokers plasma.  
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Figure 35: Extracted blank plasma for nicotinine, cotinine, trans-3-hydroxycotinine, nornicotine 
and norcotinine 
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7.2.6. Precision and accuracy 
 Within-assay & between-assay, precision & accuracy experiments were performed by 
analyzing eight extracted calibration and four levels of QC standards (Table 5). The pooled 
blank plasma samples from HIV-negative non-smokers were used to prepare a calibration 
curve and QC standards. The standard samples were prepared based on the procedure 
described earlier [132]. Precision was determined by analyzing six replicates at each of the 
four levels of QC standards. Accuracy was reported as the percentage difference between the 
mean concentrations divided by the nominal concentration, multiplied by 100. Accuracy was 
required to be ±15% of the nominal value of all the standards, except at LLOQ level where an 
accuracy of ±20% was accepted according to the guidance for industry bioanalytical method 
validation in Food and Drug Administration guidelines published in May 2001 
(www.fda.gov). Precision was calculated using the CV (standard deviation/mean 
concentration) multiplied by 100. Precision of the method was required to be less than ≤15% 
of the nominal concentration, except in the LLOQ where ≤20% was an accepted CV. 
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Table 5: Precision and Accuracy of CC and QC standards for nicotine and its 
metabolites in pooled blank human plasma 
  Within-day: CC (n=4), QC (n=6) Between-day : CC (n=6), 
QC(n=6) 
Analyte Nominal  
Conc 
(ng/mL) 
Calculated 
Conc 
(ng/mL) 
Precision 
(% CV) 
Accuracy 
(%)  
Calculated 
Conc 
(ng/mL) 
Precision 
(% CV) 
Accuracy 
(%)  
Nicotine 
CC std-1 504.00 476.57 7.6 94.6 543.9 3.8 107.9 
CC std-2 201.60 175.18 8.1 86.7 179.0 6.5 88.6 
CC std-3 80.64 78.57 5.5 97.5 91.6 9.1 113.7 
CC std-4 30.64 32.63 5.5 106.6 32.3 5.9 105.7 
CC std-5 10.11 11.24 12.6 114.7 9.9 15.4 100.6 
CC std-6 3.03 3.18 12.4 102.6 2.9 1.7 92.6 
CC std-7 1.06 1.07 5.1 97.3 1.1 4.9 102.2 
CC std-8 0.53 0.51 3.8 96.3 0.47 10.3 88.7 
High QC 504.00 483.33 5.3 95.9 483.3 5.3 95.9 
Middle 
QC 
80.64 70.71 13.5 87.7 71.7 13.6 88.9 
Low QC 3.03 2.64 23.3 87.0 2.82 16.3 93.2 
Lower 
LOQ  
QC 
1.06 1.22 31.5 114.8 1.16 27.8 109.1 
Nornicotine 
CC std-1 504.00 544.00 3.8 107.9 527.2 7.3 104.6 
CC std-2 201.60 179.10 6.5 88.8 179.2 6.4 88.9 
CC std-3 80.64 90.38 8.9 112.1 90.7 9.3 112.4 
CC std-4 30.64 32.27 5.9 105.3 32.5 5.9 105.8 
CC std-5 10.11 10.19 14.4 100.7 10.3 13.1 102.3 
CC std-6 3.03 2.99 2.2 98.6 3.0 1.6 99.1 
CC std-7 1.06 1.08 6.2 101.8 1.08 6.2 101.8 
CC std-8 0.53 0.55 23.4 103.4 0.57 22.5 106.6 
High QC 504.00 483.33 5.3 95.9 483.33 5.3 95.9 
Middle 
QC 
80.64 70.71 13.5 87.7 71.44 14.8 88.6 
Low QC 3.03 2.82 16.3 93.2 2.82 16.3 93.2 
Lower 
LOQ  
1.06 1.17 18.4 110.7 1.24 22.4 117.0 
Cotinine 
CC std-1 504.00 518.83 7.3 102.9 504.83 8.7 100.2 
CC std-2 201.60 179.60 6.4 89.1 181.43 6.7 90.0 
CC std-3 80.64 90.55 9.2 112.2 90.11 10.0 111.7 
CC std-4 30.64 31.94 7.5 104.2 31.61 6.9 103.2 
CC std-5 10.11 10.69 11.2 105.6 10.85 10.6 107.3 
CC std-6 3.03 2.98 2.1 98.4 2.99 2.7 98.8 
CC std-7 1.06 1.06 6.8 100.3 1.09 8.4 102.5 
CC std-8 0.53 1.49 14.8 81.7 1.49 148.0 281.8 
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Analyte Nominal 
Conc 
(ng/mL) 
Calculated 
Conc 
(ng/mL) 
Precision 
(%CV) 
Accuracy 
(%) 
Calculated 
Conc 
(ng/mL) 
Precision 
(%CV) 
Accuracy 
(%) 
High QC 504.00 480.83 5.1 95.4 478.00 4.6 94.8 
Middle 
QC 
80.64 70.61 12.4 87.6 72.44 7.4 89.8 
Low QC 3.03 2.84 14.6 93.9 2.84 14.5 93.7 
Lower 
LOQ  
1.06 1.19 18.7 112.3 1.21 17.6 114.5 
Norcotinine 
CC std-1 504.00 545.67 3.8 108.3 545.67 3.8 108.3 
CC std-2 201.60 180.60 6.0 89.6 180.60 6.0 89.6 
CC std-3 80.64 92.61 8.0 114.8 93.94 8.0 116.5 
CC std-4 30.64 32.44 6.6 105.9 31.44 6.7 102.6 
CC std-5 10.11 10.19 14.4 100.7 10.35 14.5 102.4 
CC std-6 3.03 2.98 2.0 98.2 2.99 1.6 98.8 
CC std-7 1.06 0.99 7.3 93.1 1.02 11.2 96.2 
CC std-8 0.53 0.64 19.9 119.8 0.62 17.9 117.3 
High QC 504.00 478.00 4.7 94.8 484.50 3.7 96.1 
Middle 
QC 
80.64 74.27 6.1 92.1 77.27 8.6 95.8 
Low QC 3.03 2.95 4.0 97.5 3.00 1.9 99.1 
Lower 
LOQ  
1.06 1.19 18.7 112.3 1.17 15.9 110.7 
Trans 3’-hydroxy cotinine 
CC std-1 504.00 511.67 7.4 101.5 529.17 7.8 105.0 
CC std-2 201.60 183.10 6.0 90.8 182.43 6.1 90.5 
CC std-3 80.64 89.61 9.4 111.1 90.27 10.2 111.9 
CC std-4 30.64 30.94 7.4 101.0 31.44 6.7 102.6 
CC strd-
5 
10.11 11.02 9.8 109.0 10.69 12.7 105.7 
CC std-6 3.03 2.98 2.9 98.2 3.01 2.2 99.3 
CC std-7 1.06 1.05 7.4 99.4 1.07 10.9 100.9 
CC std-8 0.53 2.39 116.8 451.6 0.61 19.3 115.1 
High QC 504.00 484.17 3.7 96.1 484.17 3.7 96.1 
Middle 
QC 
80.64 73.61 7.4 91.3 75.44 10.7 93.6 
Low QC 3.03 3.02 0.4 99.8 3.00 1.9 98.9 
Lower 
LOQ  
1.06 1.12 9.2 106.0 1.11 10.1 105.0 
CC-calibration curve; QC- quality control; LOQ- lower limit of quantitation 
 
7.2.7. Recovery, matrix effect, and stability of analytes in plasma from non-smokers 
 Recovery of nicotine and its metabolites was estimated by analyses of two sets of six 
replicates of extracted plasma at low, middle, and high QC standards and post-spiked 
(represent 100% recovery) samples along with IS (Table 6). The three levels of recovered QC 
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standards were prepared in blank extracted plasma from non-smokers. The aqueous dilutions 
were post-spiked in non-smoker blank plasma sample to get the same concentrations (504.0, 
80.6, 3.03 ng/mL). An overall extraction recovery was determined by comparing the mean 
peak area ratios of the analytes with the IS obtained from the extracted QC (matrix samples 
from non-smokers versus the unextracted standards).  
Matrix effect of nicotine and its metabolites along with IS was evaluated by analyzing 
2 sets of six replicates of each low, middle, and high QC standards from post-spiked (extracted 
blank plasma samples), and spiked standards in aqueous solutions (represent no matrix effect) 
(Table 6). Ninety blank matrix samples from a non-smoker and 18 samples of each analyte 
were processed and extracted as described above. The aqueous stock QC dilutions (low, 
middle, and high) were spiked in the extracted blank samples to obtain the QC standards 
(504.0, 80.6, and 3.03 ng/mL). Similarly, these QC standards were prepared by spiking 
analytes in reconstitution solution to obtain the same concentrations. Matrix ion suppression 
was calculated by comparing the mean peak area ratios of each analyte and IS generated from 
the post-spiked QC standards from plasma samples from non-smokers with reconstituted 
spiked QC standards. A relative matrix effect was estimated by comparing the mean peak area 
ratios of the analytes to IS obtained from the post-spiked QC. 
Six replicates of stability samples at concentrations of 504.0, 80.64, and 3.03 ng/mL 
were prepared for each analyte in pooled plasma from the non-smokers (Table 7). They were 
stored at -800C for several weeks to estimate the degradation of analyte in the matrix. Stability 
QC samples were extracted along with freshly prepared calibration standards in pooled plasma 
from the non-smokers. The stability samples were frozen and stored for 6 months at -800C. 
Stability QC samples were freeze-thawed for three cycles, and analyzed with freshly prepared 
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calibration curve standards. The linearity of the analysis was determined using freshly spiked 
calibration standards, which were analyzed in duplicate along with stability samples (bench 
top, freeze-thaw stability) processed as described previously [132]. 
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Table 6: Recovery and matrix effect of QC standards of nicotine and its metabolites in 
pooled blank human plasma 
  Recovery (n=6) Matrix effect (n=6) 
Analyte Nominal conc 
(ng/mL) 
% CV % Recovery % CV %Matrix 
effect 
Nicotine 
High QC 504.00 5.6 97.9 5.7 97.6 
Middle QC 80.64 8.4 102.9 8.3 102.5 
Low QC 3.03 24.4 95.7 27.2 91.6 
Nornicotine 
High QC 504.00 8.6 98.5 9.8 100.9 
Middle QC 80.64 8.3 102.5 8.9 101.1 
Low QC 3.03 22.9 86.7 23.6 86.1 
Cotinine 
High QC 504.00 9.7 100.9 5.6 97.9 
Middle QC 80.64 9.1 99.5 8.4 102.9 
Low QC 3.03 29.3 89.6 24.4 95.7 
Norcotinine 
High QC 504.00 9.7 100.9 9.6 101.2 
Middle QC 80.64 9.1 99.5 8.7 100.2 
Low QC 3.03 29.3 89.6 21.0 83.2 
Trans 3’-hydroxy cotinine 
High QC 504.00 8.7 104.2 9.7 103.2 
Middle QC 80.64 11.3 102.8 9.0 106.2 
Low QC 3.03 23.5 86.6 15.7 90.5 
CC- calibration curve; QC- quality control; CV- coefficient of variation  
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Table 7: Benchtop and freeze thaw stability of QC standards of nicotine and its 
metabolites in pooled blank human plasma 
  Bench top (n=6) Freeze-thaw (n=6) 
Analyte Nominal 
conc.(ng/mL) 
Calculated 
conc.(ng/mL) 
% 
CV 
   % 
stability 
 
Calculated 
conc.(ng/mL) 
% 
CV 
% 
stability 
Nicotine 
High QC 504.00 511.71 9.3 101.5 512.01 9.2 101.6 
Middle QC 80.64 83.19 7.1 103.2 82.89 6.8 102.8 
Low QC 3.03 2.56 13.3 88.6 2.68 15.2 93.5 
Nornicotine 
High QC 504.00 564.28 22.8 112.0 574.01 20.3 113.9 
Middle QC 80.64 79.67 14.2 98.9 78.26 15.7 97.1 
Low QC 3.03 3.00 10.3 101.9 2.78 15.0 96.5 
Cotinine 
High QC 504.00 523.86 8.4 103.9 562.01 19.8 111.5 
Middle QC 80.64 81.87 6.6 101.6 76.36 14.8 94.8 
Low QC 3.03 2.49 14.7 87.6 2.67 14.7 94.0 
Norcotinine 
High QC 504.00 528.38 13.8 104.8 577.01 19.7 114.5 
Middle QC 80.64 83.19 14.2 103.2 81.36 14.4 101.0 
Low QC 3.03 2.69 13.2 94.5 3.00 14.5 104.8 
Trans 3’-hydroxy cotinine 
High QC 504.00 507.28 9.9 100.7 520.56 9.6 103.3 
Middle QC 80.64 82.37 7.3 102.3 78.28 13.5 97.1 
Low QC 3.03 2.76 15.2 95.5 2.69 14.0 94.5 
CC- calibration curve; QC- quality control; LOQ- lower limit of quantitation; %CV- percentage 
of coefficient of variation. 
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7.2.8. Patient recruitment 
 Patient recruitment has been previously described [209]. Briefly, following 
Institutional Review Board approval from the University of Missouri-Kansas City and 
Cameroonian Ministry of Health Regional Hospital in Bamenda, Cameroon, we recruited our 
subjects in Cameroon, Africa using strict inclusion and exclusion criteria. For Smokers 
category, we recruited 11 volunteers (7 males, 4 females) who reported a smoking history of 
1-2 packs per day at least for the past 3 years. For HIV- positive smoker category, we recruited 
4 individuals (3 males and 1 female) with CD4 counts ranging between 100-500 cells/µL with 
a similar smoking history. The demographics in both groups including packs per day and 
duration of smoking are similar, except for diagnostic dates of the infection for HIV-positive 
smoker category. The male to female ratio is relatively high in both the categories owing to 
the low prevalence of smoking among women in Cameroon, especially in HIV-infected 
population. Our exclusion criteria include: pregnant females, individuals under 21 years or 
over 65 years (smoking is illegal in the US among youth and individuals >65 have an altered 
metabolism of tobacco constituents), patients with either hepatitis B, malaria, and TB, a CD4 
count <100 or >500 CD4 lymphocytes/µL for HIV-positive group, and those receiving either 
antiretroviral drugs, traditional medicines, or over the counter drugs. We conducted the 
clinical screening tests for malaria, hepatitis, and TB infections using standard procedures as 
described [180, 210-212]. After recruitment, 60 ml of blood was drawn from each individual 
followed by determination of their CD4 counts (Table 3) using Becton Dickenson instrument 
in Provincial Regional Hospital, Bamenda, Cameroon. The viral load of HIV-infected 
smokers was determined in plasma using real time reverse transcriptase polymerase chain 
reaction by Roche Amplicor System (Biocentric) at Pasteur center, Bamenda, Cameroon. The 
remaining plasma samples were shipped to our lab (Kansas City, USA) and stored at -80ºC 
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until further analysis. Six control samples were also collected from non-smoker healthy 
volunteers at the University of Missouri-Kansas city (4 males, 2 females) ranging in age from 
25-45 years for optimizing the method.  HIV-positive and HIV-negative smoker plasma 
samples were processed and extracted according to the sample preparation and extraction 
protocols described above. 
7.2.9. Statistical analysis 
 The concentration of all analytes in the plasma from subjects was calculated by 
Analyst software (AB Sciex, Foster City, CA). The statistical significance (p-values) was 
calculated using one-way analysis of variance and the mean and standard deviations were 
calculated using Microsoft excel software. The LC-MS/MS data of nicotine, cotinine, trans 
3’-hydroxycotinine, nornicotine, and norcotinine obtained from HIV-positive and HIV-
negative smokers was analyzed using boxplot by SPSS IBM statistical software. 
7.3. Results  
7.3.1. System suitability and carry-over tests 
 The system suitability test resulted in <2% variation for nicotine and its metabolites. 
The %CV for nicotine and nornicotine with nicotine-d4 as IS were 0.72 and 1.97, respectively 
(Table 8). Similarly, the %CV for cotinine, trans 3’-hydroxycotinine, and norcotinine with 
their IS cotinine-d3 were 1.01, 0.77, and 0.31, respectively. The carry-over test for nicotine 
and its metabolites at the highest calibrator did not show any carry over to the blank sample. 
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Table 8: System suitability test for all analytes compared to IS represented in % CV 
 
 
Nicotine Nicotine-d4 
(IS) 
Area ratio 
(Analyte/IS) 
Nornicotine Nicotine-
d4 (IS) 
Area ratio 
(Analyte/IS) 
1141682 1897707 0.5911 2185983 1897707 1.1519 
1149019 1931564 0.5949 2142384 1931564 1.1091 
1171239 1943119 0.6028 2162761 1943119 1.1130 
1148919 1939139 0.5925 2173457 1939139 1.0980 
1161239 1943519 0.5975 2152861 1943519 1.1077 
1184409 1979449 0.5984 2153761 1979449 1.0881 
Mean  0.596198   1.11130 
SD  0.0042781   0.021844 
%CV  0.72   1.97 
Cotinine Cotinine-d3 
(IS) 
Area ratio 
(Analyte/IS) 
Norcotinine Cotinine-
d3 (IS) 
Area ratio 
(Analyte/IS) 
2999425 2273971 1.3190 3771038 2273971 1.6583 
3060224 2316229 1.3212 3804754 2316229 1.6427 
3134471 2313156 1.3551 3815535 2313156 1.6495 
3033583 2290737 1.3243 3781464 2290737 1.6508 
3100583 2390728 1.3243 3790161 2390728 1.6508 
3103501 2298747 1.3243 3879214 2298747 1.6508 
Mean  1.32803      1.65048 
SD  0.013436     0.004958 
%CV  1.01     0.31 
Trans 3’hydroxy 
cotinine 
Cotinine-d3 
(IS) 
Area ratio 
(Analyte/IS) 
3479011 2273971 1.5299 
3549332 2316229 1.5324 
3589533 2313156 1.5518 
3485113 2290737 1.5214 
3525243 2390728 1.5214 
3486313 2298747 1.5214 
Mean  1.52971 
SD  0.011852 
%CV  0.77 
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7.3.2. Specificity, selectivity, limit of quantification, and linearity of calibration 
standards 
Nicotine and its metabolites, as well as IS were separated from endogenous 
interference peaks of the blank plasma matrix (Figure 35). Figure 30, 31 shows the extracted 
chromatogram peaks for LLOQ and ULOQ with IS. The LLOQ for nicotine and its 
metabolites in plasma was obtained at 0.53 ng/mL. The mean LLOQ peak areas for nicotine, 
cotinine, trans 3’-hydroxycotinine, nornicotine, and norcotinine were 1254, 4902, 941, 481, 
and 1689, respectively. Similarly, the mean ULOQ peak area for nicotine, cotinine, trans 3’-
hydroxycotinine, nornicotine, and norcotinine were 153522, 1293454, 523735, 134858, and 
575084, respectively. Figure 32-34 represents an example of a QC extracted sample validation 
of LQC (3.03 ng/mL), MQC (80.64 ng/mL), and HQC (504 ng/mL) chromatogram peak 
responses of nicotine, its metabolites, and IS in control plasma. The coefficient of 
determination (R2) for nicotine and its metabolites ranged from 0.9963-0.9994 (Figure 36).  
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Figure 36: Linear regression analysis of CC standards of nicotine and its metabolites in 
pooled blank human plasma 
132 
 
7.3.3. Accuracy and precision 
The best linear fit and least-square residuals for the standards were achieved with a 
1/X weighing factor that yielded a mean linear regression equation for the calibration curve. 
The assay was linear over the range of 0.53-504 ng/mL with R2 ≥ 0.996 (n=6). A regression 
equation and coefficient of determination were obtained as follows (Figure 35): nicotine: y = 
0.0003x + 0.0035, trans 3'-hydroxycotinine: y = 0.0068x + 0.0055, nornicotine: y = 0.0009x 
+ 0.0073, cotinine: y = 0.0103x - 0.0289, and norcotinine: y = 0.007x + 0.024. The % accuracy 
at LLOQ between the days ranged as follows: 109.1-114.8 % for nicotine, 110.7-117% for 
nornicotine, 112.3-114.5% for cotinine, 110.7-112.3 % for norcotinine, and 105-106 % for 
trans 3’-hydroxycotinine (Table 8).  
7.3.4. Recovery, matrix effect, and stability of analytes in plasma from non-smokers 
The percentage recovery of nicotine, cotinine, trans 3’-hydroxycotinine, nornicotine, 
and norcotinine ranged from 95.7-102.9%, 89.6-100.9%, 86.6-104.2%, 86.7-102.5%, and 
89.6-100.9%, respectively (Table 6). Six replicates of LQC, MQC, and HQC were tested for 
a matrix effect. The % matrix effects were between 91.6-102.5%, 95.7-102.9%, 90.5-106.2%, 
86.1-101.1%, and 83.2-101.2% for nicotine, cotinine, trans 3’-hydroxycotinine, nornicotine, 
and norcotinine, respectively (Table 6). The stability results, which are presented as 
percentage of stability (Table 7), yielded bench top stability of <13% and freeze-thaw stability 
of ~14% for nicotine and its metabolites. The degradation of nicotine and its metabolites were 
determined to be <15% at LQC, MQC and HQC levels. 
7.3.5. Quantitative estimation of nicotine and its metabolites in plasma 
Nicotine and its metabolites cotinine, trans 3’-hydroxycotinine, nornicotine, and 
norcotinine were determined at ng/mL levels in the plasma of both HIV-positive and HIV-
negative smokers (Table 9). Nicotine concentration in the HIV-negative smokers ranged from 
133 
 
10.87 to 61.59 ng/mL, while nicotine concentration in the HIV-positive smokers ranged from 
1.9 to 12.3 ng/mL. The concentrations of cotinine, trans 3’-hydroxycotine, nornicotine, and 
norcotinine ranged 2.3-123.38 ng/mL, 1.5-94.19 ng/mL, 1.09-4.10 ng/mL, and 0.63-3.87 
ng/mL, respectively in HIV-negative smokers. However, the concentrations of cotinine, trans 
3’-hydroxycotinine, nornicotine, and norcotinine concentrations ranged 56.00-95.1 ng/mL, 
12.20-34.1 ng/mL, 4.50-8.40 ng/mL and 1.30-2.20 ng/mL, respectively in HIV-positive 
smokers (Table 9). There were no significant differences in the concentration of nicotine and 
its metabolites between male and female subjects when analyzed for HIV-negative smokers 
(data not shown). The mean nicotine concentration in the plasma of HIV-positive smokers 
(6.98 ± 4.26 ng/mL) was 5-fold lower than HIV-negative smokers (33.38 ± 16.41 ng/mL) 
(Figure 37, Table 9). The mean concentration of nicotine metabolite nornicotine was 3-fold 
higher in HIV-positive smokers (5.83 ± 1.8 ng/mL) than HIV-negative smokers (2.58 ± 1.01 
ng/mL). Although not statistically significant, the mean concentration of cotinine was also 
higher in HIV-positive smokers (78.08 ± 16.67 ng/mL) than HIV-negative smokers (77.15 ± 
40.52 ng/mL). However, the mean concentrations of other nicotine metabolites were not 
altered (Figure 37, Table 9).  
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Table 9: Nicotine and its metabolites levels in plasma from HIV-positive and HIV-
negative smokers 
 
 
  
HIV-negative smokers 
Patient 
# 
CD4 
Count 
Nicotine 
(ng/mL) 
Cotinine 
(ng/mL) 
Trans 
3’-hydroxycotinine 
(ng/mL) 
Nornicotine 
(ng/mL) 
Norcotinine 
(ng/mL) 
1 1416 10.87 2.33 2.28 4.10 0.88 
2 938 33.07 115.55 68.19 3.97 2.45 
3 1488 14.85 123.38 24.33 2.15 1.61 
4 1289 27.49 84.93 4.86 1.65 1.19 
5 742 28.96 79.51 94.19 3.61 3.28 
6 936 53.06 65.49 3.43 2.91 0.63 
7 1438 61.59 119.04 71.65 1.91 3.87 
8 1039 51.45 98.37 33.28 1.64 2.42 
9 500 17.10 23.59 1.50 2.46 0.87 
10 700 31.86 38.45 18.86 2.94 1.17 
11 921 36.91 98.02 20.12 1.09 1.15 
Mean  33.38 77.15 31.15 2.58 1.77 
SD  16.41 40.52 32.38 1.01 1.08 
HIV-positive smokers 
2 584 6.50 56.00 34.10 4.70 1.60 
3 13 1.90 75.80 12.20 4.50 1.30 
4 540 12.30 85.40 14.00 5.70 1.40 
5 412 7.20 95.10 22.50 8.40 2.20 
Mean       6.98     78.08               20.70         5.83       1.63 
SD      4.26    16.67               10.00        1.8       0.40 
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Boxplot shows distribution of all individuals, median, first quartile below the median, third 
quartiles above the median and outliers in both HIV-positive smokers and HIV-negative 
smokers plasma.    
 
  
Figure 37: Box plots representing the levels of nicotine and its metabolites in 
plasma of HIV-negative and HIV-postive smokers 
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7.4. Discussion 
In this study, we have developed a simple, fast, and sensitive ESI-LC-MS/MS 
analytical method to simultaneously determine the concentrations of nicotine and four of its 
metabolites in plasma samples. This method enables the determination of concentrations of 
nicotine and its metabolites in HIV-positive and HIV-negative smokers. To our knowledge, 
this is the first report demonstrating the application of an ESI-LC-MS/MS method for 
concurrent determination of the concentrations of nicotine and four of its metabolites with a 
sensitivity of <1 ng/mL. Of importance, this is also the first report to show the difference in 
the concentrations of nicotine and its metabolites in HIV-positive from HIV-negative 
smokers.  
In general, LC-MS/MS bioanalytical results are frequently inconsistent because of 
ineffective sample preparation and extraction methods. These problems, however, can be 
eliminated by modifying sample extraction techniques and mass spectrometry parameters 
including MRM transitions. Liquid-liquid and solid-phase extractions are generally the most 
effective approach. However, they are expensive and time consuming [213]. The elimination 
of unwanted water-soluble compounds, such as phosphates and sulfates from plasma, are 
important in electrospray ionization technique. Zinc sulfate and phosphate present in the 
plasma has been shown to cause ion suppression of analytes leading to inconsistent results 
during the ESI analysis [213-215]. In addition to extraction and sample preparation during the 
LC-MS/MS analysis, pH of the reconstitution solution and mobile phase are important factors 
to achieve optimal chromatographic separation, peak resolution, reproducibility, and 
reliability. Furthermore, reconstitution of the solution also plays an important role in the 
ionization of analytes in the electrospray ionization method. By considering all the above array 
of parameters, we have developed a simple and rapid ESI-LC-MS/MS technique to 
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simultaneously estimate nicotine and its four metabolites in plasma by using strong cation 
exchange SPE. In this technique, the use of formic acid and ammoniated methanolic solutions 
for SPE cartridge conditioning and elution, respectively, enabled the generation of clear and 
reliable samples. We found an increased ionization and peak response upon reconstituting in 
acetonitrile: water: formic acid mixture compared to other reconstitution solutions such as 
acetonitrile, methanol, and its mixtures. 
 The system suitability test results showed that the method is consistent and 
reproducible for all analytes. Carry-over test results showed that there is no significant carry-
over to confound results of the next samples analyzed. The assay conditions had adequate 
specificity for nicotine and its metabolites, and no interfering peaks were observed with 
retention times coinciding with the peak of interest. The signal-to-noise ratio of all analytes 
was measured at LLOQ level and found to be >5-fold that of the extracted blank peak area. 
High signal-to-noise ratio suggests a relatively high quality of extraction efficiency and 
selectivity, with minimal plasma endogenous interference. The chromatogram peak response 
and intensity of nicotine and its metabolites were proportional to the concentrations from 
LLOQ to ULOQ with two IS, which strongly suggests that the method is reproducible and 
robust. Moreover, this method was relatively more sensitive than the other methods, because 
The LLOQ (0.53 ng/mL) for nicotine and its metabolites including cotinine, trans 3’-
hydroxycotinine, nornicotine and norcotinine, was 2- to 5-fold higher than other reported 
methods (LLOQ: 2-10 ng/mL) [140, 141, 203, 216]. More importantly, this level of sensitivity 
was obtained with five analytes simultaneously as opposed to the reported methods, in which, 
the methods were developed with 2-3 analytes simultaneously. Generally, the optimization of 
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LLOQ and extraction are difficult using the plasma matrix as opposed to other matrices 
because plasma has more endogenous interferences than many other matrices.  
 The results of the accuracy and precision chromatograms suggest the method is robust, 
precise, and accurate for the analysis of nicotine and its metabolites in the plasma. The 
calibration curve showed good linearity for nicotine and its metabolites over the entire 
calibration range. All previously reported LC-MS/MS methods have used ammonium acetate 
or ammonium formate buffers in their mobile phase systems with a proton adducts in negative 
and positive modes [140, 215]. Such ammoniated buffer mobile phase systems may enhance 
ionization of analytes and clog the peak tubes, pump seals, and precipitate in the flow line of 
the mobile phase. This would lead to an increase in backup pressure in the HPLC column 
causing leakage of the samples. Therefore, the optimization of nicotine and its metabolites in 
a formic acid mobile phase system with a proton adduct [M+H]+ in the positive ion mode is 
considered superior than the other mobile phase. Formic acid-containing mobile phases have 
the advantage over the ammoniated buffer mobile phase systems, because the former mobile 
phase system never becomes obstructed, and maintains a consistent pressure in the HPLC 
column [213]. Second, this mobile phase system is easy to clean owing to lack of precipitation. 
The nicotine and its metabolites were all eluted from the column within the same retention 
time (~2 min) showing a sharp resolution peak. The analytes were separated and quantified 
based on their mass and charge ratio (m/z), which is relatively fast and efficient compared 
with other reported methods [140, 217]. 
 The recovery efficiency of this method is higher than the previous methods [99, 171], 
and the peak response is also reproducible. Previously, we have developed a liquid-liquid 
extraction method for nicotine and its metabolites in astrocytic and monocytic cell lines [99, 
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202]. However, in the present method we used strong cation exchange SPE cartridges for 
plasma sample analysis. Plasma has numerous complex endogenous interfering components 
compared to astrocytes and monocytes matrices. During optimization of the plasma 
extraction, we tested several other SPE techniques using different solvent conditions and 
elution methods such as strong anion SPE and lipophilic-hydrophilic balance SPE. The current 
method is more sensitive than other reported methods [139, 140], and is able to quantify 
nicotine and its metabolites at LLOQ level without any interference, with high reproducibility 
and high accuracy. In the currently described sample preparation technique, all plasma 
samples including controls, standards, and test samples were pretreated with aqueous formic 
acid solution to make them more acidic prior to SPE. Under acidic conditions we found the 
results were consistent without any interference. The nicotine and its four metabolites were 
stable for 48 weeks with three freeze-thaw cycles at -800C and for 5 hours at ambient 
temperature.  
 Using our newly developed LC-MS/MS technique, we analyzed nicotine and its 
metabolites in the plasma of HIV-positive and HIV-negative smokers. These individuals were 
recruited with strict exclusion criteria to reduce the possibility of confounding by other drugs 
or co-morbidities. The exclusion criteria were critical to determine the specific effects of mild-
to-moderate smoking in HIV-positive patients without any interference by antiretroviral 
therapy, other medications, or other substances of abuse. The nicotine level is ~5-fold lower 
in HIV-positive smokers than HIV-negative smokers strongly suggesting that HIV infection 
increases the metabolism of nicotine (Fig. 38). This hypothesis is further strengthened by the 
findings that the levels of nicotine metabolites, cotinine, and nornicotine are relatively higher 
in HIV-positive than HIV-negative smokers. CYP2A6 is known to metabolize nicotine into 
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the major metabolite cotinine and other minor metabolites including nornicotine [218]. 
Cotinine is further metabolized into trans 3’-hydroxycotinine, norcotinine, and other minor 
metabolites by CYP2A6 [127, 219].  
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The remaining mean relative amounts ± SD (ng/mL) of nicotine, cotinine, nornicotine, 
norcotinine and trans 3’-hydroxycotinine found in the plasma of HIV-positive smokers (n=4) 
and HIV-negative smokers plasma (n=11) are shown in parenthesis. The intensity of arrows 
suggests relative contribution and amounts of CYP2A6-mediated pathways for nicotine 
metabolism. The nicotine is mainly metabolized to cotinine followed by trans 3’-
hydroxycotinine. In addition, nicotine is also metabolized by other pathways to nornicotine 
and norcotinine. 
Figure 38: Scheme of nicotine metabolism representing the concentrations of nicotine and 
its metabolites 
142 
 
Collectively, these results suggest that nicotine metabolism is enhanced significantly 
in HIV-positive smokers compared with HIV-negative smokers. Enhanced nicotine 
metabolism is known to increase ROS and reactive metabolites leading to increased cell 
toxicity and cancer of the lungs, esophagus, and liver [177]. This may lead to an increased 
risk of cancer in HIV-positive smokers compared to HIV-negative smokers. Indeed, our 
recently published data from these patients showed an increase in oxidative DNA damage in 
the plasma of HIV-positive smokers compared to HIV-negative smokers [209]. We also 
reported enhanced oxidative stress that was correlated with an increase in the viral load in 
HIV-positive smokers compared with HIV-positive non-smokers [209]. Previous reports also 
suggest a role of smoking in increased viral replication and the possible association with 
increased oxidative stress [72, 100, 168].  
7.5. Conclusion 
In conclusion, since the prevalence of smoking is higher in HIV-positive individuals 
than the general population [59] and in turn smoking is associated with increased viral 
replication [69-71], it is important to understand the underlying mechanism of 
smoking/nicotine-mediated HIV replication. This report suggests a possible role of nicotine 
metabolism in oxidative stress-mediated increase in viral replication in HIV-positive smokers. 
However, further studies are necessary to elucidate this mechanism to confirm the role of 
CYP2A6-mediated nicotine metabolism, especially in monocytes/macrophages, in HIV 
replication.  
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CHAPTER 8 
SUMMARY AND FUTURE DIRECTIONS 
8.1. Summary and significance 
Assessment of the mortality rates among AIDS patients has revealed that the risk of 
death is twice as high among smokers in the HIV-infected population compared to the non-
HIV-infected population. There is an evidence from the literature suggesting that smoking is 
associated with decline in CD4 cell counts in the HIV-infected population, despite of the 
higher baseline CD4 cell counts observed among smokers than non-smokers [77]. However, 
the role of smoking in the progression to AIDS is unknown. Recent reports from the literature 
have also demonstrated the toxic effects of the tobacco constituents, nicotine and nicotine-
derived nitrosamine ketones (NNK) in neurons, microglia, and white blood cells, which are 
exposed to the virus or viral proteins [23, 24]. For example, the treatment with NNK to mouse 
microglial cells and in vivo injection of mouse with NNK showed an increase in ROS, as well 
as an increase in the levels of proinflammatory cytokines [23]. However, the mechanism of 
tobacco-mediated toxicity and decreased efficacy of HAART is largely unknown. 
The present study investigated the role of CYPs in tobacco/nicotine-mediated 
oxidative stress in HIV cell models, and their possible link to HIV pathogenesis and 
neuroAIDS. The experiments in specific aim 1 were designed to determine the role of 
CYP2A6 in nicotine metabolism in HIV cell models, SVGA astrocytes (chapter 4). It can be 
noted that the role of CYP2A6 in nicotine metabolism in other HIV model, U937 monocytes 
were earlier performed by Jin et al. 2012. In Specific Aim 2, CSC-mediated CYP induction, 
oxidative stress, and cell death in U937 monocytes and HIV replication in primary 
macrophages were investigated (chapter 5). In Specific Aim 3, the levels of CYP2A6 and 
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antioxidant enzymes (AOE) were determined in blood monocytes isolated from a cohort of 
patients (Healthy, smokers, HIV and HIV smokers) using a cross-sectional ex vivo study 
design (chapter 6). In Specific Aim 4, upon developing a sensitive and robust LC-MS/MS 
method for nicotine and its metabolites, their levels were determined in plasma samples of 
smokers and HIV Smokers from ex vivo study (chapter 7).  
Results from Specific aim 1 showed that nicotine induced CYP1A1 and CYP2A6 at 
both mRNA and protein levels in SVGA astrocytes. Nicotine also increased the production of 
ROS in these cells. The role of CYP2A6 in nicotine metabolism-mediated oxidative stress 
were further demonstrated using a specific CYP2A6 inhibitor, tryptamine. Results from 
Specific aim 2 demonstrated that CSC increases CYP1A1 induction and oxidative stress, 
which were significantly higher than that caused by nicotine. CSC treatment also induced 
caspase-3-mediated apoptosis in U937 monocytes. Finally, CSC treatment enhanced HIV 
replication in HIV-infected primary macrophages as determined by p24 antigen levels. Results 
from Specific aim 3 demonstrated that mild-to-moderate smoking increases viral load in HIV-
infected smokers in ART naïve subjects. In addition, smoking and HIV both independently 
increased oxidative DNA damage in plasma and monocytes. Higher oxidative stress was 
further observed in HIV-infected smokers when compared to other cohorts independently. 
Our results demonstrated that the levels of mRNA of the most antioxidant genes are not altered 
in HIV positive and/or smoker groups compared to HIV-negative non-smokers. As expected, 
the results showed that the levels of CYP2A6 mRNA is increased in HIV negative smokers 
compared to HIV-negative non-smokers However, the level of CYP2A6 mRNA was only 
marginally increased in HIV-positive non-smokers and HIV positive smokers compared to 
HIV-negative non-smokers. Results from Specific aim 4 showed that the nicotine level is ~5-
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fold lower in HIV-positive smokers than HIV-negative smokers strongly suggesting that HIV 
infection increases the metabolism of nicotine. This hypothesis is further strengthened by the 
findings that the levels of nicotine metabolites, cotinine, and nornicotine are relatively higher 
in HIV-positive than HIV-negative smoker.  
8.2. Conclusions and future directions 
The role of oxidative stress as a result of production of ROS, including nitric oxides 
has been implicated in HIV pathogenesis. Similarly, previous literature and our current 
findings demonstrate that smoking and oxidative stress both are independently associated with 
increased HIV replication. Thus, we suggest that smoking-mediated oxidative stress may be 
responsible for increased HIV replication. Since CYP-mediated metabolism of tobacco 
constituents is known to produce reactive oxygen species in the liver, it is reasonable to 
conclude that CYP-mediated pathways contribute to the DNA damage in both plasma and 
monocytes. Our results showing relatively low levels of DNA damage in monocytes suggest 
that CYP-mediated metabolic pathway also exists in monocytes. Our speculation is consistent 
with our earlier observation that although monocytes contain relatively low levels of CYP 
enzymes compared to the liver, the relative level of CYP2A6 in monocytes is much higher 
that other CYP enzymes [190]. Therefore, we suggest that although CYP2A6 in smokers and 
HIV positive non-smokers are not induced, the basal level of CYP2A6 is sufficient to 
metabolize tobacco constituents and endogenous compounds and produce ROS. Furthermore, 
our observation is consistent with the recent finding that CYP2A6-mediated metabolism of 
nicotine produces ROS in monocytes and astrocytes [99], which may be responsible for 
increased DNA damage in monocytes. Our studies also demonstrated an increased metabolism 
of nicotine in HIV positive smokers compared to HIV negative smokers. It is also possible 
that the increased metabolism is due to increased activity of enzyme rather than the actual 
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protein level. An increase in enzyme activity through substrate-mediated enhance stability of 
enzyme is known in the P450 system [192].   
An increase in oxidative stress could be as a result of both, CYP-mediated hepatic 
metabolism of smoking constituents and/or endogenous compounds and lack of induction of 
AOEs. Although we suggest a possible association of CYP and oxidative stress pathways in 
HIV replication, other pathways cannot be excluded. Therefore, there is a need to further 
investigate CYP or alternative pathways in smoking-mediated HIV pathogenesis up on 
treatment with CSC as well as the active constituents of CSC (for e.g. PAH, benzyl 
naphthalene, phenanthrene) in in vitro HIV-infected macrophages as well as in an in vivo HIV-
infected humanized mice model.  
In summary, our in vitro and ex vivo studies have shown the phenomenon of enhanced 
oxidative damage, nicotine metabolism, and HIV replication in HIV-infected smokers. Since 
we employed a cross sectional study design in delineating the above phenomenon, 
furthermore there is an urge to investigate the mechanism delineating the role of CYP-
mediated oxidative stress on cytotoxicity and viral replication. Therefore, an ex vivo study 
following longitudinal design using large number of individuals would help in identifying 
specific targets for CYP pathway to alleviate smoking-mediated HIV pathogenesis and drug 
interactions.  
  
147 
 
References 
1. WHO report on the global tobacco epidemic , 2011: Warning about the dangers of 
tobacco. 2011. 
2. Messner, B., et al., Apoptosis and necrosis: two different outcomes of cigarette smoke 
condensate-induced endothelial cell death. Cell death & disease, 2012. 3: p. e424. 
3. Muller, T. and A. Hengstermann, Nrf2: friend and foe in preventing cigarette smoking-
dependent lung disease. Chemical research in toxicology, 2012. 25(9): p. 1805-24. 
4. Gvinianidze, K. and D. Tsereteli, Tobacco smoking attributable mortality and years 
of potential life lost in Georgia. Georgian medical news, 2012(206): p. 52-7. 
5. World report on the global tobacco epidemic, 2009: Implementing smoking free 
environments. . 2009. 
6. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of 
carcinogenic risks to humans / World Health Organization, International Agency for 
Research on Cancer, 2004. 83: p. 1-1438. 
7. Jauniaux, E. and G.J. Burton, Morphological and biological effects of maternal 
exposure to tobacco smoke on the feto-placental unit. Early human development, 
2007. 83(11): p. 699-706. 
8. de la Chica, R.A., et al., Chromosomal instability in amniocytes from fetuses of 
mothers who smoke. JAMA : the journal of the American Medical Association, 2005. 
293(10): p. 1212-22. 
9. Rice, J.M. and J.M. Ward, Age dependence of susceptibility to carcinogenesis in the 
nervous system. Annals of the New York Academy of Sciences, 1982. 381: p. 274-89. 
10. Bodnar, J.A., et al., Mainstream smoke chemistry analysis of samples from the 2009 
US cigarette market. Regulatory toxicology and pharmacology : RTP, 2012. 64(1): p. 
35-42. 
11. Coggins, C.R., E.J. Sena, and M.J. Oldham, A comprehensive evaluation of the 
toxicology of cigarette ingredients: inorganic compounds. Inhalation toxicology, 
2011. 23 Suppl 1: p. 157-71. 
12. Banerjee, A.G., V.K. Gopalakrishnan, and J.K. Vishwanatha, Inhibition of nitric 
oxide-induced apoptosis by nicotine in oral epithelial cells. Molecular and cellular 
biochemistry, 2007. 305(1-2): p. 113-21. 
13. Xu, J., et al., Nicotine inhibits apoptosis induced by cisplatin in human oral cancer 
cells. International journal of oral and maxillofacial surgery, 2007. 36(8): p. 739-44. 
14. Zhou, Y., et al., Nicotine decreases the cytotoxicity of doxorubicin towards MCF-7 
and KB-3.1 human cancer cells in culture. Journal of the National Medical 
Association, 2007. 99(4): p. 319-27. 
15. Arredondo, J., A.I. Chernyavsky, and S.A. Grando, Nicotinic receptors mediate 
tumorigenic action of tobacco-derived nitrosamines on immortalized oral epithelial 
cells. Cancer biology & therapy, 2006. 5(5): p. 511-7. 
16. Lee, H.J., et al., Effects of nicotine on proliferation, cell cycle, and differentiation in 
immortalized and malignant oral keratinocytes. Journal of oral pathology & medicine 
: official publication of the International Association of Oral Pathologists and the 
American Academy of Oral Pathology, 2005. 34(7): p. 436-43. 
148 
 
17. Elias, S.T., et al., Cytotoxic effect of tobacco extracts on human oral squamous cell 
carcinoma cell-line. Oral oncology, 2010. 46(12): p. 869-73. 
18. Wannhoff, A., et al., Oxidative and nitrosative stress and apoptosis in oral mucosa 
cells after ex vivo exposure to lead and benzo[a]pyrene. Toxicology in vitro : an 
international journal published in association with BIBRA, 2013. 27(2): p. 915-921. 
19. Benowitz, N.L., Pharmacology of nicotine: addiction, smoking-induced disease, and 
therapeutics. Annual review of pharmacology and toxicology, 2009. 49: p. 57-71. 
20. Keyler, D., et al., Effects of nicotine infusion on the metabolism of the tobacco 
carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in rats. Cancer 
letters, 2003. 202(1): p. 1-9. 
21. Wong, H.L., et al., Metabolic activation of the tobacco carcinogen 4-
(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal 
nasal microsomes. Chemical research in toxicology, 2005. 18(6): p. 913-8. 
22. Bao, Z., et al., Metabolism of nicotine and cotinine by human cytochrome P450 2A13. 
Drug metabolism and disposition: the biological fate of chemicals, 2005. 33(2): p. 258-
61. 
23. Ghosh, D., et al., Tobacco carcinogen induces microglial activation and subsequent 
neuronal damage. Journal of neurochemistry, 2009. 110(3): p. 1070-81. 
24. Chuang, C.H. and M.L. Hu, Synergistic DNA damage and lipid peroxidation in 
cultured human white blood cells exposed to 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-
butanone and ultraviolet A. Environmental and molecular mutagenesis, 2006. 47(2): 
p. 73-81. 
25. Bhagwat, S.V., et al., Preferential effects of nicotine and 4-(N-methyl-N-nitrosamine)-
1-(3-pyridyl)-1-butanone on mitochondrial glutathione S-transferase A4-4 induction 
and increased oxidative stress in the rat brain. Biochemical pharmacology, 1998. 
56(7): p. 831-9. 
26. Bloom, A.J., et al., Use of a predictive model derived from in vivo endophenotype 
measurements to demonstrate associations with a complex locus, CYP2A6. Human 
molecular genetics, 2012. 21(13): p. 3050-62. 
27. Crampsie, M.A., et al., Phenylbutyl isoselenocyanate modulates phase I and II 
enzymes and inhibits 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone-induced DNA 
adducts in mice. Cancer prevention research, 2011. 4(11): p. 1884-94. 
28. Rahman, I., Oxidative stress, chromatin remodeling and gene transcription in 
inflammation and chronic lung diseases. Journal of biochemistry and molecular 
biology, 2003. 36(1): p. 95-109. 
29. Whang, Y.M., et al., Wnt5a Is Associated with Cigarette Smoke-Related Lung 
Carcinogenesis via Protein Kinase C. PloS one, 2013. 8(1): p. e53012. 
30. Duong, C., et al., Glutathione peroxidase-1 protects against cigarette smoke-induced 
lung inflammation in mice. American journal of physiology. Lung cellular and 
molecular physiology, 2010. 299(3): p. L425-33. 
31. Margaret, A.L., E. Syahruddin, and S.I. Wanandi, Low activity of manganese 
superoxide dismutase (MnSOD) in blood of lung cancer patients with smoking history: 
relationship to oxidative stress. Asian Pacific journal of cancer prevention : APJCP, 
2011. 12(11): p. 3049-53. 
32. Sandhu, R.K., et al., Smoking, smoking cessation, and risk of sudden cardiac death in 
women. Circulation. Arrhythmia and electrophysiology, 2012. 5(6): p. 1091-7. 
149 
 
33. Bishop, E., E.H. Theophilus, and I.M. Fearon, In vitro and clinical studies examining 
the expression of osteopontin in cigarette smoke-exposed endothelial cells and 
cigarette smokers. BMC cardiovascular disorders, 2012. 12: p. 75. 
34. Nemmar, A., et al., Short-Term Systemic Effects of Nose-Only Cigarette Smoke 
Exposure in Mice: Role of Oxidative Stress. Cellular physiology and biochemistry : 
international journal of experimental cellular physiology, biochemistry, and 
pharmacology, 2013. 31(1): p. 15-24. 
35. Saalu, L.C., The incriminating role of reactive oxygen species in idiopathic male 
infertility: an evidence based evaluation. Pakistan journal of biological sciences: 
PJBS, 2010. 13(9): p. 413-22. 
36. Zhu, Z., et al., The alteration of protein profile induced by cigarette smoking via 
oxidative stress in mice epididymis. The international journal of biochemistry & cell 
biology, 2013. 45(3): p. 571-82. 
37. Huang, J., et al., Telomere susceptibility to cigarette smoke-induced oxidative damage 
and chromosomal instability of mouse embryos in vitro. Free radical biology & 
medicine, 2010. 48(12): p. 1663-76. 
38. Sobinoff, A.P., et al., Jumping the gun: smoking constituent BaP causes premature 
primordial follicle activation and impairs oocyte fusibility through oxidative stress. 
Toxicology and applied pharmacology, 2012. 260(1): p. 70-80. 
39. Ashraf, M.W., Levels of heavy metals in popular cigarette brands and exposure to 
these metals via smoking. TheScientificWorldJournal, 2012. 2012: p. 729430. 
40. Samuel, J.B., et al., Gestational cadmium exposure-induced ovotoxicity delays puberty 
through oxidative stress and impaired steroid hormone levels. Journal of medical 
toxicology : official journal of the American College of Medical Toxicology, 2011. 
7(3): p. 195-204. 
41. Ghibaudi, E.M., et al., Can estrogenic radicals, generated by lactoperoxidase, be 
involved in the molecular mechanism of breast carcinogenesis? Redox report : 
communications in free radical research, 2000. 5(4): p. 229-35. 
42. Ponnusamy, M. and L. Pari, Protective role of diallyl tetrasulfide on cadmium-induced 
testicular damage in adult rats: a biochemical and histological study. Toxicology and 
industrial health, 2011. 27(5): p. 407-16. 
43. Miksys, S., et al., Smoking, alcoholism and genetic polymorphisms alter CYP2B6 
levels in human brain. Neuropharmacology, 2003. 45(1): p. 122-32. 
44. Khokhar, J.Y., S.L. Miksys, and R.F. Tyndale, Rat brain CYP2B induction by nicotine 
is persistent and does not involve nicotinic acetylcholine receptors. Brain research, 
2010. 1348: p. 1-9. 
45. Lee, A.M., et al., CYP2B6 is expressed in African Green monkey brain and is induced 
by chronic nicotine treatment. Neuropharmacology, 2006. 50(4): p. 441-50. 
46. von Weymarn, L.B., J.A. Chun, and P.F. Hollenberg, Effects of benzyl and phenethyl 
isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers. 
Carcinogenesis, 2006. 27(4): p. 782-90. 
47. Global HIV/AIDS Response, Epidemic update and health sector progress towards 
Universal Access. Progress Report 2011. p. pp 11-47. 
48. Okeudo, C., B.U. Ezem, and E.C. Ojiyi, Human immuno-deficiency virus antibody 
seroprevalence among pregnant women at booking at a university teaching hospital 
150 
 
in South-Eastern Nigeria. Nigerian journal of medicine : journal of the National 
Association of Resident Doctors of Nigeria, 2012. 21(2): p. 227-30. 
49. Bork, K., et al., Infant feeding modes and determinants among HIV-1-infected African 
Women in the Kesho Bora Study. Journal of acquired immune deficiency syndromes, 
2013. 62(1): p. 109-18. 
50. Rempel, H., et al., Monocyte Activation in HIV/HCV Coinfection Correlates with 
Cognitive Impairment. PloS one, 2013. 8(2): p. e55776. 
51. Gray, J.M. and D.L. Cohn, Tuberculosis and HIV Coinfection. Seminars in respiratory 
and critical care medicine, 2013. 34(1): p. 32-43. 
52. Burgoyne, R.W. and D.H. Tan, Prolongation and quality of life for HIV-infected adults 
treated with highly active antiretroviral therapy (HAART): a balancing act. The 
Journal of antimicrobial chemotherapy, 2008. 61(3): p. 469-73. 
53. Xia, C., et al., HIV-associated dementia in the era of highly active antiretroviral 
therapy (HAART). Microbes and infection / Institut Pasteur, 2011. 13(5): p. 419-25. 
54. Mothobi, N.Z. and B.J. Brew, Neurocognitive dysfunction in the highly active 
antiretroviral therapy era. Current opinion in infectious diseases, 2012. 25(1): p. 4-9. 
55. Vivithanaporn, P., M.J. Gill, and C. Power, Impact of current antiretroviral therapies 
on neuroAIDS. Expert review of anti-infective therapy, 2011. 9(4): p. 371-4. 
56. Purohit, V., R. Rapaka, and D. Shurtleff, Drugs of abuse, dopamine, and HIV-
associated neurocognitive disorders/HIV-associated dementia. Molecular 
neurobiology, 2011. 44(1): p. 102-10. 
57. Unique Interactions Between Tobacco Use and HIV/AIDS (R03) N.I.o.D.A. (NIDA), 
Editor. 2009: Bethesda, Maryland 20892. 
58. Murray, C.J. and A.D. Lopez, Alternative projections of mortality and disability by 
cause 1990-2020: Global Burden of Disease Study. Lancet, 1997. 349(9064): p. 1498-
504. 
59. Burkhalter, J.E., et al., Tobacco use and readiness to quit smoking in low-income HIV-
infected persons. Nicotine & tobacco research : official journal of the Society for 
Research on Nicotine and Tobacco, 2005. 7(4): p. 511-22. 
60. Cigarette Smoking Among Adults—United States,2004. November 11, 2005, CDC. 
61. Feldman, J.G., et al., Association of cigarette smoking with HIV prognosis among 
women in the HAART era: a report from the women's interagency HIV study. 
American journal of public health, 2006. 96(6): p. 1060-5. 
62. Kalra, R., et al., Immunosuppressive and anti-inflammatory effects of nicotine 
administered by patch in an animal model. Clinical and diagnostic laboratory 
immunology, 2004. 11(3): p. 563-8. 
63. Sopori, M., Effects of cigarette smoke on the immune system. Nature reviews. 
Immunology, 2002. 2(5): p. 372-7. 
64. Singh, S.P., et al., Acute and chronic nicotine exposures modulate the immune system 
through different pathways. Toxicology and applied pharmacology, 2000. 164(1): p. 
65-72. 
65. Hodge-Bell, K.C., et al., Pulmonary inflammation in mice exposed to mainstream 
cigarette smoke. Inhalation toxicology, 2007. 19(4): p. 361-76. 
66. Razani-Boroujerdi, S., et al., Chronic nicotine inhibits inflammation and promotes 
influenza infection. Cellular immunology, 2004. 230(1): p. 1-9. 
151 
 
67. McMaster, S.K., et al., Cigarette smoke inhibits macrophage sensing of Gram-
negative bacteria and lipopolysaccharide: relative roles of nicotine and oxidant stress. 
British journal of pharmacology, 2008. 153(3): p. 536-43. 
68. Yamaguchi, Y., et al., Oxidants in the gas phase of cigarette smoke pass through the 
lung alveolar wall and raise systemic oxidative stress. Journal of pharmacological 
sciences, 2007. 103(3): p. 275-82. 
69. Abbud, R.A., et al., Enhanced production of human immunodeficiency virus type 1 by 
in vitro-infected alveolar macrophages from otherwise healthy cigarette smokers. The 
Journal of infectious diseases, 1995. 172(3): p. 859-63. 
70. Rock, R.B., et al., Potentiation of HIV-1 expression in microglial cells by nicotine: 
involvement of transforming growth factor-beta 1. Journal of neuroimmune 
pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 
2008. 3(3): p. 143-9. 
71. Zhao, L., et al., Mechanisms and genes involved in enhancement of HIV infectivity by 
tobacco smoke. Toxicology, 2010. 278(2): p. 242-8. 
72. Boelaert, J.R., et al., Iron and oxidative stress as a mechanism for the enhanced 
production of human immunodeficiency virus by alveolar macrophages from 
otherwise healthy cigarette smokers. The Journal of infectious diseases, 1996. 173(4): 
p. 1045-7. 
73. Smith, T.J., et al., Enzymes involved in the bioactivation of 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone in patas monkey lung and liver microsomes. Carcinogenesis, 
1997. 18(8): p. 1577-84. 
74. Helleberg, M., et al., Mortality attributable to smoking among HIV-1-infected 
individuals: a nationwide, population-based cohort study. Clinical infectious diseases 
: an official publication of the Infectious Diseases Society of America, 2013. 56(5): p. 
727-34. 
75. Minkoff, H., et al., Relationship between smoking and human papillomavirus 
infections in HIV-infected and -uninfected women. The Journal of infectious diseases, 
2004. 189(10): p. 1821-8. 
76. Kaner, R.J., F. Santiago, and R.G. Crystal, Up-regulation of alveolar macrophage 
matrix metalloproteinases in HIV1(+) smokers with early emphysema. Journal of 
leukocyte biology, 2009. 86(4): p. 913-22. 
77. Marshall, M.M., M.C. McCormack, and G.D. Kirk, Effect of cigarette smoking on HIV 
acquisition, progression, and mortality. AIDS education and prevention : official 
publication of the International Society for AIDS Education, 2009. 21(3 Suppl): p. 28-
39. 
78. Wojna, V., et al., Associations of cigarette smoking with viral immune and cognitive 
function in human immunodeficiency virus-seropositive women. Journal of 
neurovirology, 2007. 13(6): p. 561-8. 
79. Manda, V.K., et al., Chronic exposure to nicotine and saquinavir decreases 
endothelial Notch-4 expression and disrupts blood-brain barrier integrity. Journal of 
neurochemistry, 2010. 115(2): p. 515-25. 
80. Benowitz, N.L., J. Hukkanen, and P. Jacob, 3rd, Nicotine chemistry, metabolism, 
kinetics and biomarkers. Handbook of experimental pharmacology, 2009(192): p. 29-
60. 
152 
 
81. Hernando-Rodriguez, M., et al., Role of cytochrome P-450 genetic polymorphisms in 
oral carcinogenesis. Journal of oral pathology & medicine : official publication of the 
International Association of Oral Pathologists and the American Academy of Oral 
Pathology, 2012. 41(1): p. 1-8. 
82. Kulbacka, J., J. Saczko, and A. Chwilkowska, [Oxidative stress in cells damage 
processes]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 
2009. 27(157): p. 44-7. 
83. Murphy, S.E., V. Raulinaitis, and K.M. Brown, Nicotine 5'-oxidation and methyl 
oxidation by P450 2A enzymes. Drug metabolism and disposition: the biological fate 
of chemicals, 2005. 33(8): p. 1166-73. 
84. Hukkanen, J., P. Jacob, 3rd, and N.L. Benowitz, Metabolism and disposition kinetics 
of nicotine. Pharmacological reviews, 2005. 57(1): p. 79-115. 
85. Guo, L., et al., [Correlation between smoking and the polymorphisms of cytochrome 
P450 1A1-Msp I and glutathione S-transferase T1 genes and oral cancer]. Hua xi kou 
qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of 
stomatology, 2012. 30(2): p. 187-91. 
86. Chi, A.C., et al., Differential induction of CYP1A1 and CYP1B1 by benzo[a]pyrene in 
oral squamous cell carcinoma cell lines and by tobacco smoking in oral mucosa. Oral 
oncology, 2009. 45(11): p. 980-5. 
87. Igarashi, T., et al., Macrophage are the principal reservoir and sustain high virus 
loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic 
simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 
infections of humans. Proceedings of the National Academy of Sciences of the United 
States of America, 2001. 98(2): p. 658-63. 
88. Montaner, L.J., et al., Advances in macrophage and dendritic cell biology in HIV-1 
infection stress key understudied areas in infection, pathogenesis, and analysis of viral 
reservoirs. Journal of leukocyte biology, 2006. 80(5): p. 961-4. 
89. Kedzierska, K. and S.M. Crowe, The role of monocytes and macrophages in the 
pathogenesis of HIV-1 infection. Current medicinal chemistry, 2002. 9(21): p. 1893-
903. 
90. Aquaro, S., et al., Human immunodeficiency virus infection and acquired 
immunodeficiency syndrome dementia complex: role of cells of monocyte-macrophage 
lineage. Journal of neurovirology, 2005. 11 Suppl 3: p. 58-66. 
91. Kim, W.K., X. Avarez, and K. Williams, The role of monocytes and perivascular 
macrophages in HIV and SIV neuropathogenesis: information from non-human 
primate models. Neurotoxicity research, 2005. 8(1-2): p. 107-15. 
92. Nottet, H.S., Interactions between macrophages and brain microvascular endothelial 
cells: role in pathogenesis of HIV-1 infection and blood - brain barrier function. 
Journal of neurovirology, 1999. 5(6): p. 659-69. 
93. Persidsky, Y. and H.E. Gendelman, Mononuclear phagocyte immunity and the 
neuropathogenesis of HIV-1 infection. Journal of leukocyte biology, 2003. 74(5): p. 
691-701. 
94. Persidsky, Y., et al., Microglial and astrocyte chemokines regulate monocyte 
migration through the blood-brain barrier in human immunodeficiency virus-1 
encephalitis. The American journal of pathology, 1999. 155(5): p. 1599-611. 
153 
 
95. Jin, M., A. Kumar, and S. Kumar, Ethanol-mediated regulation of cytochrome P450 
2A6 expression in monocytes: role of oxidative stress-mediated PKC/MEK/Nrf2 
pathway. PloS one, 2012. 7(4): p. e35505. 
96. Jin, M., et al., Effect of alcohol on drug efflux protein and drug metabolic enzymes in 
U937 macrophages. Alcoholism, clinical and experimental research, 2011. 35(1): p. 
132-9. 
97. Nagai, F., et al., Cytochrome P450 (CYP) expression in human myeloblastic and 
lymphoid cell lines. Biological & pharmaceutical bulletin, 2002. 25(3): p. 383-5. 
98. Hodges, V.M., G.Y. Molloy, and S.N. Wickramasinghe, Demonstration of mRNA for 
five species of cytochrome P450 in human bone marrow, bone marrow-derived 
macrophages and human haemopoietic cell lines. British journal of haematology, 
2000. 108(1): p. 151-6. 
99. Jin, M., et al., A LC-MS/MS method for concurrent determination of nicotine 
metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: 
implications in oxidative stress in HIV + smokers. Journal of neuroimmune 
pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 
2012. 7(1): p. 289-99. 
100. Aquaro, S., et al., The contribution of peroxynitrite generation in HIV replication in 
human primary macrophages. Retrovirology, 2007. 4: p. 76. 
101. McCartney, E.M., et al., Alcohol metabolism increases the replication of hepatitis C 
virus and attenuates the antiviral action of interferon. The Journal of infectious 
diseases, 2008. 198(12): p. 1766-75. 
102. Osna, N.A., et al., Proteasome activation by hepatitis C core protein is reversed by 
ethanol-induced oxidative stress. Gastroenterology, 2008. 134(7): p. 2144-52. 
103. Ghosh, C., et al., Cellular localization and functional significance of CYP3A4 in the 
human epileptic brain. Epilepsia, 2011. 52(3): p. 562-71. 
104. Crothers, K., et al., Impact of cigarette smoking on mortality in HIV-positive and HIV-
negative veterans. AIDS education and prevention : official publication of the 
International Society for AIDS Education, 2009. 21(3 Suppl): p. 40-53. 
105. Das, S., et al., In vitro nicotine induced superoxide mediated DNA fragmentation in 
lymphocytes: protective role of Andrographis paniculata Nees. Toxicology in vitro : 
an international journal published in association with BIBRA, 2009. 23(1): p. 90-8. 
106. Kleinsasser, N.H., et al., The tobacco alkaloid nicotine demonstrates genotoxicity in 
human tonsillar tissue and lymphocytes. Toxicological sciences : an official journal of 
the Society of Toxicology, 2005. 86(2): p. 309-17. 
107. Vanden Heuvel, J.P., et al., CYP1A1 mRNA levels as a human exposure biomarker: 
use of quantitative polymerase chain reaction to measure CYP1A1 expression in 
human peripheral blood lymphocytes. Carcinogenesis, 1993. 14(10): p. 2003-6. 
108. Lambert, N., et al., Human cytochrome P450's are pro-oxidants in iron/ascorbate-
initiated microsomal lipid peroxidation. Free radical research, 1996. 24(3): p. 177-85. 
109. Sharma, A., et al., Cytochrome P450 2A isoenzymes in freshly prepared blood 
lymphocytes isolated from rats and validation as a biomarker for clinical studies in 
humans. Xenobiotica; the fate of foreign compounds in biological systems, 2013. 
43(4): p. 311-9. 
154 
 
110. Kranick, S.M. and A. Nath, Neurologic complications of HIV-1 infection and its 
treatment in the era of antiretroviral therapy. Continuum, 2012. 18(6 Infectious 
Disease): p. 1319-37. 
111. Li, J., et al., Human immunodeficiency virus type 1 efficiently binds to human fetal 
astrocytes and induces neuroinflammatory responses independent of infection. BMC 
neuroscience, 2007. 8: p. 31. 
112. Wang, T., et al., HIV-1-infected astrocytes and the microglial proteome. Journal of 
neuroimmune pharmacology : the official journal of the Society on NeuroImmune 
Pharmacology, 2008. 3(3): p. 173-86. 
113. Shah, A., et al., HIV-1 gp120 induces expression of IL-6 through a nuclear factor-
kappa B-dependent mechanism: suppression by gp120 specific small interfering RNA. 
PLoS One, 2011. 6(6): p. e21261. 
114. Shah, A. and A. Kumar, HIV-1 gp120-mediated increases in IL-8 production in 
astrocytes are mediated through the NF-kappaB pathway and can be silenced by 
gp120-specific siRNA. Journal of neuroinflammation, 2010. 7: p. 96. 
115. Hawkins, B.T., et al., Nicotine increases in vivo blood-brain barrier permeability and 
alters cerebral microvascular tight junction protein distribution. Brain research, 2004. 
1027(1-2): p. 48-58. 
116. Lockman, P.R., et al., Chronic nicotine exposure alters blood-brain barrier 
permeability and diminishes brain uptake of methyllycaconitine. Journal of 
neurochemistry, 2005. 94(1): p. 37-44. 
117. Midde, N.M., et al., Genetically expressed HIV-1 viral proteins attenuate nicotine-
induced behavioral sensitization and alter mesocorticolimbic ERK and CREB 
signaling in rats. Pharmacology, biochemistry, and behavior, 2011. 98(4): p. 587-97. 
118. Dicke, K.E., S.M. Skrlin, and S.E. Murphy, Nicotine and 4-(methylnitrosamino)-1-(3-
pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug metabolism and 
disposition: the biological fate of chemicals, 2005. 33(12): p. 1760-4. 
119. Li, J., et al., Human immunodeficiency virus type 1 efficiently binds to human fetal 
astrocytes and induces neuroinflammatory responses independent of infection. BMC 
Neurosci, 2007. 8: p. 31. 
120. Liu, X., et al., HIV-1 Nef induces CCL5 production in astrocytes through p38-MAPK 
and PI3K/Akt pathway and utilizes NF-kB, CEBP and AP-1 transcription factors. Sci 
Rep, 2014. 4: p. 4450. 
121. Nookala, A.R., et al., HIV-1 Tat-mediated induction of CCL5 in astrocytes involves 
NF-kappaB, AP-1, C/EBPalpha and C/EBPgamma transcription factors and JAK, 
PI3K/Akt and p38 MAPK signaling pathways. PLoS One, 2013. 8(11): p. e78855. 
122. Guo, X., et al., Vitamin C protective role for alcoholic liver disease in mice through 
regulating iron metabolism. Toxicology and industrial health, 2011. 27(4): p. 341-8. 
123. Armstrong, A.W., et al., Smoking and pathogenesis of psoriasis: a review of oxidative, 
inflammatory and genetic mechanisms. The British journal of dermatology, 2011. 
165(6): p. 1162-8. 
124. Williams, J.F., Cytochrome P450 isoforms. Regulation during infection, inflammation 
and by cytokines. The Journal of the Florida Medical Association, 1991. 78(8): p. 517-
9. 
155 
 
125. Atluri, V.S., et al., Human synaptic plasticity gene expression profile and dendritic 
spine density changes in HIV-infected human CNS cells: role in HIV-associated 
neurocognitive disorders (HAND). PLoS One, 2013. 8(4): p. e61399. 
126. Nair, M.P., et al., Methamphetamine enhances HIV-1 infectivity in monocyte derived 
dendritic cells. J Neuroimmune Pharmacol, 2009. 4(1): p. 129-39. 
127. Hecht, S.S., et al., 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human 
liver microsomes: formation of a lung carcinogen precursor. Proceedings of the 
National Academy of Sciences of the United States of America, 2000. 97(23): p. 
12493-7. 
128. Smith, T.J., G.D. Stoner, and C.S. Yang, Activation of 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, 
lipoxygenase, and hydroperoxides. Cancer research, 1995. 55(23): p. 5566-73. 
129. Demizu, Y., et al., Alterations of cellular redox state during NNK-induced malignant 
transformation and resistance to radiation. Antioxidants & redox signaling, 2008. 
10(5): p. 951-61. 
130. Kadlubar, S., et al., Phenotypic CYP2A6 variation and the risk of pancreatic cancer. 
JOP : Journal of the pancreas, 2009. 10(3): p. 263-70. 
131. Jin, M., et al., A LC-MS/MS Method for Concurrent Determination of Nicotine 
Metabolites and Role of CYP2A6 in Nicotine Metabolism in U937 Macrophages: 
Implications in Oxidative Stress in HIV + Smokers. Journal of neuroimmune 
pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 
2011. 
132. Earla, R., et al., Development and validation of a fast and sensitive bioanalytical 
method for the quantitative determination of glucocorticoids--quantitative 
measurement of dexamethasone in rabbit ocular matrices by liquid chromatography 
tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis, 2010. 
52(4): p. 525-33. 
133. Zhang, W., et al., Evaluation of methoxsalen, tranylcypromine, and tryptamine as 
specific and selective CYP2A6 inhibitors in vitro. Drug metabolism and disposition: 
the biological fate of chemicals, 2001. 29(6): p. 897-902. 
134. Rodriguez-Antona, C., et al., Cytochrome P450 expression in human hepatocytes and 
hepatoma cell lines: molecular mechanisms that determine lower expression in 
cultured cells. Xenobiotica; the fate of foreign compounds in biological systems, 2002. 
32(6): p. 505-20. 
135. Hecht, S.S., Tobacco smoke carcinogens and lung cancer. Journal of the National 
Cancer Institute, 1999. 91(14): p. 1194-210. 
136. Miksys, S., E. Hoffmann, and R.F. Tyndale, Regional and cellular induction of 
nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. 
Biochemical pharmacology, 2000. 59(12): p. 1501-11. 
137. Lu, Y., et al., Ethanol induction of CYP2A5: permissive role for CYP2E1. Drug 
metabolism and disposition: the biological fate of chemicals, 2011. 39(2): p. 330-6. 
138. Joshi, M. and R.F. Tyndale, Induction and recovery time course of rat brain CYP2E1 
after nicotine treatment. Drug metabolism and disposition: the biological fate of 
chemicals, 2006. 34(4): p. 647-52. 
139. Marclay, F. and M. Saugy, Determination of nicotine and nicotine metabolites in urine 
by hydrophilic interaction chromatography-tandem mass spectrometry: Potential use 
156 
 
of smokeless tobacco products by ice hockey players. Journal of chromatography. A, 
2010. 1217(48): p. 7528-38. 
140. Miller, E.I., et al., A novel validated procedure for the determination of nicotine, eight 
nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by 
solid-phase extraction coupled with liquid chromatography-electrospray ionization-
tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in 
the biomedical and life sciences, 2010. 878(9-10): p. 725-37. 
141. Byrd, G.D., R.A. Davis, and M.W. Ogden, A rapid LC-MS-MS method for the 
determination of nicotine and cotinine in serum and saliva samples from smokers: 
validation and comparison with a radioimmunoassay method. Journal of 
chromatographic science, 2005. 43(3): p. 133-40. 
142. Byrd, G.D. and M.W. Ogden, Liquid chromatographic/tandem mass spectrometric 
method for the determination of the tobacco-specific nitrosamine metabolite NNAL in 
smokers' urine. Journal of mass spectrometry : JMS, 2003. 38(1): p. 98-107. 
143. Nakayama, H., et al., Nicotine metabolism by rat hepatic cytochrome P450s. 
Biochemical pharmacology, 1993. 45(12): p. 2554-6. 
144. Messina, E.S., R.F. Tyndale, and E.M. Sellers, A major role for CYP2A6 in nicotine 
C-oxidation by human liver microsomes. The Journal of pharmacology and 
experimental therapeutics, 1997. 282(3): p. 1608-14. 
145. Nakajima, M., et al., Role of human cytochrome P4502A6 in C-oxidation of nicotine. 
Drug metabolism and disposition: the biological fate of chemicals, 1996. 24(11): p. 
1212-7. 
146. Zhang, X., et al., CYP2A13: variable expression and role in human lung microsomal 
metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone. The Journal of pharmacology and experimental therapeutics, 
2007. 323(2): p. 570-8. 
147. Zhou, X., et al., Role of CYP2A5 in the clearance of nicotine and cotinine: insights 
from studies on a Cyp2a5-null mouse model. The Journal of pharmacology and 
experimental therapeutics, 2010. 332(2): p. 578-87. 
148. Reddy, P.V., et al., HIV-1 gp120 induces antioxidant response element-mediated 
expression in primary astrocytes: role in HIV associated neurocognitive disorder. 
Neurochem Int, 2012. 61(5): p. 807-14. 
149. Steele, M.L. and S.R. Robinson, Reactive astrocytes give neurons less support: 
implications for Alzheimer's disease. Neurobiol Aging, 2012. 33(2): p. 423 e1-13. 
150. Johnson, J.A., et al., The Nrf2-ARE pathway: an indicator and modulator of oxidative 
stress in neurodegeneration. Annals of the New York Academy of Sciences, 2008. 
1147: p. 61-9. 
151. Vargas, M.R. and J.A. Johnson, The Nrf2-ARE cytoprotective pathway in astrocytes. 
Expert reviews in molecular medicine, 2009. 11: p. e17. 
152. Reddy, P.V., et al., HIV-1 gp120 induces antioxidant response element-mediated 
expression in primary astrocytes: Role in HIV associated neurocognitive disorder. 
Neurochemistry international, 2011. 
153. Yokota, S., et al., Human CYP2A6 is regulated by nuclear factor-erythroid 2 related 
factor 2. Biochemical pharmacology, 2011. 81(2): p. 289-94. 
157 
 
154. Miksys, S. and R.F. Tyndale, Nicotine induces brain CYP enzymes: relevance to 
Parkinson's disease. Journal of neural transmission. Supplementum, 2006(70): p. 177-
80. 
155. Savarino, A., G.P. Pescarmona, and J.R. Boelaert, Iron metabolism and HIV infection: 
reciprocal interactions with potentially harmful consequences? Cell biochemistry and 
function, 1999. 17(4): p. 279-87. 
156. Sopori, M.L., et al., Nicotine-induced modulation of T Cell function. Implications for 
inflammation and infection. Advances in experimental medicine and biology, 1998. 
437: p. 279-89. 
157. Smith, C.J., et al., IARC carcinogens reported in cigarette mainstream smoke and their 
calculated log P values. Food Chem Toxicol, 2003. 41(6): p. 807-17. 
158. Smith, C.J. and C. Hansch, The relative toxicity of compounds in mainstream cigarette 
smoke condensate. Food Chem Toxicol, 2000. 38(7): p. 637-46. 
159. Pryor, W.A., et al., The radicals in cigarette tar: their nature and suggested 
physiological implications. Science, 1983. 220(4595): p. 425-7. 
160. Fields, W.R., et al., Gene expression in normal human bronchial epithelial (NHBE) 
cells following in vitro exposure to cigarette smoke condensate. Toxicol Sci, 2005. 
86(1): p. 84-91. 
161. Hellermann, G.R., et al., Mechanism of cigarette smoke condensate-induced acute 
inflammatory response in human bronchial epithelial cells. Respir Res, 2002. 3: p. 22. 
162. Nagaraj, N.S., et al., Cigarette smoke condensate induces cytochromes P450 and aldo-
keto reductases in oral cancer cells. Toxicol Lett, 2006. 165(2): p. 182-94. 
163. Kumar, M.B., R.W. Tarpey, and G.H. Perdew, Differential recruitment of coactivator 
RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. J Biol 
Chem, 1999. 274(32): p. 22155-64. 
164. Catalfamo, M., C. Le Saout, and H.C. Lane, The role of cytokines in the pathogenesis 
and treatment of HIV infection. Cytokine & growth factor reviews, 2012. 23(4-5): p. 
207-14. 
165. Van der Meide, P.H. and H. Schellekens, Cytokines and the immune response. 
Biotherapy, 1996. 8(3-4): p. 243-9. 
166. Katsikis, P.D., Y.M. Mueller, and F. Villinger, The cytokine network of acute HIV 
infection: a promising target for vaccines and therapy to reduce viral set-point? PLoS 
pathogens, 2011. 7(8): p. e1002055. 
167. Vandergeeten, C., R. Fromentin, and N. Chomont, The role of cytokines in the 
establishment, persistence and eradication of the HIV reservoir. Cytokine & growth 
factor reviews, 2012. 23(4-5): p. 143-9. 
168. Israel, N. and M.A. Gougerot-Pocidalo, Oxidative stress in human immunodeficiency 
virus infection. Cellular and molecular life sciences : CMLS, 1997. 53(11-12): p. 864-
70. 
169. Stehbens, W.E., Oxidative stress in viral hepatitis and AIDS. Experimental and 
molecular pathology, 2004. 77(2): p. 121-32. 
170. Malvy, D.J., et al., Relationship of plasma malondialdehyde, vitamin E and 
antioxidant micronutrients to human immunodeficiency virus-1 seropositivity. Clinica 
chimica acta; international journal of clinical chemistry, 1994. 224(1): p. 89-94. 
158 
 
171. Ande, A., et al., An LC-MS/MS method for concurrent determination of nicotine 
metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress 
in SVGA astrocytes. Drug Alcohol Depend, 2012. 125(1-2): p. 49-59. 
172. Anzenbacher, P. and E. Anzenbacherova, Cytochromes P450 and metabolism of 
xenobiotics. Cell Mol Life Sci, 2001. 58(5-6): p. 737-47. 
173. Pal, D. and A.K. Mitra, MDR- and CYP3A4-mediated drug-drug interactions. J 
Neuroimmune Pharmacol, 2006. 1(3): p. 323-39. 
174. Walubo, A., The role of cytochrome P450 in antiretroviral drug interactions. Expert 
Opin Drug Metab Toxicol, 2007. 3(4): p. 583-98. 
175. Dempsey, D., P. Jacob, 3rd, and N.L. Benowitz, Accelerated metabolism of nicotine 
and cotinine in pregnant smokers. The Journal of pharmacology and experimental 
therapeutics, 2002. 301(2): p. 594-8. 
176. Nelson, M. and M. Lipman, Management of advanced HIV disease in patients with 
tuberculosis or hepatitis co-infection. International journal of clinical practice, 2006. 
60(8): p. 976-83. 
177. Ande, A., et al., Tobacco smoking effect on HIV-1 pathogenesis: role of cytochrome 
P450 isozymes. Expert opinion on drug metabolism & toxicology, 2013. 
178. Buch, S., et al., Cocaine and HIV-1 interplay in CNS: cellular and molecular 
mechanisms. Current HIV research, 2012. 10(5): p. 425-8. 
179. Silverstein, P.S., et al., Methamphetamine toxicity and its implications during HIV-1 
infection. Journal of neurovirology, 2011. 17(5): p. 401-15. 
180. Vallari, A., et al., Four new HIV-1 group N isolates from Cameroon: Prevalence 
continues to be low. AIDS research and human retroviruses, 2010. 26(1): p. 109-15. 
181. Hughes, D.A., et al., Numerical and functional alterations in circulatory lymphocytes 
in cigarette smokers. Clinical and experimental immunology, 1985. 61(2): p. 459-66. 
182. Tollerud, D.J., et al., The effects of cigarette smoking on T cell subsets. A population-
based survey of healthy caucasians. The American review of respiratory disease, 1989. 
139(6): p. 1446-51. 
183. Kedzierska, K. and S.M. Crowe, Cytokines and HIV-1: interactions and clinical 
implications. Antiviral chemistry & chemotherapy, 2001. 12(3): p. 133-50. 
184. Kelder, W., et al., Beta-chemokines MCP-1 and RANTES are selectively increased in 
cerebrospinal fluid of patients with human immunodeficiency virus-associated 
dementia. Annals of neurology, 1998. 44(5): p. 831-5. 
185. Thea, D.M., et al., Plasma cytokines, cytokine antagonists, and disease progression in 
African women infected with HIV-1. Annals of internal medicine, 1996. 124(8): p. 757-
62. 
186. Burnham, E.L., E.J. Kovacs, and C.S. Davis, Pulmonary cytokine composition differs 
in the setting of alcohol use disorders and cigarette smoking. American journal of 
physiology. Lung cellular and molecular physiology, 2013. 304(12): p. L873-82. 
187. Barbieri, S.S., et al., Cytokines present in smokers' serum interact with smoke 
components to enhance endothelial dysfunction. Cardiovascular research, 2011. 90(3): 
p. 475-83. 
188. Levitzky, Y.S., et al., Relation of smoking status to a panel of inflammatory markers: 
the framingham offspring. Atherosclerosis, 2008. 201(1): p. 217-24. 
189. Allam, E., et al., Effects of tobacco on cytokine expression from human endothelial 
cells. Oral Dis, 2013. 19(7): p. 660-5. 
159 
 
190. de-Torres, J.P., et al., Smokers with CT detected emphysema and no airway obstruction 
have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra. PLoS One, 2013. 8(4): 
p. e60260. 
191. Kedzierska, K. and S.M. Crowe, Cytokines and HIV-1: interactions and clinical 
implications. Antivir Chem Chemother, 2001. 12(3): p. 133-50. 
192. Elbim, C., et al., The role of phagocytes in HIV-related oxidative stress. J Clin Virol, 
2001. 20(3): p. 99-109. 
193. Suzuki, K., et al., The relationship between smoking habits and serum levels of 8-
OHdG, oxidized LDL antibodies, Mn-SOD and carotenoids in rural Japanese 
residents. J Epidemiol, 2003. 13(1): p. 29-37. 
194. Ma, Q., Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol, 
2013. 53: p. 401-26. 
195. Chochola, J., A.D. Strosberg, and M. Stanislawski, Release of hydrogen peroxide from 
human T cell lines and normal lymphocytes co-infected with HIV-1 and mycoplasma. 
Free Radic Res, 1995. 23(3): p. 197-212. 
196. Torre, D., A. Pugliese, and F. Speranza, Role of nitric oxide in HIV-1 infection: friend 
or foe? Lancet Infect Dis, 2002. 2(5): p. 273-80. 
197. Raza, H., A. John, and A. Nemmar, Short-term effects of nose-only cigarette smoke 
exposure on glutathione redox homeostasis, cytochrome P450 1A1/2 and respiratory 
enzyme activities in mice tissues. Cell Physiol Biochem, 2013. 31(4-5): p. 683-92. 
198. Jin, M., et al., Effect of alcohol on drug efflux protein and drug metabolic enzymes in 
U937 macrophages. Alcohol Clin Exp Res, 2011. 35(1): p. 132-9. 
199. Earla, R., et al., Enhanced nicotine metabolism in HIV-1-positive smokers compared 
with HIV-negative smokers: simultaneous determination of nicotine and its four 
metabolites in their plasma using a simple and sensitive electrospray ionization liquid 
chromatography-tandem mass spectrometry technique. Drug Metab Dispos, 2014. 
42(2): p. 282-93. 
200. Torimoto, N., et al., Direct interaction between substrates and endogenous steroids in 
the active site may change the activity of cytochrome P450 3A4. Biochemistry, 2003. 
42(51): p. 15068-77. 
201. Zangar, R.C., D.R. Davydov, and S. Verma, Mechanisms that regulate production of 
reactive oxygen species by cytochrome P450. Toxicol Appl Pharmacol, 2004. 199(3): 
p. 316-31. 
202. Ande, A., et al., An LC-MS/MS method for concurrent determination of nicotine 
metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress 
in SVGA astrocytes. Drug and alcohol dependence, 2012. 125(1-2): p. 49-59. 
203. Shu, I. and P. Wang, Simultaneous serum nicotine, cotinine, and trans-3'-
hydroxycotinine quantitation with minimal sample volume for tobacco exposure status 
of solid organ transplant patients. Journal of chromatography. B, Analytical 
technologies in the biomedical and life sciences, 2013. 928: p. 139-45. 
204. Jarvis, M.J., et al., Measuring nicotine intake in population surveys: comparability of 
saliva cotinine and plasma cotinine estimates. Nicotine & tobacco research : official 
journal of the Society for Research on Nicotine and Tobacco, 2003. 5(3): p. 349-55. 
205. Jarvis, M.J., et al., Comparison of tests used to distinguish smokers from nonsmokers. 
American journal of public health, 1987. 77(11): p. 1435-8. 
160 
 
206. Bernert, J.T., et al., Interlaboratory comparability of serum cotinine measurements at 
smoker and nonsmoker concentration levels: a round-robin study. Nicotine & tobacco 
research : official journal of the Society for Research on Nicotine and Tobacco, 2009. 
11(12): p. 1458-66. 
207. Beyer, J., et al., Detection and validated quantification of toxic alkaloids in human 
blood plasma--comparison of LC-APCI-MS with LC-ESI-MS/MS. Journal of mass 
spectrometry : JMS, 2007. 42(5): p. 621-33. 
208. Jacob, P., 3rd, et al., Determination of the nicotine metabolites cotinine and trans-3'-
hydroxycotinine in biologic fluids of smokers and non-smokers using liquid 
chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure 
and for phenotyping cytochrome P450 2A6 activity. Journal of chromatography. B, 
Analytical technologies in the biomedical and life sciences, 2011. 879(3-4): p. 267-
76. 
209. Ande, A., et al., Effect of mild-to-moderate smoking on viral load, cytokines, oxidative 
stress, and cytochrome P450 enzymes in HIV-infected individuals. PLoS One, 2015. 
10(4): p. e0122402. 
210. Yamaguchi, J., et al., HIV-1 Group N: evidence of ongoing transmission in Cameroon. 
AIDS research and human retroviruses, 2006. 22(5): p. 453-7. 
211. Yamaguchi, J., et al., HIV infections in northwestern Cameroon: identification of HIV 
type 1 group O and dual HIV type 1 group M and group O infections. AIDS research 
and human retroviruses, 2004. 20(9): p. 944-57. 
212. Bodelle, P., et al., Identification and genomic sequence of an HIV type 1 group N 
isolate from Cameroon. AIDS research and human retroviruses, 2004. 20(8): p. 902-
8. 
213. Earla, R., et al., Bioanalytical method validation of rapamycin in ocular matrix by 
QTRAP LC-MS/MS: application to rabbit anterior tissue distribution by topical 
administration of rapamycin nanomicellar formulation. Journal of chromatography. 
B, Analytical technologies in the biomedical and life sciences, 2012. 908: p. 76-86. 
214. Clavijo, C., et al., Development and validation of a semi-automated assay for the 
highly sensitive quantification of Biolimus A9 in human whole blood using high-
performance liquid chromatography-tandem mass spectrometry. Journal of 
chromatography. B, Analytical technologies in the biomedical and life sciences, 2009. 
877(29): p. 3506-14. 
215. Bogusz, M.J., et al., Simultaneous LC-MS-MS determination of cyclosporine A, 
tacrolimus, and sirolimus in whole blood as well as mycophenolic acid in plasma using 
common pretreatment procedure. Journal of chromatography. B, Analytical 
technologies in the biomedical and life sciences, 2007. 850(1-2): p. 471-80. 
216. Shakleya, D.M. and M.A. Huestis, Simultaneous and sensitive measurement of 
nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human plasma by 
liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, 
Analytical technologies in the biomedical and life sciences, 2009. 877(29): p. 3537-
42. 
217. Kataoka, H., et al., Determination of nicotine, cotinine, and related alkaloids in human 
urine and saliva by automated in-tube solid-phase microextraction coupled with liquid 
chromatography-mass spectrometry. Journal of pharmaceutical and biomedical 
analysis, 2009. 49(1): p. 108-14. 
161 
 
218. Benowitz, N.L. and P. Jacob, 3rd, Metabolism of nicotine to cotinine studied by a dual 
stable isotope method. Clin Pharmacol Ther, 1994. 56(5): p. 483-93. 
219. Levi, M., et al., Prediction methods for nicotine clearance using cotinine and 3-
hydroxy-cotinine spot saliva samples II. Model application. Journal of 
pharmacokinetics and pharmacodynamics, 2007. 34(1): p. 23-34. 
 
  
162 
 
VITA 
 
Anusha Ande was born on July 15, 1989, in Bhimavaram, India. She was educated at 
public schools in Bhimavaram and graduated from high school by securing the first highest 
GPA in the district. She attended Andhra University, college of Pharmaceutical sciences, the 
second oldest Pharmacy school in India. She obtained her Bachelor’s degree of Science in 
Pharmacy in 2010 with distinction. After graduation from college, Ms. Ande joined the 
interdisciplinary Ph.D. program at University of Missouri-Kansas City (UMKC) in the fall of 
2010, majoring in Pharmacology and Pharmaceutical Sciences as co-discipline. Her keen 
interest and progress in research led her to publish 8 manuscripts in peer reviewed journals. 
She maintained a GPA of 4.0/4.0 with an outstanding performance in coursework. She also 
presented her work at various international conferences by poster presentations as well as a 
podium talk upon receiving Early Career Investigator Travel Award twice from the conference 
committee. During her graduate study at UMKC, Ms. Ande was bestowed with several awards 
and scholarships, including Best Student Award (2011), Dean’s Scholar Award (2012), 
Women Council Graduate Assistant Fund Award (2012, 2013, 2014, 2015), Preparing Future 
Faculty Award (2013-2014) (awarded to the six outstanding graduate students among all the 
graduate students from the university), and Robert C. Lanman Graduate Pharmacology 
Scholarship (2014). 
 
  
163 
 
APPENDIX 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
Dec 10, 2015 
 
 
 
This is a License Agreement between Anusha Ande ("You") and 
Elsevier ("Elsevier") provided by Copyright Clearance Center 
("CCC"). The license consists of your order details, the terms and 
conditions provided by Elsevier, and the payment terms and 
conditions. 
All payments must be made in full to CCC. For payment 
instructions, please see information listed at the bottom of this 
form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Anusha Ande 
Customer address 2464 Charlotte st 
  KANSAS CITY, MO 64108 
License number 3687300981772 
License date Aug 13, 2015 
Licensed content 
publisher 
Elsevier 
Licensed content 
publication 
Drug and Alcohol Dependence 
Licensed content title An LC–MS/MS method for concurrent 
determination of nicotine metabolites and the 
role of CYP2A6 in nicotine metabolite-mediated 
oxidative stress in SVGA astrocytes 
Licensed content 
author 
Anusha Ande,Ravinder Earla,Mengyao Jin,Peter 
S. Silverstein,Ashim K. Mitra,Anil 
Kumar,Santosh Kumar 
Licensed content date 1 September 2012 
Licensed content 
volume number 
125 
Licensed content issue 
number 
1-2 
Number of pages 11 
164 
 
Start Page 49 
End Page 59 
Type of Use reuse in a thesis/dissertation  
Intended publisher of 
new work 
other 
 
Portion full article  
Format both print and electronic  
Are you the author of 
this Elsevier article? 
Yes 
 
Will you be translating? No  
Title of your 
thesis/dissertation 
CYTOCHROME P450 ENZYMES AND OXIDATIVE 
STRESS IN TOBACCO/NICOTINE MEDIATED 
HIV-1 PATHOGENESIS 
 
Expected completion 
date 
Oct 2015 
 
Estimated size (number 
of pages) 
250 
 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD  
VAT/Local Sales Tax 0.00 USD / 0.00 GBP 
Total 0.00 USD   
Terms and Conditions   
 
 
 
  
165 
 
BENTHAM SCIENCE PUBLISHERS LICENSE 
TERMS AND CONDITIONS 
Dec 10, 2015 
 
 
 
This is a License Agreement between Anusha Ande ("You") and 
Bentham Science Publishers ("Bentham Science Publishers") provided 
by Copyright Clearance Center ("CCC"). The license consists of your 
order details, the terms and conditions provided by Bentham Science 
Publishers, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment 
instructions, please see information listed at the bottom of this 
form. 
License Number 3687780981677 
License date Aug 14, 2015 
Licensed content 
publisher 
Bentham Science Publishers 
Licensed content 
publication 
Mini-Reviews in Organic Chemistry 
Licensed content title Alcohol and Smoking Mediated Oxidative Stress 
in Organ Toxicities: Role of Cytochrome P450 
Systems 
Licensed copyright line Bentham Science Publisher 
Licensed content author Anusha Ande 
Licensed content date November 2013 
Type of Use Thesis/Dissertation 
Requestor type Author of requested content 
Format Print, Electronic 
Portion chapter/article 
Rights for Main product 
Duration of use Life of current edition 
Creation of copies for 
the disabled 
no 
With minor editing 
privileges 
no 
In the following 
language(s) 
Original language of publication 
With incidental 
promotional use 
no 
The lifetime unit 
quantity of new product 
0 to 499 
166 
 
The requesting 
person/organization is: 
Anusha Ande/University of Missouri-Kansas City 
Title of your thesis / 
dissertation 
CYTOCHROME P450 ENZYMES AND OXIDATIVE 
STRESS IN TOBACCO/NICOTINE MEDIATED HIV-1 
PATHOGENESIS 
Expected completion 
date 
Oct 2015 
Expected size (number 
of pages) 
250 
Billing Type Invoice  
Billing Address Anusha Ande 
2464 Charlotte st 
HSB 3219 
 
KANSAS CITY, MO 64108 
United States 
Attn: Anusha Ande 
 
Total 0.00 USD  
Terms and Conditions  
 
  
167 
 
INFORMA HEALTHCARE LICENSE 
TERMS AND CONDITIONS 
Dec 10, 2015 
 
 
 
This Agreement between Anusha Ande ("You") and Informa 
Healthcare ("Informa Healthcare") consists of your license details and 
the terms and conditions provided by Informa Healthcare and 
Copyright Clearance Center. 
License Number 3692550207527 
License date Aug 13, 2015 
Licensed Content 
Publisher 
Informa Healthcare 
Licensed Content 
Publication 
Expert Opinion on Drug Metabolism & Toxicology 
Licensed Content Title Tobacco smoking effect on HIV-1 pathogenesis: 
role of cytochrome P450 isozymes 
Licensed Content 
Author 
Anusha Ande, Carole McArthur, Anil Kumar, et al 
Licensed Content Date Nov 1, 2013 
Licensed Content 
Volume Number 
9 
Licensed Content 
Issue Number 
11 
Licensed Content 
Start Page 
1453 
Licensed Content End 
Page 
1464 
Type of Use Dissertation/Thesis  
Requestor type Author 
Format print and electronic 
Portion Full article 
Will you be 
translating? 
no 
Number of copies 50 
Order reference 
number 
None 
Title of your thesis / 
dissertation 
CYTOCHROME P450 ENZYMES AND OXIDATIVE 
STRESS IN TOBACCO/NICOTINE MEDIATED HIV-1 
PATHOGENESIS 
Expected completion 
date 
Oct 2015 
168 
 
Estimated Size 
(pages) 
250 
Requestor Location Anusha Ande 
2464 Charlotte st 
HSB 3219 
 
KANSAS CITY, MO 64108 
United States 
Attn: Anusha Ande 
 
Billing Type Invoice  
Billing Address Anusha Ande 
2464 Charlotte st 
HSB 3219 
 
KANSAS CITY, MO 64108 
United States 
Attn: Anusha Ande 
 
Total 0.00 USD  
Terms and Conditions  
 
  
169 
 
 
